Module 5 — Full Multi-Target Comprehensive Stack Protocol

Purpose. This is the Module 5 protocol for the all-in, multi-target integrated regimen — the patient who wants GLP-1 RA primary weight-management plus lean-mass preservation plus visceral-fat targeting plus post-weight-loss skin-laxity support, deployed as a coordinated multi-phase clinical program rather than as a simultaneous-initiation polypharmacy event. The protocol IS the integration logic: when each component starts, when each cycles, when each tapers, how the monitoring panels stack without duplication, how the injection burden is operationally manageable, and how the patient-counseling beats present the full regimen with the candor that the off-label-for-the-combined-regimen reality requires.

Sequencing is load-bearing. This protocol is NOT a “start everything at once” regimen. §4 Initiation covers ONLY the GLP-1 RA backbone start (Months 0-4 of the program). §5 Maintenance is where the lean-mass adjunct typically layers in (Months 4-9, paired with the first DEXA showing elevated lean-mass-loss fraction). §7-§8 phasing covers when the visceral-fat adjunct and the skin-laxity adjunct layer in (Tesa+AOD typically Months 6-12 in VAT-dominant phenotypes; GHK-Cu typically initiated at the ~30+ lb / ~13.6+ kg cumulative-loss milestone or at the GLP-1 maintenance-phase transition). The phasing logic is the protocol’s most distinctive structural feature relative to the simpler Module 5 stacks.

Stack composition (recap).

Backbone — GLP-1 RA (1 compound, weekly or daily by molecule): semaglutide / tirzepatide / retatrutide / survodutide / cagrilintide / CagriSema / IcoSema / liraglutide / orforglipron. Chosen per phenotype + access per [[Module 5 - Phenotype-Guided Decision Tree Protocol]].

Lean-mass adjunct — CJC-1295 + Ipamorelin + MOTS-c (3-compound stack, 2-3× weekly SC): Sequenced at Month 4-9 typically, anchored to the first post-titration DEXA showing elevated lean-mass-loss fraction (the practitioner-observation trigger established in [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §1.2). 12-16-week cycles with 4-8 week washout; typically 1-3 cycles aligned with the GLP-1’s active-weight-loss arc.

Visceral-fat adjunct — Tesamorelin + AOD-9604 (2-compound stack, daily SC): OPTIONAL; indicated for VAT-dominant phenotypes per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §1.2. Redundant in many cases if backbone is retatrutide or survodutide — the glucagon-receptor agonist arm of those compounds produces thermogenesis and VAT-selective reduction at magnitudes that often obviate the tesamorelin add-on (Pattern V direction-of-effect; §9 stack-redundancy rules). Daily SC; typically Months 6-12; 12-26-week duration with reassessment at the 6-month VAT-imaging timepoint.

Post-weight-loss skin support — GHK-Cu (sequenced, weekly to daily SC + daily topical): Initiated at the ~30+ lb / ~13.6+ kg cumulative-loss milestone (the laxity-onset window per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §1.3) or at the GLP-1 maintenance-phase transition. Topical layer continuous; injectable layer cycled per the GHK-Cu protocol (15 days 1 mg/day + 15 days 2 mg/day + 15-day washout, or quarterly cycle structure).

Pattern Z anchor calibration — Anchor 5 is DOMINANT for this protocol. Most of the stack is off-label for the combined regimen even where individual components are FDA-approved-for-marketing-claims for their own indications. Patient counseling beats throughout §10 lead with this combined-off-label framing per Pattern Z calibration anchor 5 (off-label / extrapolation transparency from /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md). Anchor 4 (multi-dimensional comparator framing) governs §10.4-§10.5 where the patient weighs the comprehensive stack against simpler alternatives (GLP-1 alone; GLP-1 + lean-mass only; GLP-1 + visceral only). Anchors 1+2 (compounded counseling) apply to every component’s regulatory framing. Anchor 3 (pregnancy) is operationally amplified because the multi-component nature means multiple pharmacokinetic washouts to coordinate.

Injection-burden framing — Pattern Z.injection-framing applies transparently, not minimizingly. A patient on the full stack at peak overlap is managing: 1 weekly GLP-1 RA injection + 2-3× weekly CJC-Ipa SC + daily Tesa SC (if indicated) + daily AOD-9604 SC (if indicated) + weekly to daily GHK-Cu SC during cycles. Peak overlap is uncommon — the phasing structure means most patients are on 2-3 compounds simultaneously at any given time, not 7. But peak overlap can occur (typically Months 6-9) and the protocol’s §10 counseling is honest about that. Pattern Z.injection-framing: self-injection is a routine clinical skill equivalent to insulin self-injection; the protocol does not pre-load with “daunting” or “intimidating” vocabulary. But it also does NOT minimize — peak-overlap logistics are real and are discussed factually with the patient before initiation.

Cumulative monitoring-burden framing. Baseline DEXA + 3-monthly metabolic labs (HbA1c, lipids, insulin, IGF-1, UACR, ALT/AST, lipase) + ophthalmology baseline (NAION pre-screen for semaglutide backbone; standard fundoscopy for all GLP-1 RA backbones in T2D phenotype) + DEXA repeat at 6 and 12 months + body-composition tracking + cancer-surveillance baseline (PSA in men ≥40; mammography in women ≥40) carried forward as on-protocol surveillance per the GH-secretagogue component. The monitoring panel is the union of the component-protocol panels with deduplication; §3 documents the integrated panel that prevents redundant lab orders.

Cost stack. 1, 000−2,500/month all-in is a working estimate, dependent on the specific backbone selection, FDA-approved vs compounded pathways for each component, insurance coverage for each indication (which is highly indication-specific and not uniformly favorable for the combined regimen), and the active-component count at any given month given the phasing structure. The §10 cost-and-access conversation is one of the load-bearing counseling beats; the protocol does not minimize the cost reality.

§4-§5-§7-§8 phasing is the protocol’s distinctive structural feature. Where a single-compound protocol locates initiation in §4 and maintenance in §5 with a relatively contained phasing question, this multi-compound stack distributes phasing across §4 (backbone initiation only), §5 (backbone maintenance + lean-mass adjunct layer-in), §7 (visceral-fat adjunct layer-in trigger logic), and §8 (skin-laxity adjunct trigger logic + multi-component taper coordination). Read all four sections together for the full phasing picture; reading any one in isolation will mislead.

Pattern AA + AA.marketing-claims load-bearing precision throughout. Each component’s regulatory status is preserved at every reference: semaglutide / tirzepatide / liraglutide are FDA-approved-for-marketing-claims for specific indications (CWM, T2D, MASH, CVOT, CKD, OSA per molecule); retatrutide / survodutide / cagrilintide / CagriSema / IcoSema / orforglipron are investigational at various Phase 3 readout / submission states (regulatory status verified at protocol-iteration time per §11); CJC-1295 / Ipamorelin / MOTS-c are NOT FDA-approved-for-marketing-claims for any drug indication (research peptides via 503A compounding under post-2023 FDA Category 2 listing); tesamorelin is FDA-approved-for-marketing-claims for HIV-associated lipodystrophy (Egrifta / Egrifta SV / Egrifta WR; BLA022505) and the non-HIV visceral-fat use is off-label use of an FDA-approved drug; AOD-9604 is NOT FDA-approved-for-marketing-claims for any drug indication (development-discontinued 2007 by sponsor; 503A bulks list category 2); GHK-Cu is NOT FDA-approved as a drug (topical = cosmetic-ingredient category; injectable = research-classified peptide via 503A). The combined regimen as a whole is off-label even when each individual component is on-label for some indication, because no FDA approval exists for the combined regimen. §10.6 counseling beat is anchored on this combined-off-label framing.

Indication scope and patient phenotypes
Selection criteria (inclusion / relative exclusion / contraindications)
Pre-treatment workup (integrated panel)
Initiation protocol (backbone-only; Months 0-4)
Maintenance protocol + lean-mass adjunct layer-in (Months 4-9)
Side-effect management (cross-component AE class algorithms)
Plateau and non-response algorithm + visceral-fat adjunct layer-in trigger logic
Discontinuation and tapering + skin-laxity adjunct trigger logic + multi-component coordination
Combination rules (THE STACK IS THE COMBINATION; redundancy logic; sequencing rules)
Patient counseling beats (Pattern Z calibration-anchor-compliant)
Source citations
Clinical decision tree

Appendices

A. Verification gate — four-step cycle applied to this multi-component protocol
B. Pattern discipline summary — multi-component-stack-specific enforcement
C. Self-audit on phasing logic, monitoring deduplication, and Pattern Z compliance

Cross-references

Per-canonical backbone protocols: [[Semaglutide Protocol]], [[Tirzepatide Protocol]], [[Retatrutide Protocol]], [[Survodutide Protocol]], [[Liraglutide Protocol]], [[Cagrilintide Protocol]], [[CagriSema Protocol]], [[IcoSema Protocol]], [[Orforglipron Protocol]]
Adjunct protocols: [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]], [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]], [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]]
Phenotype routing: [[Module 5 - Phenotype-Guided Decision Tree Protocol]]
Template: /Methodology/Protocol Template.md
Pattern Z calibration anchor: /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md
System observations: /Methodology/AC2-26 - System Observations.md (Patterns R / R.1 / R.2 / V / W / Z / Z.injection-framing / Z.research-precision / AA / AA.marketing-claims / AB / AB.4 / N.1)
Editorial framework: /Methodology/Synergy Editorial Framework.md
Voice profile: /Methodology/Voice Profile - Dr. Jeff Gross MD.md

1. Indication scope and patient phenotypes

1.1 Purpose

This protocol covers a comprehensive multi-target weight-management regimen for the patient who wants integrated GLP-1 RA primary therapy plus lean-mass preservation plus visceral-fat targeting plus post-weight-loss skin support as a coordinated multi-phase clinical program. The clinical question this protocol answers is not “can the patient lose weight?” — a single GLP-1 RA addresses that question. The question is: for a patient with substantial weight to lose and body-composition optimization goals beyond total-weight reduction, how do the four mechanism layers (primary appetite/satiety/glucose-metabolism axis; GH-axis lean-mass preservation; GH-axis-and-lipolytic visceral-fat targeting; tripeptide-copper regenerative dermal support) sequence into a coherent multi-month-to-multi-year clinical arc?

Pattern R.1 enforcement at this section: §1 opens with what the comprehensive stack IS (a coordinated multi-phase clinical program targeting four body-composition-and-metabolic outcomes through complementary mechanism layers) and for whom (patients with substantial weight to lose, body-composition optimization goals, acceptance of multi-injection regimen, often post-bariatric-surgery weight-regain or athletic-aspirational presentations). Regulatory framing — the combined regimen is off-label as a whole; component regulatory statuses are heterogeneous — is presented as factual scope in §1, with the operational counseling at §10.

Pattern R.2 enforcement at this section: the indication scope is locked at protocol-design step — comprehensive multi-target stack for patients meeting the §1.4 phenotype triggers; phased sequencing per §4-§8; not a “start everything at once” regimen. The protocol does NOT drift mid-document into “this is just a more-aggressive GLP-1 protocol” framing, or into “this is the protocol for patients who want maximum results” framing, or into “this is what every GLP-1 patient should be on” framing — those mis-framings would each be Pattern R.2 design-step failures. The protocol is a phenotype-indicated multi-target stack for a defined patient population with defined clinical triggers, not a “more is better” upgrade path.

Pattern AA + AA.marketing-claims discipline at this section: every component’s regulatory status is anchored to its component-canonical and to its specific indication. The combined regimen is off-label as a whole. §10.6 patient-counseling beat anchors on this combined-off-label framing per Pattern Z calibration anchor 5.

1.2 Indication categories — where the comprehensive stack applies

The Module 5 Protocol Template (/Methodology/Protocol Template.md §1.2) enumerates eight indication categories. The comprehensive stack does not address any single indication category in isolation; it addresses a cross-category clinical phenotype that engages multiple indication-category dimensions simultaneously:

Primary indication anchor — Chronic weight management (CWM) for adults with substantial weight-loss target. The GLP-1 RA backbone is the load-bearing component for this indication; the backbone choice is phenotype-routed per [[Module 5 - Phenotype-Guided Decision Tree Protocol]]. For non-diabetic obesity BMI ≥30 with >15-20% target weight loss, semaglutide / tirzepatide / retatrutide (investigational) / cagrilintide / CagriSema (regulatory status verified at iteration time) / orforglipron (investigational) are typical primary choices. For T2D + obesity, the choice incorporates the glycemic-control dimension; for ASCVD, the CVOT-evidence dimension; for CKD-in-T2D, the FLOW-evidence dimension; for MASH F2-F3, the ESSENCE-evidence (semaglutide) or pipeline-evidence (tirzepatide / retatrutide) dimension. The comprehensive stack is added when the patient’s profile triggers one or more of the §1.4 stack-specific phenotype indicators on top of the primary indication.
Indication category 8 anchor — Lean mass / body composition (peptide stacks). The CJC-Ipa+MOTS-c stack is the load-bearing component for this indication, layered on the GLP-1 RA backbone per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §1.2 triggers. This is the second indication-category dimension the comprehensive stack engages.
Adjunct indication anchor — Visceral adipose tissue reduction (off-label adjunct). The Tesa+AOD stack is the load-bearing component for this indication, layered when the §1.4 VAT-dominant phenotype trigger is met per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §1.2. Often redundant with retatrutide / survodutide / CagriSema / IcoSema backbones because the glucagon-receptor or amylin-receptor mechanism in those backbones produces VAT-selective effects that obviate the tesamorelin add-on for many patients (§9.4 stack-redundancy rules).
Adjunct indication anchor — Post-weight-loss skin laxity (cosmetic-adjunct regenerative). The GHK-Cu protocol is the load-bearing component, sequenced at the ~30+ lb / ~13.6+ kg cumulative-loss milestone or at the GLP-1 maintenance-phase transition per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §1.3.

The remaining indication categories (CV risk reduction, MASH, CKD, OSA, HFpEF) intersect with the comprehensive stack indirectly — they are typically addressed by the GLP-1 RA backbone selection rather than by adding additional indication-specific components. The comprehensive stack does not extend the backbone’s CVOT / MASH / CKD / OSA effects via the adjunct layers; the adjuncts target body-composition and skin-quality outcomes specifically.

1.3 Mechanism foundation — four mechanism layers, one integrated stack

The comprehensive stack engages four mechanism layers that converge on the multi-target body-composition outcome. Each layer is mechanism-distinct from the others; the layers are mechanism-additive, not mechanism-duplicative (with the noted retatrutide / survodutide ↔︎ tesamorelin partial-redundancy exception in §9.4).

Layer 1 — Primary appetite / satiety / glucose-metabolism axis (GLP-1 RA backbone). The backbone engages one or more of the GLP-1R / GIPR / glucagon-R / amylin-R receptor axes (compound-specific per backbone choice) to produce central appetite suppression, delayed gastric emptying, glucose-dependent insulin secretion, and (for triagonists and amylin-class combinations) additional metabolic effects (glucagon-mediated thermogenesis; amylin-mediated satiety). The backbone is the load-bearing component for total-weight reduction; the other three layers do not drive weight loss directly — they shape the composition of the loss and the post-loss tissue response. The backbone choice is phenotype-routed per [[Module 5 - Phenotype-Guided Decision Tree Protocol]]; common comprehensive-stack backbone choices include semaglutide (broad indication scope; SELECT / ESSENCE / FLOW / STEP-HFpEF evidence stack), tirzepatide (higher weight-loss magnitude per SURMOUNT-1 / SURMOUNT-5 head-to-head per [[Tirzepatide Protocol]]), retatrutide (highest investigational weight-loss magnitude; TRIUMPH program per [[Retatrutide Protocol]]), and survodutide (GLP-1/glucagon dual with thermogenesis component per [[Survodutide Protocol]]).

Layer 2 — GH-axis lean-mass preservation (CJC-Ipa+MOTS-c stack). This layer engages two complementary GH-axis mechanisms (GHRH-pathway activation via CJC-1295 Mod-GRF 1-29; ghrelin-receptor pathway activation via Ipamorelin; the two together producing 7-10× supra-additive GH pulse amplitude per Teichman 2006 PMID 16352683 and Ionescu & Bhatt 2006 PMID 17018654) plus a parallel mitochondrial AMPK / myostatin-inhibition / exercise-mimesis pathway via MOTS-c (Lee 2015 PMID 25738459; Kim 2021 PMID 33554779; Reynolds 2021 PMID 33473109). The stack’s clinical question is the lean-mass-loss fraction of the GLP-1-driven weight loss — the Phase-3-pooled DEXA data across STEP and SURMOUNT programs document a ~20-32% lean-mass-loss-fraction range (Look 2025 PMID 39996356; Beavers 2025 PMID 39996356), and the layered stack’s practitioner-observation target is a reduction toward ~15-20% lean-mass-loss fraction in adherent patients with Tier 1 foundation (resistance training + 1.2-1.6 g/kg protein + vitamin D adequacy + sleep). The mechanism foundation is documented in detail in [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §1.3.

Layer 3 — VAT-selective lipolysis and lipolytic adjunct (Tesa+AOD stack). This layer engages the GHRH-R-mediated pulsatile endogenous GH release → hepatic IGF-1 elevation → VAT-selective lipolysis cascade (tesamorelin; FDA-approved-for-marketing-claims for HIV-lipodystrophy abdominal-fat reduction; Falutz Phase 3 program PMIDs 18057338 / 18690162 / 20101189; off-label for non-HIV visceral adiposity), plus the AOD-9604 hGH C-terminal fragment lipolysis pathway decoupled from GH-receptor signaling (Heffernan 2001 PMID 11713213; development-discontinued 2007 by sponsor; preclinical-load-bearing evidence base). The clinical question is the visceral-fat fraction of body composition — the GLP-1 RA backbone also reduces VAT (substantially, in proportion to total weight loss; imaging substudies within STEP / SURMOUNT / SCALE programs), and the tesamorelin add-on is mechanism-additive for the VAT-dominant phenotype where residual VAT remains after the backbone’s response. For retatrutide / survodutide / CagriSema / IcoSema backbones, the glucagon-receptor thermogenesis component or amylin-receptor satiety component produces enhanced VAT reduction relative to GLP-1-monotherapy backbones, often obviating the tesamorelin add-on — the §9.4 stack-redundancy rules govern this decision. The mechanism foundation is documented in [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §1.3.

Layer 4 — Tripeptide-copper regenerative dermal support (GHK-Cu). This layer engages the GHK-Cu fibroblast collagen-synthesis pathway, the SOD-mediated antioxidant pathway, the ferritin iron-release blockade, and the NF-κB / TNF-α / IL-6 anti-inflammatory cascade (Pickart and Maquart corpus; mechanism-rationale evidence base with cosmetic-formulation topical-efficacy data set as the load-bearing Phase-3-equivalent evidence per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §1.8). The clinical question is the dermal-remodeling support during the 12-24-month post-weight-loss skin-remodeling window. The GHK-Cu layer is the only layer that is sequenced rather than concurrent with the active-weight-loss phase — it is initiated at the ~30+ lb / ~13.6+ kg cumulative-loss milestone (the laxity-onset threshold per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §1.3) or at the GLP-1 maintenance-phase transition, after most of the active-weight-loss has occurred and the dermis is in the remodeling window where the regenerative support is mechanistically relevant.

Mechanism integration — non-redundant cross-layer biology. The four layers engage distinct receptor and signaling pathways:

Layer 1 (GLP-1 RA): GLP-1R / GIPR / glucagon-R / amylin-R (compound-specific) — central appetite, glucose homeostasis, gastric emptying, thermogenesis (for glucagon component), satiety (for amylin component).
Layer 2 (CJC-Ipa+MOTS-c): GHRH-R + GHS-R1a + AMPK pathway + myostatin / FOXO pathway — pulsatile GH release with IGF-1 elevation, mitochondrial metabolic regulation, anabolic skeletal-muscle signaling.
Layer 3 (Tesa+AOD): GHRH-R (tesamorelin; same family as CJC-1295 but distinct molecule and PK) + hypothesized β3-AR / hormone-sensitive lipase pathway (AOD-9604; mechanism characterization preclinical and incomplete) — VAT-selective lipolysis, hepatic-fat reduction, decoupled-from-GHR adipose lipolysis.
Layer 4 (GHK-Cu): fibroblast collagen-synthesis pathway, antioxidant / anti-inflammatory cascade, dermal-remodeling biology — regenerative tissue support during the dermal remodeling window.

The Layer 2 ↔︎ Layer 3 partial redundancy at the GHRH-R level (both CJC-1295 and tesamorelin are GHRH analogs; the receptor-engagement axis is shared) is addressed in §9.4 stack-design rules: the two are not co-administered simultaneously in standard practice — when both lean-mass-preservation and visceral-fat-targeting goals are present, the typical sequencing is CJC-Ipa+MOTS-c during the active-weight-loss-with-lean-mass-concern phase, followed by transition to or addition of Tesa+AOD during a visceral-fat-targeted phase. The §9.4 rules document the specific phasing and the rationale.

1.4 Phenotype-targeting taxonomy — who is the comprehensive-stack patient

The Module 5 phenotype taxonomy (/Methodology/Protocol Template.md §1.3) applies, with comprehensive-stack-specific refinement. The comprehensive stack is not appropriate for every GLP-1 RA patient — it is appropriate for a defined phenotype population with multiple stack-specific clinical triggers. Single-trigger patients (e.g., lean-mass-concern only) are routed to the corresponding single-adjunct stack (e.g., CJC-Ipa+MOTS-c alone, not the comprehensive stack); two-or-more-trigger patients with the clinical profile and patient-preference alignment for the comprehensive integration are the stack’s target population.

Primary phenotype triggers — at least two of these must be present:

Substantial weight-loss target — 50+ lb / 22+ kg. Patients with shorter weight-loss arcs (5-10% body-weight reduction; <50 lb) typically do not warrant the comprehensive layered stack because the absolute-magnitude clinical concerns (lean-mass loss; visceral-fat residual; skin-laxity onset) are smaller and often manageable with simpler approaches (Tier 1 foundation alone; GLP-1 + lean-mass adjunct only). The 50+ lb / 22+ kg threshold is the practitioner-observation anchor for when the cumulative body-composition concerns warrant the integrated stack approach.
Body-composition optimization goal beyond total-weight reduction. Patients explicitly seeking lean-mass preservation, visceral-fat targeting, and skin-quality support as discrete clinical outcomes — not just “weight loss” generically. This phenotype trigger is identified at the initial clinical consultation by patient-articulated goals (athletic / performance / longevity convergence; post-bariatric-surgery weight-regain after prior loss-and-regain experience; cosmetic + metabolic + functional convergence).
Acceptable to multi-injection regimen, or at least willing to discuss the tradeoffs openly. The comprehensive stack at peak overlap involves managing multiple injection compounds simultaneously (§10.7 logistics counseling). Patients who reflexively decline multi-injection regimens are routed to simpler stacks or to single-component GLP-1 therapy; patients who are at minimum willing to engage the logistics discussion openly are candidates for the comprehensive approach. The patient’s prior injection-experience baseline (insulin self-injection history; GLP-1 RA self-injection adherence; fertility-hormone self-injection history; biologic self-injection history) is relevant to this trigger assessment.
Documented or anticipated lean-mass-loss-fraction concern. Either an early-cycle DEXA on the GLP-1 backbone showing elevated lean-mass-loss fraction (>30% of total weight loss as lean mass at 12 weeks per the practitioner-observation expectation in [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §1.2), or a phenotype predictor of elevated lean-mass-loss-fraction risk (post-menopausal female; ≥50 age with sarcopenia-progression risk factors; high-baseline-lean-mass athletic phenotype; ≥65 age; documented pre-existing sarcopenia signal).
Documented or anticipated visceral-fat residual concern. Either baseline imaging (DEXA VAT; abdominal MRI; CT) showing visceral-fat predominance disproportionate to total adiposity, or a phenotype predictor of elevated VAT-residual risk (insulin-resistant obesity with android distribution; MASLD/MASH; metabolic-syndrome cluster; HIV-lipodystrophy context).
Cumulative loss trajectory likely to trigger skin-laxity onset. Patients with target weight loss in the 50+ lb range will typically cross the ~30+ lb / ~13.6+ kg laxity-onset threshold during the active-weight-loss arc per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §1.3. Skin-quality concern is an anticipatory phenotype trigger rather than a baseline trigger — most patients are not in skin laxity at protocol initiation, but the trajectory predicts the GHK-Cu indication will emerge.

Typical comprehensive-stack patient profiles — the three canonical presentations:

Profile A — Post-bariatric-surgery weight-regain with pharmacological + adjunct preservation strategy. Patient previously underwent sleeve gastrectomy or Roux-en-Y with substantial weight loss followed by partial regain over 5-10 years; now presenting with weight-loss target of 50-80+ lb to return toward post-surgical nadir, with body-composition concerns shaped by the prior loss-and-regain experience (prior lean-mass loss now compounded by aging and inactivity; prior skin laxity that may have resolved partially but remains as cosmetic concern; metabolic profile shaped by the prior surgery’s mechanism context). Profile A patients often have specific awareness of the body-composition dimensions because of their prior experience; they are typically high-information patients with articulated multi-target goals.
Profile B — Athletic-aspirational adult with cosmetic + performance + longevity convergence. Midlife (typically 40-60 age) adult with high baseline lean mass, active resistance-training history, body-composition optimization as a baseline lifestyle goal, presenting with weight loss target driven by visceral-fat / metabolic-marker / aesthetic considerations rather than by gross obesity. Profile B patients are typically not in the BMI ≥30 chronic-weight-management label range for some backbones (they may be BMI 27-30 with comorbidity, or BMI 30-35 with athletic-recomposition goals); the comprehensive stack’s lean-mass-preservation layer is particularly load-bearing for this profile because the patient’s body-composition starting point is high baseline lean mass that is at significant risk during caloric deficit.
Profile C — Polycondition metabolic-syndrome patient seeking integrated management. Adult with BMI ≥35, T2D, MASLD/MASH F2-F3 or precursor, ASCVD risk factors, OSA, with weight-loss target of 60-100+ lb. The polycondition presentation drives the comprehensive-stack consideration because multiple indication-category dimensions intersect (CWM + T2D + MASH or CV + OSA + body-composition optimization). Backbone choice typically routes to semaglutide (broadest indication coverage), tirzepatide (higher weight-loss magnitude), or retatrutide (highest investigational magnitude; SURMOUNT / TRIUMPH-class effect-sizes); adjunct layers add per the §1.4 triggers.

Phenotypes for which the comprehensive stack is NOT appropriate:

Shorter weight-loss arcs (<50 lb / <22 kg). Single-adjunct or backbone-alone approaches are typically appropriate; the comprehensive stack’s complexity and cost are disproportionate to the body-composition concerns at this loss magnitude.
Patient-preference decline of multi-injection regimen. Routed to oral / weekly-only regimens (orforglipron oral if appropriate; weekly-only backbone without adjuncts).
Hard contraindication to any single component. Routed through the per-component §2.4 exclusion algorithms; if a hard contraindication eliminates a load-bearing layer (e.g., active malignancy → GH-axis components contraindicated → comprehensive stack collapses to GLP-1 RA backbone alone), the comprehensive stack indication is not met.
Pregnancy or planned pregnancy within the 8-week-pre-conception window. Pre-conception planning collapses to GLP-1 RA discontinuation per [[Semaglutide Protocol]] §8.4 or backbone-specific equivalent; adjunct layers are also discontinued; the comprehensive stack is not initiated within the pre-conception window.
Cost / access constraint that cannot support the cumulative regimen. The §10 cost-and-access conversation is honest about the 1, 000−2,500/month cumulative cost; patients for whom this is prohibitive are routed to backbone-alone approaches or to phased single-adjunct approaches over a longer time frame.

1.5 Cross-reference to case construction

The comprehensive-stack worked clinical cases (presented in Sections 4-8 examples and in standalone case files at /Conditions/) are constructed against the §1.4 phenotype taxonomy using the case-construction conventions documented in M5.10 Case Study — Patient Questions. The three canonical patient profiles in §1.4 (Profile A post-bariatric weight-regain; Profile B athletic-aspirational; Profile C polycondition metabolic-syndrome) anchor most worked examples in §4-§8. A protocol that presents a phenotype in a case but does not anchor that phenotype to a §1.4 trigger combination is a Pattern R.2 design-step failure: the case is generating phenotype categories rather than instantiating them against the locked indication scope.

1.6 Worked example — the canonical comprehensive-stack patient (Profile A)

For continuity across §4-§8 worked-example sections, the canonical comprehensive-stack patient introduced here:

Patient. 52-year-old female, BMI 38.5 (218 lb / 99 kg at 5’4“), prior Roux-en-Y gastric bypass at age 39 with substantial weight loss to BMI 26 at the post-surgical nadir, gradual weight regain over the past 8 years to current BMI 38.5. Post-menopausal (natural menopause at 50). Comorbidity profile: T2D HbA1c 7.4 on metformin 1000 mg BID; dyslipidemia on rosuvastatin 20 mg; HTN on lisinopril 20 mg; mild MASLD on imaging at last hepatology follow-up; OSA on CPAP; no ASCVD events but elevated 10-year ASCVD risk; no MTC / MEN-2 personal or family history; no pancreatitis history; no diabetic retinopathy on dilated exam 6 months ago; UACR 45 mg/g (microalbuminuria); eGFR 78; no NAION risk factors; up-to-date mammography (negative); annual gynecologic exam negative.

Body-composition baseline (DEXA at clinical-pathway entry). Total lean mass 49 kg; total fat mass 50 kg; VAT 2,100 g (above the 2,000 g VAT-dominance threshold per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §1.4). Grip strength 22 kg (low for age and sex per EWGSOP2 reference; sarcopenic-risk signal). 5-time sit-to-stand 14 seconds (above the 12-second EWGSOP2 cutoff; mildly impaired physical performance).

Patient goals — articulated at consultation. “I lost 90 pounds with the gastric bypass and felt great, but I’ve gained back 75 of them over the past 8 years. I know the GLP-1 medications can help — my endocrinologist already mentioned them — but I’m worried I’ll lose muscle again the way I did after the bypass surgery, when I felt weak and my skin sagged a lot. I want to do this in a way that protects my muscle as much as possible, deals with the belly fat that’s been the worst part for me, and maybe helps with skin if I lose a lot again.”

Phenotype trigger summary.

Substantial weight-loss target: yes — patient’s stated target is BMI 28-30 (return toward post-surgical nadir), requiring ~50-60 lb / 22-27 kg loss.
Body-composition optimization goal: yes — explicitly articulated lean-mass-preservation, visceral-fat-targeting, and skin-quality concerns.
Multi-injection acceptance: yes — patient has prior insulin-injection experience (during gestational diabetes pregnancies pre-bypass) and articulates willingness to discuss multi-component regimen tradeoffs.
Lean-mass concern: yes — post-menopausal, ≥50 age, low baseline grip strength, prior lean-mass loss history.
VAT-residual concern: yes — baseline VAT 2,100 g; android distribution; MASLD; metabolic-syndrome cluster.
Cumulative-loss trajectory predicting skin-laxity onset: yes — 50-60 lb target loss will cross the ~30 lb laxity-onset threshold; prior skin laxity history after gastric bypass.

Trigger count: 6/6 of the §1.4 primary triggers. This is the canonical Profile A comprehensive-stack candidate. The §4 initiation discussion, §5 maintenance-and-lean-mass-adjunct-layer-in, §7 visceral-fat-adjunct-layer-in, and §8 skin-laxity-adjunct-trigger and multi-component coordination are all developed against this canonical patient in the worked-example sections.

Pattern AA precision applied to §1.6. The patient’s prior gastric-bypass status is a clinical-history dimension, not a contraindication to any stack component; the prior loss-and-regain experience is the §1.4 Profile A canonical presentation. The patient’s T2D status is an indication-category overlap (T2D + CWM) and shapes the backbone choice (semaglutide 1.0-2.0 mg for T2D + CWM with potential FLOW-anchored CKD-risk-reduction co-indication given the UACR; or tirzepatide for higher-magnitude weight loss with SURPASS-2 head-to-head HbA1c advantage; or retatrutide investigational if the patient elects participation in or post-approval access to the highest-magnitude triagonist). The backbone choice is a §4 + §10 conversation; the comprehensive-stack framing accommodates any of the three primary candidate backbones.

Pattern Z calibration anchor 5 applied to §1.6. The off-label / extrapolation framing for the comprehensive stack as a combined regimen is explicit: each individual component is on-label or off-label or investigational per its own regulatory state, but the combined regimen has no FDA approval, no Phase 3 RCT, and no labeled indication. The patient is informed at §10.6 that the combined regimen is an off-label clinical-judgment integration of components with individual evidence bases of varying strength; the integration logic is mechanism-based and practitioner-experience-based, not Phase-3-RCT-confirmed at the combined-regimen level. This is the load-bearing patient-counseling framing throughout §10.

2. Selection criteria (inclusion / relative exclusion / contraindications)

2.1 Purpose

Define who the comprehensive stack is for, who it is not for, and who it must not be on. §2 operationalizes the §1 indication scope into actionable clinical screening criteria. For a multi-component stack, the screening is the union of the component-protocol screening criteria — a patient must meet the inclusion criteria for the backbone, for the lean-mass adjunct, for the visceral-fat adjunct (if indicated by §1.4 trigger), and for the skin-laxity adjunct (at the §8 trigger timepoint). A patient who fails any single component’s hard contraindication at any layer is not a candidate for that layer; the comprehensive stack collapses to the non-contraindicated subset.

§2 is structured into three sub-blocks per the Protocol Template §2 architecture: inclusion criteria (positive — who the stack IS for), relative exclusion criteria (clinician-judgment — who the stack may not be for), and hard contraindications (absolute — who the stack must not be on at the specified component level).

Pattern R.1 enforcement at this section: §2 opens with inclusion criteria — who the comprehensive stack IS for — before exclusions and contraindications. The architectural ordering (2.2 inclusion → 2.3 relative exclusion → 2.4 hard contraindication) is the Pattern R.1 design-time enforcement.

Pattern AA enforcement: every contraindication is anchored to its source — FDA boxed warning, FDA labeled contraindication, or post-marketing signal with primary-source citation — at the component level. The comprehensive-stack-level contraindication picture is the union of the component-level contraindication pictures.

2.2 Inclusion criteria — the comprehensive-stack-eligible phenotype

A patient is eligible for the comprehensive stack if all of the following are met:

Backbone-level inclusion criteria met for the selected GLP-1 RA per the corresponding component protocol’s §2.2. For semaglutide CWM: adult age ≥18 with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity per [[Semaglutide Protocol]] §2.2. For tirzepatide CWM: adult age ≥18 with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity per [[Tirzepatide Protocol]] §2.2. For other backbones, per the respective component protocol. The comprehensive stack does not modify the backbone inclusion criteria — the patient must meet the backbone’s standalone inclusion criteria first.
Lean-mass adjunct §1.4 phenotype trigger present per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §1.2 (age ≥50 with sarcopenia-progression risk; documented elevated lean-mass-loss fraction; functional measure decline; high-target-weight-loss trajectory >15-20%; athletic / high-baseline-lean-mass phenotype; pre-discontinuation set-point preservation). At least one of these triggers is present at protocol entry, or is anticipated to emerge within the first 12 weeks on the backbone.
Tier 1 foundation adherence demonstrated or committable. Per the lean-mass adjunct protocol §1.5, the Tier 1 foundation (resistance training 2-3× weekly with progressive overload; 1.2-1.6 g/kg protein intake daily; vitamin D adequacy; sleep adequacy) is the load-bearing intervention for lean-mass preservation. The adjunct stack is layered on top of, not in place of, the Tier 1 foundation. Patients who cannot or will not commit to Tier 1 foundation adherence are not stack candidates — the stack’s effect-size depends on the foundation being in place.
Multi-injection regimen acceptance or willingness to discuss tradeoffs openly. §1.4 phenotype trigger.
Body-composition baseline (DEXA) obtainable. Either a recent DEXA (within 3 months) is on file, or the patient is willing to undergo baseline DEXA before adjunct initiation. The body-composition baseline is the load-bearing monitoring anchor for the stack’s outcome assessment.
Comprehensive informed-consent framing acceptable to patient. Per §10.6 — the patient understands the combined regimen is off-label at the integration level, that each component carries its own regulatory state, and that the integration logic is mechanism-and-practitioner-experience-based rather than Phase-3-RCT-confirmed at the combined-regimen level.

The comprehensive stack inclusion criteria are stricter than backbone-alone inclusion criteria. A patient eligible for semaglutide CWM is not automatically eligible for the comprehensive stack; the additional adjunct-specific triggers, Tier 1 foundation commitment, and informed-consent framing must all align.

2.3 Relative exclusion criteria — clinician-judgment phenotype

Relative exclusion criteria are component-specific. A relative exclusion at any single component level routes that component’s inclusion through a clinician-judgment pathway; depending on the component, the comprehensive stack may proceed without that component or with enhanced surveillance for that component. The relative exclusion criteria are the union of the component-protocol relative exclusion lists:

Backbone-level relative exclusions per the GLP-1 RA component protocols. Typical Module 5 backbone relative exclusions include severe gastroparesis (GI AE risk amplified); active or recent (within 12 months) acute pancreatitis; severe gastrointestinal disease; diabetic retinopathy with rapid-HbA1c-improvement risk (SUSTAIN-6 retinopathy-complication signal in semaglutide; class-applicable consideration); severe renal impairment outside the FLOW-anchored eGFR 25-75 range (for semaglutide CKD-in-T2D indication; backbone-specific); severe hepatic impairment outside trial-enrolled range; active eating disorder (anorexia / bulimia / BED with active purging — appetite-suppression mechanism contraindicated); active malignancy on therapy (clinician judgment with oncology co-management for the backbone; see hard contraindication implication for adjunct layers below).

Lean-mass adjunct relative exclusions per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §2.3: T2D with diabetic retinopathy (untreated proliferative DR escalates to hard contraindication; treated stable DR is relative exclusion); pre-T2D where GH-axis stimulation may push toward overt T2D; cancer-survivor status >5 years from treatment completion (relative exclusion with oncologist clearance per the 2022 consensus statement PMID 35319491; <5 years from treatment is hard contraindication); severe renal or hepatic impairment; OSA (CPAP-adherent OSA is relative exclusion with surveillance; severe untreated OSA is excluded); psychiatric adherence concern (multi-component reconstitution and timing requires reliable adherence — patients with active psychiatric instability are routed to backbone-only).

Visceral-fat adjunct relative exclusions per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §2.3: tesamorelin-specific relative exclusions include elevated baseline IGF-1; baseline glucose intolerance (tesamorelin may worsen glucose tolerance at the GH-axis level); active or recent acute pancreatitis (tesamorelin labeled cautionary use); proliferative diabetic retinopathy (relative exclusion with ophthalmology co-management). AOD-9604-specific relative exclusions are bounded by the limited evidence base — the relative exclusions are anchored to general peptide-injection cautions rather than to AOD-9604-specific signals.

Skin-laxity adjunct relative exclusions per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §2.3: copper-sensitivity (rare); concurrent high-dose oral copper supplementation (cumulative copper-load management); concurrent active skin infection at injection or application site (deferral until resolved).

Comprehensive-stack-level relative exclusion synthesis. If any single component is in relative exclusion, the clinician-judgment posture for that component applies; the other components may still proceed if their inclusion criteria are met. The comprehensive stack does not require all four layers — if three layers are appropriate and one is in relative exclusion with the clinician choosing to defer, the protocol operates as a 3-layer stack with the deferred layer documented and revisitable.

2.4 Hard contraindications — boxed warnings, labeled contraindications, and component-specific absolute exclusions

Hard contraindications are absolute at the component level. A hard contraindication to any single component eliminates that component from the comprehensive stack but does not necessarily eliminate the entire stack — if the eliminated component is not the load-bearing backbone, the remaining components may still be deployed.

Backbone-level hard contraindications per the GLP-1 RA component protocols and the class-wide GLP-1 RA boxed-warning framework:

Personal or family history of medullary thyroid carcinoma (MTC). FDA boxed warning class-wide for GLP-1 RAs. Absolute contraindication. Eliminates the entire backbone class; comprehensive stack is not initiated.
Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Same boxed warning. Absolute. Eliminates the backbone class.
Severe prior pancreatitis history (severe acute or chronic). Labeled cautionary use / contraindication per molecule label. Backbone-specific assessment.
Known serious hypersensitivity to the molecule or excipient. Labeled contraindication.
Pregnancy (for CWM indication). Labeled contraindication. Discontinuation trigger. Pre-conception planning per [[Semaglutide Protocol]] §8.4 or backbone-specific equivalent.

Lean-mass adjunct hard contraindications per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §2.4:

Active malignancy or <5 years from treatment completion. Absolute contraindication for GH-axis components per the 2022 consensus statement and the Renehan 2004 observational IGF-1-cancer-risk signal. Eliminates the CJC-Ipa layer; MOTS-c may be clinician-judgment-eligible (different mechanism class — AMPK / myostatin pathway, not GH-axis-direct).
Acromegaly or active pituitary tumor. Absolute. Eliminates GH-axis components.
Proliferative diabetic retinopathy. Absolute. Eliminates GH-axis components (IGF-1 elevation associated with DR progression).
MEN-2 / MTC (same as backbone-level).
Severe hypersensitivity to component.
Pregnancy or lactation.
Concurrent somatostatin analog therapy (mechanistic block of GH release).

Visceral-fat adjunct hard contraindications per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §2.4:

Tesamorelin labeled contraindications: active malignancy (Category X-equivalent caution per the GH/IGF-1 tumor-promotion concern); pregnancy (Category X per FDA label); known hypersensitivity to tesamorelin or excipient (e.g., mannitol); disrupted hypothalamic-pituitary axis (post-craniopharyngioma; post-hypophysectomy; pituitary radiation).
AOD-9604: no formal labeled contraindications (not FDA-approved as a drug); component-level cautions per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §2.4.

Skin-laxity adjunct hard contraindications per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §2.4:

Wilson’s disease (copper-overload disorder — absolute contraindication to copper-coordinated complex).
Severe hypersensitivity to GHK-Cu or excipient.
Pregnancy or lactation (relative-to-absolute per protocol §2.4; defer for the duration).
Active malignancy (per the cosmetic-adjunct relative-exclusion framing in the GHK-Cu protocol; for the comprehensive-stack patient, the lean-mass adjunct active-malignancy contraindication is more restrictive, so the comprehensive stack would already be modified).

Cross-component hard contraindication interactions. Several hard contraindications cross-cut multiple components:

Active malignancy. Hard contraindication for lean-mass adjunct (GH-axis components) and tesamorelin (Category X-equivalent caution). The backbone may continue per oncology co-management; the comprehensive stack collapses to backbone alone or backbone + GHK-Cu (the GHK-Cu cosmetic-adjunct framing accommodates active malignancy with oncologist clearance per the protocol’s §2.3).
Pregnancy or active conception. Hard contraindication for backbone (CWM-indication GLP-1 RAs) and for all adjuncts. Discontinuation of the entire stack with the pre-conception washout arithmetic per the backbone protocol (8-week label window for semaglutide and class-related compounds per the Wegovy / Ozempic label and per the 5-half-life pharmacokinetic clearance arithmetic). The comprehensive stack is not initiated within the pre-conception planning window.
Proliferative DR. Hard contraindication for lean-mass adjunct (GH-axis-IGF-1 progression concern) and for tesamorelin. Backbone may continue with ophthalmology surveillance.

The comprehensive-stack patient passes through a per-component contraindication screen at protocol entry; the screen output determines which components are eligible and which are not. A patient with no hard contraindications across all four layers is the canonical comprehensive-stack candidate; a patient with one or more hard contraindications has a modified-stack pathway (the eligible-component subset) or is routed to single-component therapy.

2.5 Worked example — selection criteria applied to the Profile A canonical patient

Continuing the §1.6 canonical patient (52-year-old female post-bariatric weight-regain, BMI 38.5, T2D HbA1c 7.4, post-menopausal, microalbuminuria, MASLD, OSA on CPAP).

Backbone-level inclusion screen. Adult age ≥18 (52 — yes). BMI ≥30 (38.5 — yes). For T2D + CWM with co-morbidity profile, the candidate backbones per [[Module 5 - Phenotype-Guided Decision Tree Protocol]] §4 (T2D status phenotype) and §11 (body-composition phenotype) include semaglutide (Wegovy 2.4 mg or Ozempic 1.0-2.0 mg), tirzepatide (Zepbound 15 mg or Mounjaro), retatrutide (investigational per status verification at iteration time), or CagriSema (investigational). For this patient, given the HbA1c 7.4 + UACR 45 + MASLD + CWM target, semaglutide 1.0-2.0 mg has the broadest indication coverage (SUSTAIN T2D + STEP CWM + SELECT-class CV-risk-reduction signal + FLOW CKD-in-T2D risk reduction + ESSENCE MASH potentially); tirzepatide has higher weight-loss magnitude (SURMOUNT-1 / SURMOUNT-5 head-to-head per [[Tirzepatide Protocol]]) and SURPASS-2 head-to-head HbA1c advantage; retatrutide has highest investigational magnitude. The §10.4 comparator conversation presents these factually to the patient.

Lean-mass adjunct inclusion screen. §1.4 triggers — age ≥50 (52 — yes); post-menopausal (yes); low baseline grip strength (22 kg — yes, sarcopenic-risk signal); high-target-weight-loss trajectory (50-60 lb target — yes); prior lean-mass loss history (post-gastric-bypass — yes). Trigger count: 5/6. Strong lean-mass adjunct indication match.

Visceral-fat adjunct inclusion screen. §1.4 trigger — baseline VAT 2,100 g (above 2,000 g VAT-dominance threshold — yes); insulin-resistant obesity (yes); MASLD (yes); android distribution (yes); metabolic-syndrome cluster (yes). Strong visceral-fat adjunct indication match. Stack-redundancy note — if backbone is retatrutide or survodutide (glucagon-receptor agonism), the tesamorelin add-on may be redundant per §9.4; if backbone is semaglutide or tirzepatide, the tesamorelin add-on retains its mechanism-additive value.

Skin-laxity adjunct inclusion screen. §1.4 anticipatory trigger — 50-60 lb target crosses the ~30 lb / ~13.6 kg laxity-onset threshold (yes); prior skin laxity history after gastric bypass (yes). Sequenced indication — GHK-Cu not initiated at protocol entry; initiated at the ~30 lb cumulative-loss milestone per §8 timing.

Hard contraindication screen. No MTC / MEN-2 personal or family history. No prior pancreatitis. No known hypersensitivity. Post-menopausal (pregnancy not applicable). No active malignancy. Up-to-date mammography (negative). No history of cancer treatment within 5 years. No acromegaly or pituitary tumor. No proliferative DR (last dilated exam 6 months ago — negative; clean for adjunct GH-axis layer; will refresh dilated exam at protocol entry for SUSTAIN-6-class-of-evidence retinopathy-rapid-improvement risk screening on the backbone). No active eating disorder. No severe hepatic / renal impairment. No Wilson’s disease. No concurrent somatostatin analog. All hard contraindication screens pass.

Relative exclusion screen. Microalbuminuria (UACR 45) — within the FLOW-anchored eGFR 25-75 range; clinician-judgment posture is enhanced surveillance, not exclusion. MASLD — clinician-judgment posture; semaglutide indication if F2-F3 fibrosis confirmed (FibroScan or biopsy would be the next workup step per §3 if F2-F3 indication is sought; for current MASLD with no documented fibrosis stage, the backbone choice does not depend on the MASH indication labeling). OSA on CPAP — CPAP-adherent OSA is relative exclusion with surveillance for the lean-mass adjunct (GH-axis-mediated soft-tissue effects can theoretically exacerbate OSA; CPAP-adherence is the mitigation). No psychiatric adherence concern. Relative exclusion screen — enhanced surveillance for MASLD, OSA, CKD; no exclusions.

Tier 1 foundation commitment. Discussed at consultation. Patient already does light cardio 3×/week; needs to add structured resistance training and assess protein intake. Pre-protocol intervention: 4-week Tier 1 foundation onboarding (nutritional consultation for protein targeting; resistance-training program initiation with personal trainer or physical therapist; vitamin D 25-OH-D check and supplementation if low; sleep adequacy review). Patient commits.

Informed-consent framing. Patient reviews and agrees to the §10.6 combined-off-label framing. Patient elects to proceed with semaglutide 2.4 mg backbone (broadest indication coverage given her comorbidity profile; semaglutide 2.0 mg for T2D coverage paired with Wegovy 2.4 mg framing per the patient’s specific T2D + CWM dual indication context — the §10.4 backbone comparator conversation walks through the semaglutide vs tirzepatide vs retatrutide tradeoffs and the patient elects semaglutide with the option to transition if non-response).

Selection outcome. Patient is a comprehensive-stack candidate. Stack composition: semaglutide backbone (Wegovy 2.4 mg titration; T2D management coordinated by endocrinologist with Ozempic 2.0 mg dosing rationale; in practice, the clinician’s choice may be one prescription Wegovy 2.4 mg for combined CWM + T2D management OR co-manage with endocrinology on separate Ozempic prescription — the §4 initiation discussion documents the practical regimen choice); lean-mass adjunct (CJC-Ipa+MOTS-c) layered in at the §5 timepoint per phasing rules; visceral-fat adjunct (Tesamorelin+AOD-9604) evaluated at the §7 timepoint per VAT-trajectory; skin-laxity adjunct (GHK-Cu) sequenced at the §8 timepoint per cumulative-loss milestone.

Pattern AA precision in §2.5. The backbone selection — semaglutide 2.4 mg for CWM (Wegovy label) co-managed with T2D management — uses the precise FDA-label framing. The patient’s specific T2D + CKD-in-T2D + MASLD profile aligns with the SUSTAIN / STEP / SELECT / FLOW / ESSENCE indication-coverage portfolio for semaglutide. The §10.4 patient-counseling beat presents the multi-dimensional comparator framing per Pattern Z calibration anchor 4.

Pattern V cross-check at §2.5. Each component-level inclusion / relative exclusion / hard contraindication screen invokes its component-protocol §2 anchors; no comprehensive-stack-level criterion is invented outside the component-protocol screening structure. The Tier 1 foundation commitment is anchored to [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §1.5 + §4.2; the body-composition baseline is anchored to the Module 5 Protocol Template §3.8 body-composition-baseline panel.

3. Pre-treatment workup (integrated panel)

3.1 Purpose

Define the pre-treatment laboratory, imaging, and clinical-assessment workup for the comprehensive stack. §3 is the operational handoff between §2 (selection criteria) and §4 (backbone initiation): a patient passing §2 enters §3 workup; only on workup completion does §4 dose initiation begin. For a multi-component stack, §3 is the integrated panel — the union of the component-protocol §3 panels with deduplication of overlapping items so the patient is not subjected to redundant lab orders.

The integrated panel is structured into eight functional sub-blocks corresponding to the Protocol Template §3 architecture plus comprehensive-stack-specific additions: standard metabolic; diabetes-specific (when T2D); MASH-specific (when MASH indication or risk profile); kidney-specific (when CKD or borderline kidney function); CV-risk-specific (when CVOT indication or ASCVD risk); organ-baseline (thyroid / pancreas / ophthalmology — class-wide for GLP-1 RAs and load-bearing for the GH-axis adjunct components); body-composition baseline (load-bearing for the lean-mass and visceral-fat adjuncts); and GH-axis-and-cancer-surveillance baseline (load-bearing for the lean-mass and visceral-fat adjuncts and for GHK-Cu copper-load surveillance).

Pattern W cross-section consistency: every lab listed in §3.2-§3.9 is reconciled with the §5 maintenance monitoring intervals (§5 cannot recommend a monitoring lab not established as a baseline lab in §3) and with the §6 AE management triggers (§6 cannot anchor an AE response to a lab not in the workup or monitoring panel).

3.2 Standard metabolic panel (Protocol Template §3.2; applies to every patient)

Comprehensive metabolic panel (CMP). Sodium, potassium, chloride, CO₂, BUN, creatinine, glucose, calcium, total protein, albumin, ALT, AST, alkaline phosphatase, total bilirubin. Hepatic / renal baseline for backbone class-wide GLP-1 RA precautions and for the GH-axis adjunct components.
Fasting lipid panel. Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, ApoB if available. Baseline for backbone CV-risk-indication considerations and for monitoring metabolic improvement on stack. Particularly load-bearing for tesamorelin (Falutz Phase 3 demonstrated triglyceride and lipid-marker improvement; one of the FDA-label-supporting endpoints).
Fasting glucose and HbA1c. Glycemic baseline. For T2D patients, anchors backbone choice and lean-mass adjunct GH-axis-glucose surveillance.
Fasting insulin (with HOMA-IR calculation). Insulin-resistance baseline. Load-bearing for visceral-fat adjunct indication (insulin-resistant obesity is the typical phenotype) and for lean-mass adjunct GH-axis-glucose surveillance.
Body weight, height, BMI, waist circumference. Anthropometric baseline. Waist circumference is the visceral-adiposity-distribution anchor that complements DEXA VAT.
Blood pressure (seated, two readings, standardized). CV-risk baseline; backbone GLP-1 RA SBP reduction is a documented secondary effect.

3.3 Diabetes-specific panel (when T2D indication or comorbidity)

Applies when the patient has T2D (whether as primary backbone indication or as comorbidity within CWM-primary indication).

HbA1c (above; standard panel).
Fasting C-peptide. Endogenous insulin reserve assessment. Distinguishes T2D from LADA from advanced beta-cell-failure T2D. Backbone choice context — patients with severely depleted C-peptide may need insulin co-management within the stack regimen.
GAD-65 antibodies and IA-2 antibodies if LADA suspected. Adult-onset diabetes with normal BMI, rapid progression, or atypical course.
Diabetes complication screen. Dilated retinal exam (also class-wide pre-treatment for GLP-1 RAs per §3.7 NAION pre-screen and SUSTAIN-6-class retinopathy-rapid-improvement signal; load-bearing for lean-mass adjunct GH-axis-DR contraindication screen); UACR (also kidney-specific panel §3.5; load-bearing for FLOW indication); monofilament / vibratory testing.
CGM data review if available. Time-in-range baseline; hypoglycemia frequency baseline. Relevant for §5 dose-adjustment if concurrent insulin or sulfonylurea.

3.4 MASH-specific panel (when MASH indication or MASH risk profile)

Applies when biopsy- or imaging-confirmed MASH is the primary backbone indication (semaglutide ESSENCE-anchored for F2-F3; backbone-specific for other compounds with MASH-program data) OR when baseline phenotype suggests MASH risk (T2D + obesity + elevated AST/ALT + waist circumference ≥102 cm men / ≥88 cm women) — the typical comprehensive-stack patient given the §1.4 phenotype trigger overlap.

AST, ALT, GGT, alkaline phosphatase, total and direct bilirubin. Hepatic-function baseline.
Platelet count. Component of FIB-4 calculation.
FIB-4 score. Non-invasive fibrosis stratification: low <1.3, indeterminate 1.3-2.67, high >2.67.
VCTE / FibroScan if FIB-4 indeterminate or high. Liver stiffness measurement (kPa) plus CAP for steatosis quantification.
Liver biopsy if biopsy-confirmed MASH indication is sought OR if alternative liver disease must be ruled out (rare in modern practice).
Hepatitis B surface antigen and Hepatitis C antibody. Rule out viral hepatitis.
Iron studies (ferritin, transferrin saturation). Rule out hereditary hemochromatosis; relevant for MASH context.
Autoimmune liver-disease screen if clinically indicated (ANA, anti-smooth muscle, anti-mitochondrial antibodies).

Comprehensive-stack-specific MASH considerations. The Stanley 2014 JAMA RCT (PMID 25038357) demonstrated tesamorelin reduced hepatic fat in HIV-associated MASLD; the off-label extrapolation to non-HIV MASH is a mechanism-rationale anchor for the visceral-fat adjunct in MASH-co-morbid patients. The comprehensive stack’s hepatic monitoring discipline carries hepatology co-management if F3 or worse fibrosis or if any liver-disease alternative is suspected.

3.5 Kidney-specific panel (when CKD indication or borderline baseline)

Applies when CKD-in-T2D is a backbone indication (FLOW-anchored semaglutide) or when baseline eGFR is 30-60 regardless of indication. For the comprehensive-stack patient with metabolic-syndrome cluster, kidney-specific panel is often indicated.

Serum creatinine, eGFR (above; CMP).
Cystatin C-based eGFR if creatinine-eGFR discordant. Particularly relevant for low-muscle-mass elderly patients.
Urine albumin-to-creatinine ratio (UACR). FLOW enrollment criterion is UACR 100-5000; backbone indication framing.
Urinalysis with microscopy. Rules out alternative kidney disease.
RAS blockade documentation. FLOW enrollment required maximally tolerated RAS blockade.
Serum bicarbonate, phosphorus, calcium, PTH if eGFR <60. CKD-MBD workup.

3.6 CV-risk-specific panel (when CVOT indication or ASCVD risk profile)

Applies when backbone CV-risk indication is sought (SUSTAIN-6 / SELECT-anchored semaglutide) or when baseline ASCVD risk profile is high.

ECG (12-lead). Baseline rhythm and conduction status.
High-sensitivity troponin if symptomatic baseline.
NT-proBNP or BNP if HFpEF-suspect (obesity + dyspnea + age ≥60).
Echocardiogram if HFpEF-suspect.
Carotid intima-media thickness or CAC score if practice workflow includes subclinical ASCVD assessment.

3.7 Organ-baseline panels (thyroid, pancreas, ophthalmology — class-wide for GLP-1 RAs + load-bearing for GH-axis adjuncts)

Class-wide pre-treatment workup for any GLP-1 RA protocol AND the load-bearing pre-treatment workup for the GH-axis adjunct components (CJC-Ipa+MOTS-c and tesamorelin).

Thyroid baseline. TSH at minimum; free T4 if TSH abnormal or if GH-axis adjunct is planned (untreated hypothyroidism blunts GH effect per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §3.4 and §7.4 worked example). Neck examination for thyroid nodules. If MTC / MEN-2 personal or family history is identified at this step → §2.4 hard contraindication; protocol does not initiate.
Pancreas baseline. Serum lipase, serum amylase (lipase more pancreas-specific). Triglycerides (hypertriglyceridemic pancreatitis context).
Ophthalmology — dilated retinal examination. Particularly for T2D patients per the §3.3 diabetes-complication-screen overlap and per the SUSTAIN-6 retinopathy-complication signal in rapid-HbA1c-improvement sub-population. Pre-treatment dilated exam for any T2D patient with HbA1c ≥9.0 or with known background DR is the protocol-recommended posture. Comprehensive-stack-specific addition — the lean-mass adjunct GH-axis-IGF-1 elevation is associated with DR progression risk; baseline DR status is a load-bearing dimension for the §1.4 lean-mass adjunct phenotype trigger evaluation and for the §2.4 hard contraindication screen.
NAION pre-screen (for semaglutide-specific NAION signal per Hathaway 2024 PMID 38958939). Post-marketing pharmacovigilance signal; not a labeled warning as of 2026-05-14; clinician-judgment includes pre-treatment screen for known optic-disc cupping (small or “disc-at-risk”), prior NAION, or unexplained visual symptoms. Pattern AA precision: post-marketing signal under evaluation, not labeled warning; §10 counseling beats frame as “signal under evaluation.”

3.8 Body-composition baseline (load-bearing for the comprehensive stack)

Body composition is the load-bearing baseline panel for the comprehensive stack because all four layers’ clinical endpoints depend on body-composition-tracked outcomes:

Dual-energy X-ray absorptiometry (DEXA) — preferred for the comprehensive-stack patient. Lean mass, fat mass, total mass, regional distribution, visceral adipose tissue (VAT) estimation via DEXA-VAT algorithm. DEXA-VAT is moderate-accuracy compared to abdominal MRI / CT but sufficient for the §1.4 visceral-fat adjunct phenotype trigger and for the §7 trajectory monitoring. BIA is acceptable if DEXA is not accessible but is less accurate for the comprehensive-stack-relevant metrics.
Abdominal MRI or CT for VAT quantification. Preferred if visceral-fat adjunct is anticipated as a load-bearing layer per §1.4 trigger; MRI is preferred over CT (no radiation; superior visceral-fat discrimination). The Falutz Phase 3 program used CT VAT measurement; the Stanley 2014 JAMA RCT used proton magnetic resonance spectroscopy for hepatic fat plus MRI for VAT. For the comprehensive-stack patient where Tesamorelin+AOD-9604 is anticipated, MRI VAT at baseline is the load-bearing imaging anchor.
Hand-grip strength (HGS) and 5-time sit-to-stand (5-STS). Functional measures per the EWGSOP2 / AWGS sarcopenia operational definitions (Cruz-Jentoft 2019 PMID 30312372; Chen 2020 PMID 32033882). Both anchored at baseline for the lean-mass adjunct trigger and ongoing monitoring.
Resting energy expenditure (REE) by indirect calorimetry if practice-equipped. Energy-expenditure phenotype baseline; relevant for the adaptive-thermogenesis-prone phenotype (post-prior-weight-loss patients like the Profile A canonical patient).
Standardized photographic baseline for the post-weight-loss skin-laxity assessment, sequenced for GHK-Cu indication at §8 trigger timepoint. Photographic protocol per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §3.5: standardized lighting, standardized positions (anterior / lateral / posterior), standardized distance, anatomical regions of concern (abdomen, upper arms, thighs, breasts / chest, posterior). The photographic baseline can be performed at protocol entry even though GHK-Cu is sequenced for later initiation — having a true protocol-entry photographic baseline enables before-and-after comparison across the full weight-loss arc, not just the GHK-Cu treatment window.

3.9 GH-axis-and-cancer-surveillance baseline (load-bearing for lean-mass and visceral-fat adjuncts)

Load-bearing for the lean-mass adjunct (GH-axis activation; IGF-1-cancer-risk literature surveillance) and for the visceral-fat adjunct (tesamorelin GH-axis activation; IGF-1 elevation as biomarker of activity). Per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §3.4 + §3.5 and per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §3.4 + §3.5:

IGF-1 (with age-and-sex-specific Z-score calculation). GH-axis baseline; load-bearing on-protocol monitoring lab. The Z-score normalization is critical because absolute IGF-1 reference ranges vary widely by age and sex. Comprehensive-stack target is mid-reference (Z-score 0 to +0.5) at baseline; upper-quartile-of-reference (Z-score 0 to +1) on-stack target during cycles.
Free T4 (in addition to TSH from §3.7). Hypothyroidism blunts GH effect and is a §7.4 lean-mass adjunct non-responder algorithm consideration.
Cortisol baseline (morning AM). Cortisol excess (Cushing’s syndrome or exogenous glucocorticoid exposure) blunts GH effect and may produce overlapping body-composition findings.
Prolactin. Pituitary baseline; abnormal value triggers pituitary workup before GH-axis adjunct initiation.
PSA (men ≥40). Cancer-surveillance baseline per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §3.4 and per the Renehan 2004 IGF-1-prostate-cancer observational association (PMID 15110491). Carried forward as on-protocol annual surveillance.
Up-to-date mammography (women ≥40 per standard screening intervals). Cancer-surveillance baseline per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §3.4 and per the Renehan 2004 IGF-1-premenopausal-breast-cancer observational association. Carried forward as on-protocol screening per standard intervals.
Family-history cancer-context documentation. First-degree family history of hormone-sensitive cancers (breast, prostate, endometrial) anchors the §10.6 patient-specific risk-benefit weighing.
Pap / cervical screen up-to-date (women). Standard cancer screening.
Colorectal cancer screening up-to-date (age-appropriate). Standard cancer screening.

Pattern AB.1 attribution discipline applied to §3.9. The IGF-1 cancer-risk literature carries two opposing signal pillars (Renehan 2004 observational association vs Child 2022 HypoCCS cohort SIR 0.92 vs Boguszewski 2022 consensus statement). The protocol’s surveillance discipline (upper-quartile-of-reference IGF-1 target; annual PSA / mammography on-stack) is the practitioner-consensus posture that integrates both signal pillars. Pattern AA precision: this is a clinician-judgment-within-practitioner-consensus surveillance posture, not FDA-label-mandated.

3.10 Copper-load surveillance baseline (for the skin-laxity adjunct layer)

Per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §3.6 + §3.7: copper-load surveillance baseline for the GHK-Cu component. Sequenced — these labs are obtained at protocol entry if GHK-Cu is anticipated, or at the §8 trigger timepoint when GHK-Cu is initiated.

Serum copper. Baseline copper status; rules out Wilson’s disease (§2.4 absolute contraindication) and rules out occult copper-deficiency.
Ceruloplasmin. Rules out Wilson’s disease (low ceruloplasmin) and provides functional copper-transport baseline.
24-hour urine copper if Wilson’s disease is suspected on clinical grounds. Standard Wilson’s-disease workup.
Concurrent copper-supplement reconciliation. Multivitamin RDA-level copper is compatible; high-dose oral copper supplementation (>2 mg/day elemental) is a §9.4 spacing-management consideration.

3.11 Worked example — pre-treatment workup for the §1.6 canonical patient

Continuing the Profile A canonical patient (52-year-old female, BMI 38.5, T2D HbA1c 7.4, post-menopausal, microalbuminuria, MASLD, OSA on CPAP, VAT 2,100 g, baseline DEXA at clinical-pathway entry already completed).

Standard metabolic panel. CMP, fasting lipid panel, fasting glucose and HbA1c, fasting insulin with HOMA-IR, weight / BMI / waist circumference, BP.

Diabetes-specific panel. HbA1c (above; current 7.4), fasting C-peptide (to confirm preserved beta-cell reserve), UACR (above; current 45 mg/g — microalbuminuria, FLOW-anchored CKD-in-T2D consideration), dilated retinal exam (refresh — last 6 months ago negative; given backbone semaglutide planned with rapid-HbA1c-improvement risk for SUSTAIN-6-class signal, repeat dilated exam at protocol entry as enhanced surveillance), monofilament / vibratory testing.

MASH-specific panel. AST, ALT, GGT, alk phos, bilirubin, platelet count, FIB-4 calculation, VCTE / FibroScan (last hepatology note documented MASLD without confirmed fibrosis stage — order VCTE for FIB-4 indeterminate-to-high or for staging confirmation; if F2-F3 confirmed, the semaglutide MASH indication per ESSENCE adds to the backbone’s indication portfolio). Viral hepatitis screen, iron studies, autoimmune liver-disease screen at clinician judgment.

Kidney-specific panel. Serum creatinine, eGFR (current eGFR 78), UACR (above; 45 mg/g — microalbuminuria within FLOW range), urinalysis with microscopy, RAS blockade documentation (patient on lisinopril 20 mg — RAS-blockade at clinician-assessed maximally-tolerated dose; nephrology consultation if uncertain about further uptitration of RAS-blockade).

CV-risk-specific panel. ECG baseline; NT-proBNP given OSA + obesity + age ≥50 — clinician judgment; echocardiogram if HFpEF-suspect on NT-proBNP elevation. CAC score per practice workflow.

Organ-baseline panels. TSH + free T4 (load-bearing for GH-axis adjunct); pancreas baseline (lipase, amylase, triglycerides); ophthalmology dilated exam (above; refresh).

Body-composition baseline. DEXA (current; lean mass 49 kg, fat mass 50 kg, VAT 2,100 g via DEXA-VAT). For the visceral-fat adjunct layer anticipated, abdominal MRI VAT quantification at the §7 trigger timepoint (not at protocol entry — DEXA-VAT is adequate for the §1.4 trigger evaluation; MRI VAT is the higher-resolution monitoring anchor at the visceral-fat adjunct phase). Hand-grip strength 22 kg (above; sarcopenic-risk signal), 5-STS 14 seconds (above; mildly impaired). REE by indirect calorimetry if practice-equipped — adaptive-thermogenesis-prone phenotype given prior gastric-bypass and post-loss history. Photographic baseline obtained (anterior / lateral / posterior; abdomen, upper arms, thighs, breasts, posterior — patient consents to photographic documentation).

GH-axis-and-cancer-surveillance baseline. IGF-1 (Z-score interpretation for age 52 female; need result), free T4 (above), cortisol AM, prolactin, mammography (above; up-to-date negative), Pap (up-to-date), colonoscopy (up-to-date or scheduled per age 50+ screening). Family-history documentation: paternal grandmother breast cancer at age 78 (low-risk by family-history category; not Lynch / BRCA-suggestive); maternal aunt thyroid cancer (papillary; not MTC; not MEN-2). PSA not applicable (female).

Copper-load surveillance baseline. Sequenced — obtained at the §8 GHK-Cu trigger timepoint (when patient reaches the ~30 lb / ~13.6 kg cumulative-loss milestone or transitions to GLP-1 maintenance phase).

Workup completion. The integrated panel above is ordered at the §3 workup visit. Results review at the next visit (typically 1-2 weeks later) before §4 backbone initiation. Any abnormal findings (e.g., FIB-4 high triggering VCTE confirmation; UACR rising above 100 triggering nephrology referral; IGF-1 baseline above upper-quartile-of-reference triggering pituitary workup before GH-axis adjunct planning) are addressed before initiation.

Pattern W cross-check applied to §3.11. Every lab and imaging modality in the worked-example panel above is reconciled with §5 maintenance monitoring intervals (§5 documents which labs repeat at quarterly, biannual, or annual cadences) and with §6 AE-trigger labs (§6 documents the trigger thresholds for dose adjustment or layer-discontinuation). No lab is introduced in §5 or §6 without baseline anchor in §3.

Pattern AA precision in §3.11. The dilated retinal exam frequency (current per 6 months; refresh at protocol entry; ongoing per the SUSTAIN-6 rapid-improvement signal posture and per the GH-axis adjunct DR-progression-risk posture) is clinician-judgment-within-label for the backbone and clinician-judgment-within-practitioner-consensus for the GH-axis adjunct. The FIB-4 + VCTE pathway for MASH staging is clinician-judgment standard-of-care, not FDA-label-mandated for non-MASH-indication-specific use.

4. Initiation protocol (backbone-only; Months 0-4)

4.1 Purpose

Define the comprehensive-stack initiation — which is ONLY the backbone titration during Months 0-4. The lean-mass adjunct, visceral-fat adjunct, and skin-laxity adjunct are NOT initiated in §4. They are layered in at the §5, §7, and §8 phasing timepoints respectively. The §4 phasing decision is the most distinctive structural feature of this comprehensive-stack protocol relative to the single-compound protocols: §4 is intentionally narrower than the patient’s eventual full regimen because the backbone titration must complete before adjunct layering, and because the body-composition trajectory on the backbone-alone period is the data input for the §5 adjunct-layer-in decision.

§4 is the time-sequenced action plan from Day 0 (first backbone dose) through approximately Week 16-20 (target-dose attainment for the backbone). The lean-mass adjunct layer-in decision is made at the Week 12-16 timepoint based on the Month 3 DEXA (per §5 logic); the actual lean-mass adjunct initiation typically falls at Month 4-6 after the backbone target-dose attainment and the Month 3 DEXA review.

Pattern Z calibration anchor 4 (multi-dimensional comparator framing) and anchor 5 (off-label / extrapolation transparency) are both load-bearing in §4: the backbone-choice comparator conversation is anchor 4; the combined-regimen off-label framing introduced at the initiation conversation is anchor 5. §10.4 and §10.6 carry the corresponding patient-counseling beats.

4.2 Backbone starting dose and titration

Backbone starting dose and titration follow the backbone’s own initiation protocol. The comprehensive-stack protocol does not modify the backbone titration schedule.

Semaglutide CWM (Wegovy 2.4 mg target): Starting dose 0.25 mg SC weekly per [[Semaglutide Protocol]] §4. Standard titration over 16 weeks: 0.25 mg weeks 1-4, 0.5 mg weeks 5-8, 1.0 mg weeks 9-12, 1.7 mg weeks 13-16, 2.4 mg week 17 onward. Slow-titration option doubles each interval (32 weeks to target).
Semaglutide T2D (Ozempic 1.0 or 2.0 mg target): Starting 0.25 mg per [[Semaglutide Protocol]] §4 with target-dose-specific titration.
Tirzepatide CWM (Zepbound 15 mg target): Starting 2.5 mg weekly per [[Tirzepatide Protocol]] §4. Standard titration to 15 mg over 20 weeks.
Tirzepatide T2D (Mounjaro): Per [[Tirzepatide Protocol]] §4 with target-dose context.
Retatrutide (investigational; TRIUMPH program): Per [[Retatrutide Protocol]] §4 with the current investigational dosing per program status.
Survodutide (investigational): Per [[Survodutide Protocol]] §4.
CagriSema (investigational): Per [[CagriSema Protocol]] §4.
IcoSema (investigational): Per [[IcoSema Protocol]] §4.
Liraglutide CWM (Saxenda 3.0 mg target): Per [[Liraglutide Protocol]] §4. Daily SC titration.
Cagrilintide (investigational monotherapy): Per [[Cagrilintide Protocol]] §4.
Orforglipron (investigational oral GLP-1 RA): Per [[Orforglipron Protocol]] §4. Oral daily — not an injectable; the comprehensive-stack injection-burden picture is modified accordingly (one less daily / weekly SC injection in the regimen).

4.3 GI tolerability management at each titration step

The comprehensive-stack does not modify the backbone GI tolerability management. The GLP-1 RA-class GI AE profile (nausea, vomiting, diarrhea, constipation, eructation, abdominal pain; peak-at-dose-escalation; attenuates within 2-4 weeks at stable dose) and the corresponding management algorithm (non-pharmacologic first — meal-size reduction, slow eating pace, low-fat composition, hydration; pharmacologic second — ondansetron 4 mg PRN; loperamide for diarrhea; polyethylene glycol for constipation; slow-titration if persistent moderate-severity) is per the backbone protocol.

Comprehensive-stack-specific consideration: the §4 backbone-titration period is also the Tier 1 foundation onboarding period. The patient is initiating resistance training, protein targeting, sleep optimization, and vitamin D supplementation in parallel with the backbone titration. The clinician communicates that this is a coordinated 4-month onboarding — the body-composition baseline established at §3, the Tier 1 foundation established at this phase, and the backbone target-dose attainment all converge at the Month 4 timepoint when the §5 maintenance phase begins.

4.4 Early monitoring cadence — comprehensive-stack-specific additions

The early-monitoring cadence layers the backbone-protocol cadence with comprehensive-stack-specific data collection:

Week 2. Post-first-dose backbone tolerability check (telehealth or message). Tier 1 foundation initiation check (resistance training started; protein-targeting strategy clarified; vitamin D supplementation initiated if low).
Week 4-6. First titration step tolerability (in-person or telehealth with weight and BP). Tier 1 foundation progress check (resistance-training adherence; protein-intake adherence assessment via food log or 24-hour recall).
Week 8-12. Mid-titration tolerability check (weight + BP + tolerability + adherence). Tier 1 foundation reinforcement. Comprehensive-stack-specific addition — early DEXA at Week 12 if practical (one DEXA cycle from baseline). The Week 12 DEXA is not typically used for the lean-mass adjunct layer-in decision (the backbone is not yet at target dose — the body-composition trajectory is incomplete) but provides an interim data point.
Week 16-20. Target-dose attainment confirmation (backbone-specific timing per the §4.2 titration schedule). Weight, BP, indication-specific labs per the backbone protocol. Comprehensive-stack-specific addition — Month 4 DEXA repeat (the load-bearing post-titration body-composition data point). HbA1c repeat if T2D context. IGF-1 baseline refresh if planned for lean-mass adjunct layer-in at §5 timepoint (so the §5 layer-in pre-adjunct IGF-1 is current).

4.5 Backbone initiation conversation — Pattern Z calibration

The §10.2 backbone initiation conversation is the load-bearing patient-counseling moment for §4. Required counseling beats per the Protocol Template §10.2:

What the backbone is (Anchor 1): name, class, mechanism in plain language.
What it does for the patient’s indication (Anchor 1, Anchor 4): expected effect-size with trial-anchor precision; comparator framing (semaglutide vs tirzepatide vs retatrutide vs others per the patient’s phenotype and the §10.4 multi-dimensional fact presentation).
The titration schedule (§4.2): standard pace and slow-titration option.
The AE profile expected at each titration step (§4.3): nausea anticipated, typically attenuates, management strategies.
The pre-conception planning beat for reproductive-age patients (Anchor 3): pharmacokinetic washout arithmetic; the 8-week label window; post-discontinuation weight-regain trajectory; re-initiation pathway. Per [[Semaglutide Protocol]] §8.4 or backbone-specific equivalent.
Cost / access realities (Anchor 2): compounded vs FDA-approved for the backbone, with the §10.3 compounded-vs-FDA-approved counseling beat for backbones where compounded options exist.
The comprehensive-stack roadmap — comprehensive-stack-specific addition. The patient is informed that the §4 initiation is the backbone-only phase, that the lean-mass adjunct, visceral-fat adjunct, and skin-laxity adjunct are sequenced for later phases per §5, §7, §8 timing, and that the Month 4 DEXA review is the load-bearing decision point for the lean-mass adjunct layer-in.
Escalation pathway (the symptoms that warrant in-person evaluation within 48 hours): severe persistent abdominal pain, vomiting with severe abdominal pain, acute vision change, signs of severe AE.

4.6 Worked example — §1.6 canonical patient backbone initiation

Continuing the Profile A canonical patient. Backbone selection: semaglutide (Wegovy 2.4 mg for CWM with co-management of T2D — patient and clinician elect this rather than tirzepatide given the broader indication coverage including potential MASH if F2-F3 confirmed on VCTE, the CKD-in-T2D consideration given UACR 45, and the patient’s articulated comfort with semaglutide based on conversation with her endocrinologist; the §10.4 comparator framing presented tirzepatide’s higher weight-loss magnitude and retatrutide’s higher investigational magnitude as legitimate alternatives that the patient could elect to transition to in §7 if response is insufficient).

Standard titration schedule (Wegovy 2.4 mg).

Week 1-4: Wegovy 0.25 mg SC weekly. First dose at clinic with technique training (patient has prior insulin-injection experience but the GLP-1 RA pre-filled pen is new technique — clinician demonstrates and observes first self-administration). Week 2 telehealth check: mild nausea Days 1-3 post-injection, self-resolved; no vomiting; appetite suppression mild; weight stable. Tier 1 foundation onboarding: patient initiated resistance training 2×/week with personal trainer; protein-targeting via 24-hour recall shows current intake ~0.9 g/kg — clinician sets target 1.4 g/kg via protein-portion guidance and protein-shake-adjunct discussion. Vitamin D 25-OH-D check at §3 workup was 28 ng/mL (suboptimal but not deficient; supplementation 2000 IU daily initiated).
Week 5-8: Wegovy 0.5 mg SC weekly. Week 5-6 in-person visit: weight down 4 lb (1.8 kg); BP 138/86 (mild reduction from baseline 142/88); nausea recurs at first 0.5 mg dose, moderate Days 1-2, manageable with meal-size reduction and one PRN ondansetron 4 mg; otherwise tolerating well. Tier 1 foundation reinforcement: resistance training continued 2×/week; protein intake now ~1.2 g/kg per follow-up 24-hour recall; vitamin D supplementation continued.
Week 9-12: Wegovy 1.0 mg SC weekly. Week 9-10 telehealth check: weight down 9 lb total (4.1 kg); nausea pattern continues with each titration step but attenuates within ~5 days; appetite suppression now noticeable in patient’s everyday eating (smaller portions easily satisfying); Tier 1 foundation: resistance training increased to 3×/week per personal trainer’s progression; protein intake stable at 1.2-1.4 g/kg; CPAP adherence maintained; sleep duration adequate (7.5 hours nightly).
Week 12 interim DEXA: total lean mass 47.5 kg (down 1.5 kg from baseline 49); total fat mass 46 kg (down 4 kg from baseline 50); VAT 1,920 g (down ~180 g from baseline 2,100). Total weight loss 5.5 kg (12 lb); lean-mass-loss fraction at this interim point is ~27% of total weight loss — within the typical 20-32% Phase-3-pooled range but trending toward the upper end. Not yet at target backbone dose; not yet a definitive lean-mass adjunct trigger but signaling the trajectory.
Week 13-16: Wegovy 1.7 mg SC weekly. Continued tolerability per pattern. Eructation (“sulfur burps”) emerges as a new mild AE at 1.7 mg dose; reassurance and food-pairing adjustments. Constipation pattern emerges; PEG laxative as needed.
Week 17-20: Wegovy 2.4 mg SC weekly (target dose). Month 4 timepoint per the comprehensive-stack §5 layer-in decision is at this phase. Month 4 DEXA at Week 18: total lean mass 46.5 kg (down 2.5 kg from baseline; lean-mass-loss fraction of total weight loss = 2.5 / 11.5 = 22% — actually within the typical Phase-3-pooled range now; the Week 12 trajectory was a partial-data interim signal that has settled toward the typical range at full target dose). VAT 1,820 g (down ~280 g from baseline). Grip strength 22 kg (stable from baseline). 5-STS 13.5 seconds (mildly improved from baseline 14).

Month 4 review and §5 layer-in decision.

The Month 4 DEXA shows lean-mass-loss fraction of ~22% — within Phase-3-pooled-typical, not yet meeting the >30% trigger threshold per the lean-mass adjunct §1.4 documented-elevated-loss-fraction trigger. However, the patient’s §1.4 anticipatory trigger profile remains strong: post-menopausal, ≥50 age, low baseline grip strength (22 kg sarcopenic-risk signal), prior lean-mass loss history. The clinician and patient discuss the §5 layer-in decision per Pattern Z calibration anchor 4 (multi-dimensional comparator):

Option A — Continue Tier 1 foundation alone; reassess at Month 7 DEXA. The current lean-mass-loss fraction is within Phase-3-pooled typical; the foundation may be adequate to keep the trajectory in that range across the rest of the active-weight-loss arc.
Option B — Initiate lean-mass adjunct at Month 4 per the §1.4 anticipatory-trigger profile despite the lean-mass-loss fraction being within typical range. The post-menopausal phenotype + low baseline grip strength is the most-at-risk subpopulation per the Mozaffarian 2025 multi-society advisory (PMID 40445127); the practitioner-observation expectation is that adding the adjunct will reduce the trajectory toward the ~15-20% practitioner-observation target.
Option C — Continue current trajectory through Month 7; if Month 7 DEXA shows lean-mass-loss fraction trending above 25%, initiate lean-mass adjunct at that timepoint. This is the partial-trigger-pathway option.

Patient elects Option B with clinician concurrence — the anticipatory trigger profile is strong enough to support layer-in at Month 4 rather than waiting for documented elevated loss fraction to emerge.

Pattern V applied to §4.6. The Phase-3-pooled lean-mass-loss-fraction range (~20-32% per Look 2025 PMID 39996356; Beavers 2025 PMID 39996356) is Tier 1 evidence; the practitioner-observation expectation on stack (~15-20% target in adherent patients) is Tier 3 / practitioner-experience evidence per the lean-mass adjunct protocol §10.6 framing. The §5 layer-in decision is anchored at that resolution; counseling does not promise the practitioner-observation effect-size but discusses it as the achievable target in adherent patients.

Pattern AA applied to §4.6. The Wegovy titration is FDA-label-recommended. The Tier 1 foundation interventions (resistance training, protein, vitamin D, sleep) are evidence-based recommendations without regulatory-claim implications. The Month 4 decision to layer in the lean-mass adjunct is clinician-judgment-within-practitioner-consensus for the un-labeled CJC-Ipa+MOTS-c regimen — the combined-stack-as-integrated-regimen is off-label, as is the lean-mass adjunct itself; the §10.6 patient-counseling beat carries this framing explicitly.

Pattern Z calibration anchor 5 applied to §4.6. The off-label / extrapolation framing for the lean-mass adjunct layer-in is explicit at the Month 4 conversation. Patient is informed: “The CJC-1295 + Ipamorelin + MOTS-c stack is not FDA-approved for any indication — these are research peptides accessed through 503A compounding. The evidence base is mechanism rationale plus the human PK/PD literature for CJC-Ipa plus practitioner-experience for the combined stack in lean-mass-preservation context. There is no Phase 3 RCT of this regimen. The combined regimen as we are discussing — adding this to your semaglutide and your Tier 1 foundation — is off-label clinical-judgment integration. We’ve documented the rationale based on your phenotype profile, and we’ll track the outcome objectively at the Month 7 DEXA. If it’s working, we continue; if it’s not, we discontinue and continue your Tier 1 foundation.”

5. Maintenance protocol + lean-mass adjunct layer-in (Months 4-9)

5.1 Purpose

Define the post-titration backbone-maintenance phase + the lean-mass adjunct layer-in phase. §5 spans Months 4-9 of the comprehensive-stack program: Month 4 is the backbone target-dose attainment + lean-mass adjunct decision; Months 4-9 is the first lean-mass adjunct cycle (12-16 weeks) plus the first cycle washout (4-8 weeks). The visceral-fat adjunct layer-in trigger is evaluated at the §7 phasing timepoint, typically Month 6-9; the skin-laxity adjunct trigger is evaluated at the §8 phasing timepoint, typically Month 6-12 or later.

§5 is the longest operational phase of the comprehensive stack during which the backbone is at target dose, the lean-mass adjunct is in its first cycle, and the patient is in the active-weight-loss arc with the body-composition outcome data accumulating for the §7 and §8 phasing decisions.

5.2 Target backbone dose

Backbone target dose per the backbone protocol. For semaglutide CWM: 2.4 mg SC weekly (Wegovy); for semaglutide T2D: 1.0 or 2.0 mg SC weekly (Ozempic). For tirzepatide CWM: 5, 10, or 15 mg SC weekly (Zepbound — target dose patient- and tolerability-determined); for tirzepatide T2D: per [[Tirzepatide Protocol]] §5. For retatrutide / survodutide / CagriSema / IcoSema / orforglipron / cagrilintide / liraglutide: per backbone protocol §5.

The comprehensive stack does not modify the backbone target-dose framework. The backbone remains the load-bearing weight-loss-driving component; its target dose is determined by the backbone protocol.

5.3 Lean-mass adjunct layer-in dosing — practitioner-consensus per `[[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]]` §4-§5

The lean-mass adjunct doses are the practitioner-consensus protocol doses per the component protocol:

CJC-1295 (Mod-GRF 1-29): 100 mcg SC bedtime, 5 days on / 2 days off, 12-16 week cycles with 4-8 week washout. Reconstituted with bacteriostatic water per compounding-pharmacy protocol. Combined with Ipamorelin in same syringe.
Ipamorelin: 200 mcg SC bedtime, combined with CJC-1295 in same syringe.
MOTS-c: 5-10 mg SC AM, 3×/week (standard schedule) or 10 mg once weekly (pulse-dose alternative); 4 weeks on / 4 weeks off cycling within the broader 12-16 week stack-cycle window.

Practical injection schedule at peak Month 4-9 overlap. Patient is now managing: 1 weekly Wegovy 2.4 mg SC (e.g., Sunday morning), 5 CJC-Ipa SC injections bedtime (e.g., Monday through Friday, off Saturday-Sunday), and 3 MOTS-c SC injections AM (e.g., Monday / Wednesday / Friday or daily-cycling-equivalent). At peak overlap, this is approximately 9 SC injections per week (1 Wegovy + 5 CJC-Ipa + 3 MOTS-c). The §10.7 logistics conversation is honest about this regimen — it is not minimized as “just a few extra injections” but is presented factually as the practical day-to-day commitment, with the Pattern Z.injection-framing posture that each individual injection is a routine clinical skill but the cumulative regimen requires sustained adherence discipline.

5.4 Monitoring intervals — integrated panel for §5 maintenance + adjunct cycle

The §5 monitoring panel is the deduplicated union of the backbone maintenance panel and the lean-mass adjunct cycle monitoring panel. The integrated cadence:

Month 4 (backbone target-dose attainment + lean-mass adjunct initiation). DEXA (load-bearing — already obtained at §4.6 Week 18; serves as both backbone post-titration body-composition and as pre-adjunct lean-mass adjunct baseline). HbA1c (T2D context). Lipid panel. UACR (FLOW-anchored). IGF-1 baseline refresh (pre-adjunct; load-bearing for the §6 IGF-1 surveillance discipline). Backbone monitoring labs per the backbone protocol §5.
Month 5 (Week 4 of adjunct cycle 1). Tolerability check (lean-mass adjunct injection-site, sleep-disturbance, flu-like / cytokine pattern, fluid-retention, carpal-tunnel, glucose-tolerance per the §6 AE class algorithms). Adherence verification. No labs at this interval (early-cycle).
Month 6 (Week 8 of adjunct cycle 1). First mid-cycle adjunct monitoring labs: IGF-1 (target Z-score 0 to +1 — upper-quartile-of-reference, not supraphysiologic); fasting glucose and HbA1c (verify no reversal of backbone-driven improving trajectory); fasting insulin. Backbone weight and BP. Lean-mass adjunct §6.7 + §6.10 thresholds applied: if HbA1c rises >0.3 percentage points from pre-adjunct baseline → §6.7 dose-adjustment trigger; if IGF-1 exceeds upper limit of age/sex reference range → §6.10.1 dose-reduction trigger. §7 visceral-fat adjunct layer-in trigger evaluation begins (§7 logic applied).
Month 7 (Week 12-16 of adjunct cycle 1; end of first cycle). Comprehensive reassessment. DEXA (load-bearing — the lean-mass-loss-fraction trajectory comparison: pre-adjunct Month 4 DEXA → post-adjunct-cycle-1 Month 7 DEXA). Functional measures (grip strength, 5-STS). IGF-1. Fasting glucose, HbA1c, fasting insulin. Backbone monitoring labs. Cycle 1 continuation / inter-cycle decision per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §5.5: continue Cycle 2 (continued active weight-loss phase with lean-mass concern); discontinue stack (lean-mass goal achieved; GLP-1 transitioning to maintenance; patient preference); modify dose or schedule. Visceral-fat adjunct layer-in decision finalized per §7.
Months 7.5-8.5 (cycle 1 washout, 4-8 weeks). Tier 1 foundation continues during washout. Backbone continues at target dose. No adjunct dosing.
Month 9 (Cycle 2 initiation if elected, OR end of cycle 1 washout if discontinuing). DEXA repeat. Functional measures. IGF-1, glucose, HbA1c. Cycle 2 initiation per Cycle 1 dosing pattern, or discontinuation of lean-mass adjunct entering the backbone-plus-Tier-1-alone phase.

5.5 Dose-adjustment triggers — across components

The §5 dose-adjustment triggers are component-specific but inter-component-aware. For the backbone: per the backbone protocol §5.4 (target-not-met, target-overshoot, AE-emergent). For the lean-mass adjunct: per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §5.4 (IGF-1 above reference range; fasting glucose or HbA1c trajectory reversal; body-composition trajectory flat; AE-emergent; patient preference).

Cross-component dose-adjustment scenarios:

Glucose-tolerance worsening at Month 6 mid-cycle adjunct monitoring. If HbA1c rises >0.3 percentage points from pre-adjunct baseline on backbone trajectory, the directional source is most likely the GH-axis component of the adjunct (CJC-Ipa) rather than the backbone (the backbone is driving glucose improvement). Lean-mass adjunct §6.7 management applies: reduce CJC-1295 dose or hold the GH-axis component temporarily while continuing MOTS-c. Backbone is not modified.
Backbone GI AE persistence at Month 5. The lean-mass adjunct can have GI AEs (MOTS-c flu-like / cytokine pattern at initiation) but these are distinct from backbone GI AEs in pattern and timing. Persistent backbone-attributable GI AEs trigger backbone-protocol §6 management (ondansetron, meal-size reinforcement, slow-titration); the lean-mass adjunct continues unless its own §6 thresholds are met.
Backbone non-response trigger at Month 4-6 (weight loss <5% at Month 6 on target backbone dose with documented adherence). Backbone non-response transitions to §7 algorithm per the backbone protocol; the lean-mass adjunct decision becomes whether to continue the adjunct on a non-responder backbone (typically no — if the backbone is not driving meaningful weight loss, the body-composition outcome is dominated by the backbone-related sub-clinical changes; the lean-mass adjunct’s clinical question is about composition of weight loss, which presupposes meaningful weight loss is occurring). §7 algorithm directs whether to transition to a higher-effect backbone (tirzepatide → retatrutide trajectory) or to discontinue altogether.

5.6 Worked example — §1.6 canonical patient through Month 9

Continuing the Profile A canonical patient. Backbone Wegovy 2.4 mg target dose attained at Week 17. Lean-mass adjunct (CJC-Ipa+MOTS-c) initiated at Month 4 per §4.6 election.

Month 4 — adjunct initiation. Patient receives reconstitution training for CJC-1295 + Ipamorelin combined-syringe bedtime dosing and for MOTS-c morning dosing. First adjunct doses Week 18-19 (timed to follow the backbone target-dose-attainment confirmation visit). Tier 1 foundation continues at established cadence (resistance training 3×/week; protein 1.2-1.4 g/kg; vitamin D supplementation; sleep adequate).

Month 5 — Week 4 of adjunct cycle 1. Tolerability check telehealth visit. CJC-Ipa: mild flushing at injection site Days 1-3; mild fluid-retention pattern Week 2 (rings tighter; weight scale shows 1-lb upward shift against the underlying weight-loss trajectory — patient counseled per §6.4 anticipatory framing that this typically attenuates within 2-4 weeks); no head-rush. MOTS-c: brief mild flu-like pattern Days 5-7 of initial week with mild myalgia and low-grade fatigue, resolved by Day 10 — per §6.3 anticipatory framing; no escalation. No sleep disturbance from bedtime CJC-Ipa; no carpal-tunnel symptoms; no glucose-symptom changes (polyuria / polydipsia / unexplained fatigue all negative). Adherence: 100% of CJC-Ipa and MOTS-c doses. Backbone Wegovy continues weekly. Weight down to 195 lb (88.5 kg; total loss 10.5 kg / 23 lb from baseline). Mild constipation pattern continues; PEG laxative as needed.

Month 6 — Week 8 of adjunct cycle 1; first mid-cycle adjunct monitoring labs. IGF-1 175 ng/mL (pre-adjunct 145 ng/mL; Z-score age 52 female now ~+0.7 — upper-quartile-of-reference per the §6.10.1 target; not above reference range). Fasting glucose 96 mg/dL (stable on backbone-driven improving trajectory). HbA1c 6.6% (down from 7.4 baseline; further improvement on backbone — the lean-mass adjunct GH-axis directional pressure has not reversed the trajectory). Fasting insulin 14 µIU/mL (down from baseline 22; improving). Weight 189 lb (85.7 kg; total loss 13.3 kg / 29 lb). BP 128/80 (further improvement). §7 visceral-fat adjunct trigger evaluation: baseline VAT 2,100 g; Month 4 DEXA VAT 1,820 g (down ~280 g); no Month 6 DEXA scheduled (next at Month 7) but waist circumference at Month 6 down 5 cm from baseline (suggesting continued VAT reduction). The §7 trigger logic is “is VAT residual a layer-in trigger after the backbone-driven response is partial-to-complete?” — at Month 6 it’s too early; the §7 decision waits for Month 7 DEXA.

Month 7 — Week 12-16 of adjunct cycle 1; end of cycle 1. Comprehensive reassessment.

Backbone status. Weight 183 lb (83 kg; total loss 16 kg / 35 lb). HbA1c 6.4%. UACR 32 mg/g (improving). Lipid panel improved. Backbone Wegovy 2.4 mg continued; backbone trajectory on-track per STEP-1 / STEP-2 effect-size envelope.
Lean-mass adjunct status. Month 7 DEXA: total lean mass 45.5 kg (vs Month 4 pre-adjunct 46.5 kg → adjunct-cycle 1 lean-mass change −1.0 kg over 12 weeks of adjunct cycle; total fat mass change over the same 12 weeks −4.5 kg; lean-mass-loss fraction over the adjunct cycle = 1.0 / 5.5 = 18%). Comparison to pre-adjunct trajectory: §4.6 Month 4 lean-mass-loss fraction at that timepoint was 22% (cumulative over the 4-month backbone-only phase); the post-adjunct cycle 12-week incremental period showed 18%, an improvement of ~4 percentage points. Functional measures: grip strength 23 kg (slight improvement from baseline 22); 5-STS 13 seconds (slight improvement from baseline 14). Cumulative total weight loss 16 kg / 35 lb; cumulative lean-mass loss 3.5 kg of total 16 kg = 22% lean-mass-loss fraction — held in the typical range with the trajectory improving in the post-adjunct phase.
IGF-1 on adjunct. 182 ng/mL (Z-score ~+0.8 — upper-quartile-of-reference; stable). No supraphysiologic elevation.
§7 visceral-fat adjunct trigger evaluation finalized. Month 7 DEXA VAT 1,680 g (down from Month 4 1,820 → −140 g over the 12-week adjunct cycle; total VAT change from baseline 2,100 → 1,680 = −420 g / −20%). The §7.4 visceral-fat adjunct layer-in trigger is “residual VAT-dominant phenotype after backbone-driven response is partial-to-complete” per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §1.2 + §7. The patient’s VAT trajectory shows continued favorable reduction; the absolute VAT 1,680 g remains above 1,500 g (a common threshold for clinically meaningful VAT-burden context); the §7 decision is whether to add the visceral-fat adjunct now (to accelerate the VAT-targeting trajectory) or to continue current backbone + lean-mass adjunct and reassess at Month 10. The §7 conversation is presented to the patient per Pattern Z anchor 4.

Cycle 1 continuation decision. Lean-mass adjunct cycle 1 has produced favorable lean-mass-loss-fraction trajectory improvement and within-protocol IGF-1 elevation. Continue Cycle 2 after the 4-8 week washout. Visceral-fat adjunct §7 decision will be revisited during the washout.

Months 7.5-8.5 — cycle 1 washout. No adjunct dosing. Backbone Wegovy continues at 2.4 mg weekly. Tier 1 foundation continues. Weight at end of washout ~178 lb (80.7 kg; total loss 18.3 kg / 40 lb — patient is past the ~30 lb / ~13.6 kg laxity-onset threshold per §8 trigger). §8 skin-laxity adjunct trigger evaluation begins.

Month 9 — Cycle 2 initiation. Patient elects to continue with Cycle 2 of the lean-mass adjunct. Cycle 2 dosing per the same protocol as Cycle 1. §8 skin-laxity adjunct §10 conversation per the cumulative-loss milestone. §7 visceral-fat adjunct decision: patient elects to defer until Month 10-12 reassessment (the favorable VAT trajectory on backbone + lean-mass adjunct suggests the additional layer may not be needed; the §7 reassessment timepoint is the decision-checkpoint).

Pattern V cross-check at §5.6. The Month 7 DEXA shows lean-mass-loss-fraction within the typical Phase-3-pooled range (~22% cumulative; ~18% incremental adjunct-cycle) with the trajectory improving in the adjunct phase. The improvement is consistent with the practitioner-observation expectation (~15-20% target on adjunct in adherent patients) per the lean-mass adjunct protocol §10.6 framing. The IGF-1 elevation to Z-score ~+0.8 is within the protocol target (upper-quartile-of-reference, Z 0 to +1). The cross-component net glucose-tolerance trajectory is favorable (HbA1c continued improvement from 7.4 to 6.4 across the Month 0-7 period; no reversal from the GH-axis component’s directional pressure).

Pattern W cross-check at §5.6. Every monitoring lab and imaging modality in the Month 5-9 panel is reconciled with §3 baseline (CMP, fasting lipid, HbA1c, fasting insulin, UACR, IGF-1, DEXA, grip strength, 5-STS, blood pressure). No monitoring metric is introduced without baseline anchor. The §6 AE-class thresholds (IGF-1 above reference; HbA1c +0.3 from pre-adjunct baseline; etc.) are applied without invoking any threshold not established at §3 or §5.

Pattern AA precision in §5.6. The Wegovy 2.4 mg maintenance dosing is FDA-label-recommended for CWM; the co-management of T2D context with the backbone semaglutide (rather than separate Ozempic prescription) is clinician-judgment-within-practice-norm. The CJC-Ipa+MOTS-c adjunct cycle is practitioner-consensus within the un-labeled protocol; no FDA label exists. The combined regimen (backbone + adjunct + Tier 1 foundation) is an off-label clinical-judgment integration; §10.6 patient-counseling beat carries this framing.

Pattern Z.injection-framing applied to §5.6. The Month 5-9 peak overlap is 1 weekly Wegovy + 5 CJC-Ipa SC bedtime + 3 MOTS-c SC AM = 9 SC injections per week. Patient is managing the regimen successfully with no adherence gaps documented. The §10.7 logistics conversation at protocol entry prepared the patient for this commitment; the actual peak-overlap experience is consistent with the prepared expectation, not a surprise burden.

6. Side-effect management (cross-component AE class algorithms)

6.1 Purpose

Define the anticipatory framing and clinician response algorithms for the adverse-event categories applicable to the comprehensive stack. §6 is the AE-by-AE-class operational reference for the integrated regimen — what to expect, when to escalate, when to discontinue at the component level versus at the stack level. The section is structured by AE class with each AE class addressed in the standard sub-structure: anticipatory framing, identification, severity grading, first-line management, escalation triggers, discontinuation triggers.

The comprehensive-stack-specific framing in §6 is attribution discipline. When an AE emerges on the multi-component regimen, the attribution question (which component is the directional source) is the load-bearing diagnostic step that determines the management response. For some AE classes (e.g., backbone GI AEs at backbone-titration timepoints), the attribution is straightforward. For others (e.g., glucose-tolerance changes when both the backbone is improving glucose and the GH-axis adjunct is providing modest opposing pressure), the attribution requires careful trajectory analysis and may require component-specific dose adjustment or temporary hold to clarify.

Pattern R applies at this section: each AE-class sub-block opens with anticipatory framing — what the AE is, why it occurs, how common it is in the per-component literature or trial program — before management. Pattern V applies: post-marketing or under-evaluation signals are framed with primary-source effect-size and population qualification.

6.2 GI AE class — backbone-driven (dominant AE class for GLP-1 RA backbone)

Anticipatory framing. GLP-1 RA-mediated delayed gastric emptying, central appetite-pathway modulation, and direct GI-motility effects produce a characteristic AE profile: nausea, vomiting, diarrhea, constipation, eructation, abdominal pain. Profile peaks at dose escalation and attenuates within 2-4 weeks at stable dose. Per the backbone protocol §6.2.

Comprehensive-stack-specific attribution discipline. GI AEs on the comprehensive stack are typically backbone-driven, particularly during the §4 titration period and the first 4-8 weeks at target dose. MOTS-c flu-like / cytokine pattern at adjunct initiation (per §6.3) is a separate AE class with a distinct timing (Day 5-10 of first MOTS-c dose; Week 1-2 of adjunct cycle initiation, not Week 1 of backbone titration). Distinguishing backbone-attributable GI AE from adjunct-attributable AE patterns by timing and by symptom-cluster differences is the operational diagnostic step.

Identification. Patient-reported during early-monitoring contacts (§4.4) and maintenance visits (§5.4). CTCAE severity grading.

First-line management. Per backbone protocol §6.2. Non-pharmacologic + ondansetron PRN.

Escalation triggers. Per backbone protocol §6.2.

Discontinuation triggers. Per backbone protocol §6.2 — backbone-level discontinuation; does not automatically discontinue adjunct layers if backbone is discontinued (adjunct layers are typically discontinued in parallel because the backbone is the load-bearing weight-loss driver, but the discontinuation is sequenced — backbone discontinuation typically precedes adjunct discontinuation, with the adjunct continuing through the current cycle while the backbone is transitioned per the §7 algorithm or §8 framing).

6.3 Transient flu-like / cytokine-pattern AE class — MOTS-c-driven (adjunct-attributable)

Anticipatory framing. Per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §6.3: MOTS-c initiation in some patients produces transient flu-like symptoms (mild myalgia, fatigue, low-grade temperature, malaise) — typically Days 5-10 of initial MOTS-c dosing; self-resolving within Week 1-2. Pattern is consistent with mild cytokine-mediated response to initial AMPK-pathway activation; mechanism is unconfirmed.

Comprehensive-stack-specific attribution. The pattern timing (Days 5-10 of MOTS-c initiation; Week 1-2 of adjunct cycle 1) distinguishes from backbone GI AE (peak at dose escalation, typically Days 1-3 post-injection for backbones with weekly dosing pattern) and from CJC-Ipa fluid-retention or head-rush (Week 1-2 of CJC-Ipa initiation, distinct symptom cluster).

Identification. Patient-reported during Week 1-2 contact at adjunct cycle initiation.

First-line management. Reassurance; symptomatic care (acetaminophen for myalgia / temperature); hydration. Self-resolving; counseling at adjunct initiation (§10) frames this expectation.

Escalation triggers. Persistent symptoms beyond Week 2; severe symptoms; atypical patterns (rash, lymphadenopathy, hepatic signal) → discontinue MOTS-c pending evaluation.

Discontinuation triggers. Persistent severe flu-like pattern or pattern suggestive of true hypersensitivity → discontinue MOTS-c permanently; CJC-Ipa component may continue if the AE is MOTS-c-specific in pattern.

6.4 Mild fluid-retention and head-rush AE class — CJC-Ipa-driven (adjunct-attributable)

Anticipatory framing. Per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §6.4: GH-axis-mediated sodium-and-water retention plus acute vasodilatory effect at injection. Typically attenuates within 2-4 weeks of a cycle.

Comprehensive-stack-specific consideration. Fluid retention against the backbone-driven weight-loss trajectory may produce confusion on the weight scale (1-2 lb upward shift over a few days, distinct from the underlying weight-loss trajectory). Patient counseling at adjunct initiation (§10) prepares the patient for this interpretation. The fluid-retention pattern is distinct from constipation-driven weight stasis (a backbone GI AE pattern that can also show up as scale-stasis); the timing (Week 1-2 of CJC-Ipa) and the symptom cluster (rings tighter, peripheral edema, head-rush) differ.

First-line management. Per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §6.4 — reassurance; salt-intake moderation if symptomatic; dose-frequency reduction (e.g., 4 on / 3 off) if persistent.

Escalation / discontinuation triggers. Per the lean-mass adjunct protocol.

6.5 Carpal-tunnel-like and joint-stiffness AE class — CJC-Ipa-driven (adjunct-attributable)

Per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §6.5 + §6.6. GH-axis activation can produce carpal-tunnel-like symptoms and joint stiffness, particularly at higher GH-secretagogue doses or in patients with pre-existing carpal-tunnel risk factors. Mechanism: fluid retention in carpal-tunnel anatomy plus IGF-1-mediated soft-tissue effects.

Comprehensive-stack-specific consideration: tesamorelin at the §7 layer-in (if added) has overlapping GH-axis biology and may produce additive carpal-tunnel-like symptoms. The §9.4 stack-redundancy rules address whether CJC-Ipa and tesamorelin co-administration is appropriate.

6.6 Glucose-tolerance trajectory AE class — cross-component attribution

Anticipatory framing. This is the load-bearing cross-component AE class on the comprehensive stack. The backbone GLP-1 RA is driving glucose improvement (HbA1c reduction; fasting glucose reduction; insulin-sensitivity improvement via weight loss and direct GLP-1R-mediated effects). The lean-mass adjunct GH-axis component (CJC-Ipa) at supraphysiologic levels antagonizes insulin sensitivity, but at the practitioner-consensus dose (upper-quartile-of-reference IGF-1 target) the insulin-antagonist effect is typically not clinically meaningful. The MOTS-c component is insulin-sensitizing (AMPK-pathway activation). The visceral-fat adjunct tesamorelin (if added at §7) has GH-axis directional pressure similar to CJC-Ipa.

Net effect: glucose-tolerance trajectory on stack is typically maintained-or-improved against pre-stack on-backbone baseline. Reversal is uncommon but is a §5.4 dose-adjustment trigger.

Identification. Per §5.4 monitoring labs — HbA1c, fasting glucose, fasting insulin at Month 6 mid-cycle adjunct monitoring and at Month 7 end-of-cycle reassessment.

Cross-component attribution diagnostic. When glucose-tolerance reversal emerges:

HbA1c rises >0.3 percentage points from pre-adjunct baseline (which was already improving on backbone). Most likely directional source: lean-mass adjunct GH-axis component (CJC-1295). Less likely: MOTS-c (insulin-sensitizing direction). Backbone is delivering opposing pressure and is unlikely to be the source unless backbone dose was concurrently changed.
Management. Reduce CJC-1295 to 50 mcg or hold the GH-axis component for 1 cycle while continuing MOTS-c and backbone. Re-check HbA1c at 4-8 weeks post-adjustment.
If glucose-tolerance reversal continues despite GH-axis dose reduction. Reassess for alternative etiology (medication interaction; subclinical infection; subclinical endocrine pattern — hypothyroidism, cortisol excess). The §7 plateau / non-response algorithm includes glucose-tolerance reversal as one of the partial-response signals warranting phenotype reassessment.

Discontinuation triggers. New-onset T2D diagnosis on stack → discontinue GH-axis components (CJC-Ipa; tesamorelin if added) permanently; continue MOTS-c at clinician judgment; continue backbone. Persistent glucose-tolerance worsening despite GH-axis dose reduction → discontinue GH-axis components permanently.

6.7 IGF-1 surveillance + cancer-surveillance — load-bearing for the GH-axis adjunct components

Anticipatory framing. Per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §6.10. The GH-axis components (CJC-Ipa; tesamorelin if added) produce IGF-1 elevation as the intended pharmacologic effect. The clinical question is not “does IGF-1 elevate” (yes — that is the mechanism) but rather “is the elevation in the therapeutic-physiologic range vs supraphysiologic range, and what are the implications for cancer surveillance.”

The IGF-1-cancer-risk literature has two opposing signal pillars:

Renehan 2004 Lancet meta-analysis (PMID 15110491). Observational association of elevated IGF-1 with prostate cancer (OR 1.49) and premenopausal breast cancer (OR 1.65). Observational; does not establish causation; load-bearing observational signal.
Child 2022 HypoCCS cohort of 15,809 adults treated with GH (PMID 35368070). Cancer incidence in this large GH-replacement cohort comparable to general population (SIR 0.92).
Boguszewski 2022 expert consensus on GH replacement in cancer survivors (PMID 35319491). “No association with cancer recurrence” in post-cancer-treatment setting, while recommending oncologist clearance and IGF-1 monitoring.

Surveillance discipline on the comprehensive stack:

Target IGF-1 in upper-quartile-of-reference (Z-score 0 to +1), not supraphysiologic. Supraphysiologic elevation is the dose-reduction trigger.
PSA monitoring in men ≥40. Baseline + annual on stack. Rise above age-specific reference range or rapid PSA velocity warrants urologic evaluation.
Mammography in women ≥40 per standard screening intervals. Up-to-date mammography required at baseline and maintained on schedule.
Family-history cancer-context counseling. Patients with first-degree family history of hormone-sensitive cancers warrant patient-specific risk-benefit weighing.
Active or recent (5y) malignancy: hard contraindication (§2.4). Cancer-survivors beyond 5 years from treatment completion: relative exclusion per the 2022 consensus statement.

Comprehensive-stack-specific addition. If tesamorelin is added at §7, the IGF-1 elevation may be additive with the CJC-Ipa elevation. §9.4 stack-redundancy rules typically avoid CJC-Ipa + tesamorelin co-administration; if both are deployed (rare exception per §9.4), the IGF-1 monitoring is intensified (monthly during the overlap period) and the cancer-surveillance discipline is enhanced.

6.8 NAION AE class — semaglutide-specific signal (backbone-specific)

Per [[Semaglutide Protocol]] §6.5. Non-arteritic anterior ischemic optic neuropathy (NAION) signal in semaglutide pharmacovigilance per Hathaway 2024 PMID 38958939. Post-marketing under-evaluation signal; not labeled contraindication or warning as of 2026-05-14.

Comprehensive-stack-specific note: if backbone is non-semaglutide (tirzepatide; retatrutide; survodutide; etc.), the NAION signal does not apply at the same evidence level — Lawrenson 2025 PMID 40383360 found the signal absent for tirzepatide per the class-differentiation finding. The backbone-choice §10.4 conversation includes this NAION class-differentiation as one of the 8+ dimensions (per Pattern Z anchor 4 verbatim canonical).

6.9 Gallbladder AE class — backbone-driven

Per the backbone protocol §6.3. GLP-1 RA association with cholelithiasis and cholecystitis demonstrated across the trial program; mechanism attributed to weight-loss-rate-related bile-supersaturation and direct gallbladder-motility effects. Backbone-specific identification and management.

6.10 Pancreatitis AE class — backbone-driven

Per the backbone protocol §6.4. Acute pancreatitis signal in GLP-1 RA pharmacovigilance; pivotal-trial data have not demonstrated statistically significant pancreatitis-incidence signal in trial populations; severe-prior-pancreatitis-history patients excluded from trial enrollment.

Comprehensive-stack-specific consideration: confirmed acute pancreatitis attributable to backbone → permanent backbone discontinuation. Adjunct layers are typically discontinued in parallel; the §7 algorithm directs whether to transition to a non-GLP-1 backbone alternative.

6.11 Injection-site AE class — cross-component

Injection-site reactions at any individual injection site can occur with any of the SC injections (backbone Wegovy / other; CJC-Ipa; MOTS-c; tesamorelin; AOD-9604; GHK-Cu when sequenced). Site rotation across distinct sites is the load-bearing prevention discipline. Lipohypertrophy can develop with site rotation failure on chronic injection schedules.

Comprehensive-stack-specific site-rotation discipline. At peak overlap (Month 6-9), patient has 4 distinct compound classes potentially injecting SC (Wegovy weekly; CJC-Ipa bedtime 5×/week; MOTS-c morning 3×/week; potentially tesamorelin + AOD-9604 daily if §7 trigger). Site-rotation strategy: alternate abdomen / thigh / upper arm for each compound; specifically rotate within abdomen quadrants for the daily injections to avoid same-quadrant accumulation. The §10.7 logistics conversation includes the site-rotation discipline.

6.12 Hypoglycemia AE class (T2D context with concurrent insulin or sulfonylurea)

Per the backbone protocol §6.7. GLP-1 RA monotherapy is not a hypoglycemia-inducing class; hypoglycemia risk emerges when GLP-1 RA is combined with insulin or sulfonylurea. Concurrent agent dose typically reduced at backbone initiation (insulin reduced ~20%; sulfonylurea reduced ~50% or discontinued).

Comprehensive-stack-specific consideration: the lean-mass adjunct MOTS-c is insulin-sensitizing; co-administration with insulin or sulfonylurea may further enhance hypoglycemia risk. Concurrent-agent dose review at lean-mass adjunct layer-in.

6.13 Tesamorelin-specific AE classes (when visceral-fat adjunct layered in at §7)

When visceral-fat adjunct is layered in at §7, the tesamorelin-specific AE classes apply per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §6:

Injection-site reactions. Tesamorelin labeled AE; per Falutz Phase 3 program.
Arthralgia. Tesamorelin labeled AE.
Peripheral edema. Tesamorelin labeled AE.
Glucose intolerance / hyperglycemia. Tesamorelin labeled AE — GH-axis-mediated; cross-references the §6.6 glucose-tolerance trajectory AE class.
Anti-tesamorelin antibody development. Tesamorelin labeled — most antibodies are non-neutralizing; some patients lose response over time and discontinue.
Hypersensitivity reactions. Labeled contraindication if severe.

The AOD-9604 AE profile is less characterized given the development-discontinued state per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §6.

6.14 GHK-Cu-specific AE classes (when skin-laxity adjunct sequenced at §8)

When GHK-Cu is sequenced in at §8, the GHK-Cu-specific AE classes apply per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §6:

Injection-site reactions (for injectable cycles).
Topical sensitivity / contact dermatitis (for topical layer).
Copper-load accumulation with concurrent high-dose oral copper supplementation.
Hypersensitivity.

6.15 Worked example — multi-AE management on the comprehensive stack

Scenario A — IGF-1 above reference range at Month 6 adjunct mid-cycle (continuing the §5.6 patient). Hypothetical variation on the Profile A canonical patient. Month 6 IGF-1 returns at 295 ng/mL — above age-specific reference range upper bound (reference upper ~280 ng/mL for age 52 female). Per §6.7 + §6.10 + per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §6.10.1: above-reference IGF-1 is dose-reduction trigger. Reduce CJC-1295 from 100 mcg to 75 mcg per injection (Ipamorelin unchanged 200 mcg). Re-check IGF-1 at Week 4 (Month 7). If IGF-1 returns to upper-quartile-of-reference, continue at reduced dose. If IGF-1 remains above reference → further reduce to 50 mcg CJC-1295 or hold for 1-2 weeks then resume at 50 mcg. Backbone Wegovy continues unchanged. MOTS-c continues unchanged. Cancer-surveillance mammography baseline status carried forward; annual repeat per standard interval. Patient counseled per §10 that the adjustment is precautionary to keep IGF-1 in the protocol-target physiologic range.

Scenario B — HbA1c trajectory reversal at Month 6 (cross-component attribution). Hypothetical variation: Month 6 HbA1c 6.9% (up from pre-adjunct baseline of 6.4% at Month 4 → reversal of +0.5 percentage points). Per §6.6 + §6.7. Most likely directional source: lean-mass adjunct CJC-1295 (GH-axis insulin-antagonist directional pressure). Management: hold CJC-1295 for 2 weeks while continuing Ipamorelin alone (Ipamorelin GH-axis pulse is partial-GH-axis-stimulation without the CJC-1295 amplification), continuing MOTS-c (insulin-sensitizing directional pressure), and continuing Wegovy backbone. Re-check HbA1c at Week 4 (Month 7) — if HbA1c trends back toward improving trajectory, the directional source was confirmed as the GH-axis component; resume CJC-1295 at 50 mcg with enhanced glucose surveillance. If HbA1c does not improve with CJC-1295 hold, reassess for alternative etiology.

Scenario C — Acute severe upper abdominal pain at Month 5 on stack. Patient presents with sudden onset severe upper abdominal pain radiating to back, vomiting. Per §6.10 + per [[Semaglutide Protocol]] §6.4. Discontinue Wegovy immediately pending evaluation. Discontinue lean-mass adjunct pending evaluation (although less likely directional source, conservative discontinuation while pancreatitis workup proceeds). Labs: lipase, amylase, CMP, CBC, lipid panel. Imaging: CT abdomen. Differential: backbone-attributable pancreatitis (most likely directional source given the time on backbone); gallstones; hypertriglyceridemic pancreatitis; alcohol-related; alternative etiology. If confirmed acute pancreatitis attributable to backbone with alternative etiologies ruled out → permanent backbone discontinuation. Adjunct discontinuation per §8 timing (cycle washout if appropriate). Transition to non-GLP-1 alternative if Module 5 indication continues, with the §7 algorithm directing the transition.

Scenario D — Acute painless monocular vision loss on Wegovy at Month 4. Per [[Semaglutide Protocol]] §6.5. Discontinue Wegovy. Urgent ophthalmology. Confirmed NAION → permanent Wegovy discontinuation. Adjunct continuation decision: lean-mass adjunct is not contraindicated by NAION (different mechanism class); if patient transitions backbone to tirzepatide (NAION signal absent per Lawrenson 2025), the lean-mass adjunct may continue. Patient and clinician decision per §10 NAION-class-differentiation conversation.

Scenario E — MOTS-c initiation flu-like pattern at Week 1 of adjunct cycle 2. Hypothetical variation: at Month 9 Cycle 2 initiation, patient experiences moderate flu-like symptoms Days 5-8 of MOTS-c restart — similar pattern but more pronounced than Cycle 1. Per §6.3. Reassurance — pattern is consistent with mild cytokine-mediated initial-AMPK-activation response; symptomatic care; expected resolution Week 1-2. Continue protocol. If pattern persists beyond Week 2 → §6.3 discontinuation discussion.

Scenario F — Injection-site lipohypertrophy at Month 8. Patient develops a lipohypertrophic nodule on left abdominal quadrant at Month 8. Per §6.11. Site-rotation discipline reinforced (the left abdominal quadrant has been receiving disproportionate share of injections; rotation to right abdomen, thighs, upper arm). Lipohypertrophic nodule typically resolves with rotation discipline; resolution monitored over 4-8 weeks.

Pattern V cross-check at §6.15. Each scenario invokes a specific monitoring trigger and a specific management response anchored to the §3 baseline labs / §5 monitoring panel / §6 AE-class algorithms. The cross-component attribution discipline (e.g., glucose-tolerance reversal attribution to GH-axis component vs alternative etiology) is anchored to mechanism direction-of-effect, not generalized.

Pattern AA precision in §6.15. The AE management algorithms invoke FDA-label-mandated actions for backbone-attributable AEs (pancreatitis → permanent discontinuation per label) and clinician-judgment-within-practitioner-consensus actions for adjunct-attributable AEs (CJC-1295 dose reduction per practitioner-consensus). The framing is precise at each step.

7. Plateau and non-response algorithm + visceral-fat adjunct layer-in trigger logic

7.1 Purpose

Define the structured clinical-decision approach when the comprehensive stack’s primary effects have not met their targets (non-response) or have stalled below clinically meaningful endpoints (plateau). §7 is the diagnostic-and-decision branch point for two distinct questions:

Backbone non-response or plateau. Is the GLP-1 RA backbone driving meaningful weight loss at its target dose? This question routes through the backbone protocol §7 algorithm (transition to higher-effect alternative; combination with cagrilintide; intensification of behavioral / nutritional / activity program). Comprehensive-stack-specific consideration: if backbone is non-responding, the entire stack is reassessed — adjunct layers presuppose backbone response and may be discontinued or paused during backbone transition.
Visceral-fat adjunct layer-in trigger evaluation. Has the patient’s VAT trajectory on backbone + lean-mass adjunct produced a residual VAT-burden that warrants the visceral-fat adjunct (Tesa+AOD) layer-in? This is the comprehensive-stack-specific §7 phasing question. The trigger logic is the load-bearing decision: when to add Tesa+AOD versus when the backbone + lean-mass adjunct combination has produced sufficient VAT reduction without the additional layer.

Pattern V applies at this section: direction-of-effect anchoring on every effect-size claim. Pattern Z calibration anchor 4 (multi-dimensional comparator framing) and anchor 5 (off-label / extrapolation transparency) are both load-bearing in §7 patient-counseling beats.

7.2 Pseudo-plateau vs true plateau vs non-response — diagnostic distinctions (per backbone protocol §7.2 + comprehensive-stack-specific)

Pseudo-plateau. Apparent stall that is in fact within normal trajectory variation, or reflects body-composition change (lean-mass preservation with continued fat-mass loss) rather than total-weight stall, or occurs in the predictable trial-trajectory pattern (most weight-loss molecules show deceleration in months 6-9 even on continued effective therapy). Comprehensive-stack-specific addition: on the lean-mass adjunct, the body-composition trajectory may show favorable shift (lean-mass preserved; fat-mass continuing to drop) at apparent total-weight stall — this is the most clinically favorable outcome pattern and is not “non-response.”

True plateau. Legitimate response stall. Trajectory inflection plus adequate observation window (typically 2-3 months at stable backbone target dose).

Non-response. Insufficient initial effect from the start. Recognized at Month 3-6 on target backbone dose with effect substantially below the trial-program-typical effect for the patient’s phenotype.

7.3 Set-point reset framing (per backbone protocol §7.3)

Weight-regulation physiology operates on a defended set-point. Loss beyond the body’s defended range tends to recruit counter-regulatory responses (increased hunger, decreased energy expenditure — adaptive thermogenesis). True plateau in CWM context is often the body’s defense at a new set-point. The protocol framing in counseling (§10) does not pathologize plateau but reframes it as biological-equilibrium attainment.

7.4 Decision tree for backbone plateau / non-response

Per the backbone protocol §7.4:

Confirm adherence. Missed doses, injection-technique issues. Prescription-refill audit.
Confirm trajectory-context. Plot patient’s curve against trial-program-typical curve.
Confirm dose attainment. Is the patient on target backbone dose?
Reassess phenotype. Patient in under-represented or out-of-trial phenotype?
If true plateau / non-response confirmed at adequate observation window:
- CWM context: Transition to higher-effect backbone (semaglutide → tirzepatide per SURPASS-2 / SURMOUNT-1 effect-size differential; or tirzepatide → retatrutide per investigational triagonist magnitude); or combination with cagrilintide pending CagriSema readout/approval; or intensification of behavioral / nutritional / activity program.
- T2D context: Transition to higher-effect agent or add SGLT2 inhibitor or add insulin per ADA/EASD progression algorithm.
- MASH context: Per semaglutide ESSENCE anchor; alternative agents limited.
- CKD / CV / OSA contexts: Per backbone protocol.

7.5 Visceral-fat adjunct layer-in trigger logic — the comprehensive-stack §7 phasing decision

The §7 visceral-fat adjunct layer-in question is distinct from backbone non-response. The patient may be on a fully responding backbone with the lean-mass adjunct in cycle, with favorable weight and lean-mass trajectories, and STILL have a residual VAT-burden that warrants Tesa+AOD consideration.

Trigger criteria per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §1.2 — at least one of:

Visceral-fat-predominant residual after backbone-driven response is partial-to-complete. The “stubborn belly after sema / tirz” phenotype. Operationally: Month 7-9 DEXA VAT remains above the patient’s clinical-meaningful threshold (typically VAT >1,500 g and disproportionate to subcutaneous fat distribution; or waist circumference still elevated above clinical targets despite total-weight loss; or VAT-to-SAT ratio still high).
Visceral-fat-predominant phenotype with concurrent MASLD/MASH where the GH-axis hepatic-fat mechanism is mechanistically additive. The Stanley 2014 JAMA RCT (PMID 25038357) demonstrated tesamorelin reduced hepatic fat in HIV-associated MASLD; mechanism extrapolation to non-HIV MASH is plausible.
Body-recomposition phenotype in midlife adult seeking VAT reduction with lean-mass preservation. Profile B canonical phenotype.
GLP-1-intolerant patient where visceral adiposity is the dominant clinical concern. Less common for the comprehensive stack (the comprehensive-stack patient is typically tolerating the backbone); applicable in edge cases where the backbone is being discontinued due to AE intolerance but the visceral-fat concern remains.

Stack-redundancy considerations — when NOT to add Tesa+AOD:

Backbone is retatrutide, survodutide, CagriSema, or IcoSema. These backbones produce enhanced VAT reduction relative to semaglutide / tirzepatide GLP-1-monotherapy through the glucagon-receptor (retatrutide; survodutide) or amylin-receptor (CagriSema; IcoSema) mechanism. The tesamorelin add-on is mechanistically redundant for many patients on these backbones; the §9.4 redundancy rules typically defer tesamorelin until the backbone’s VAT-targeting effect has been observed.
Patient on CJC-Ipa lean-mass adjunct with favorable VAT trajectory. CJC-Ipa elevates IGF-1 with secondary VAT-favorable directional effects (GH-axis metabolic biology). Co-administration of tesamorelin (another GHRH analog) is partial-mechanism-overlapping; the §9.4 stack-design rules typically do not co-administer CJC-Ipa and tesamorelin simultaneously. Two pathways apply:
- Sequential pathway: complete CJC-Ipa lean-mass cycle (12-16 weeks + washout); transition to tesamorelin in a separate phase if VAT-residual trigger remains.
- Substitution pathway: if VAT is the dominant residual concern at the §7 timepoint and lean-mass trajectory is now favorable, discontinue CJC-Ipa lean-mass adjunct after Cycle 1 or Cycle 2 and substitute tesamorelin for the visceral-fat-targeting phase. MOTS-c may continue or pause per clinician judgment.
Patient’s cumulative regimen burden is at acceptable limit. Patient preference for stack-simplification rather than adding another component. The §10.7 logistics conversation may direct toward holding off on the visceral-fat adjunct.

7.6 Decision tree for visceral-fat adjunct layer-in

Confirm backbone response is partial-to-complete. Patient is on target backbone dose; meaningful weight loss is occurring or has occurred. Backbone is not in non-response algorithm.
Confirm VAT-residual trigger. Month 7-9 DEXA VAT trajectory; consider MRI VAT for high-resolution measurement if clinically meaningful. Compare to baseline VAT and to the patient’s clinical-meaningful threshold.
Confirm Tesa+AOD inclusion criteria per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §2.2. No active malignancy; no acromegaly / pituitary tumor; no untreated proliferative DR; no pregnancy; no severe hypersensitivity.
Apply §7.5 stack-redundancy considerations. Is the backbone a retatrutide-class compound where tesamorelin is likely redundant? Is CJC-Ipa in cycle and the §9.4 co-administration rules apply?
Patient-counseling conversation per §10. Multi-dimensional comparator framing (Pattern Z anchor 4): the VAT-targeting options include (a) continuing backbone + lean-mass adjunct alone and accepting current VAT trajectory; (b) adding tesamorelin during a subsequent phase after lean-mass adjunct cycle completion; (c) substituting tesamorelin for lean-mass adjunct in the visceral-fat-targeting phase. Off-label / extrapolation framing (Pattern Z anchor 5): tesamorelin off-label for non-HIV visceral adiposity is off-label use of an FDA-approved drug; AOD-9604 is investigational with development-discontinued status. Patient elects from the options.

7.7 Worked example — §1.6 canonical patient at Month 9-10

Continuing the Profile A canonical patient. At Month 9 (Cycle 2 initiation of lean-mass adjunct), the patient is approaching the §7 decision point for visceral-fat adjunct layer-in.

Status at Month 9-10:

Backbone Wegovy 2.4 mg at target dose continuing; HbA1c 6.4% sustained; UACR 32 mg/g; backbone fully responding.
Lean-mass adjunct Cycle 2 in progress; Cycle 1 produced favorable lean-mass-loss-fraction trajectory (~18% incremental, improving trajectory).
Total weight loss ~22 kg / 48 lb cumulative from baseline 99 kg → 77 kg.
DEXA at Month 9: total lean mass 45 kg; total fat mass 32 kg; VAT 1,500 g (down from baseline 2,100 → −600 g / −29%); waist circumference down 14 cm from baseline.
MASLD context: VCTE was performed at §3 workup and showed F1 fibrosis (mild; not F2-F3 MASH indication territory); LFTs improving.

§7.5 trigger evaluation:

VAT-residual trigger: VAT 1,500 g is at the threshold; below 1,500 g would be more clearly resolved. Marginal trigger.
MASLD with GH-axis hepatic-fat mechanism additive: F1 fibrosis with improving LFTs on backbone — the MASLD context is mild and improving without tesamorelin; the additive value of tesamorelin’s hepatic-fat mechanism here is uncertain.
Body-recomposition phenotype: yes — Profile A phenotype with body-composition optimization goals.

§7.5 stack-redundancy considerations:

Backbone is semaglutide (Wegovy 2.4 mg) — not a glucagon-receptor or amylin-receptor compound where tesamorelin would be redundant.
CJC-Ipa is currently in Cycle 2 — co-administration with tesamorelin is not standard per §9.4. Sequential or substitution pathway applies.

§7.6 decision tree application:

Backbone response is complete — yes.
VAT-residual trigger is marginal (VAT 1,500 g; trajectory favorable).
Tesa+AOD inclusion criteria — yes; all hard contraindications absent.
Stack-redundancy: backbone is semaglutide (compatible); CJC-Ipa is in cycle (sequential or substitution pathway needed).
Patient-counseling conversation: discuss three options.

Patient-counseling conversation per §10 (Pattern Z anchor 4 + anchor 5):

Clinician: “Your visceral-fat trajectory has been good — you’ve reduced your VAT by about 29% from baseline, which is a substantial response on the semaglutide-and-lean-mass-stack combination. The question now is whether to add tesamorelin as a visceral-fat-targeted layer, or whether the current trajectory is sufficient.

Here’s what each option looks like:

Option A — Continue current stack through Cycle 2 of the lean-mass adjunct; reassess at Month 12. Your VAT trajectory is favorable; the additional reduction in the next 3 months on the current stack may bring VAT below 1,500 g without adding another component. Cost: lowest; injection burden: same as current; clinical evidence: backbone effect-size continuing per STEP-1 envelope plus lean-mass adjunct cycle effect.

Option B — After lean-mass adjunct Cycle 2 completes (Month 12), transition to tesamorelin for a visceral-fat-targeted phase. Tesamorelin is FDA-approved for HIV-associated lipodystrophy abdominal-fat reduction; for your visceral-fat goal, it’s off-label use of an FDA-approved drug — a standard clinical pathway. AOD-9604 is investigational with development-discontinued status; some practitioners add it as an adjunctive layer, others use tesamorelin alone. Tesamorelin is a daily SC injection at 1.4 or 2 mg. Cost: tesamorelin adds approximately $200-500/month if compounded or $2,000-3,000/month if branded; AOD-9604 adds approximately $150-300/month if compounded. Clinical evidence: Falutz Phase 3 program in HIV-lipodystrophy demonstrated approximately 15-20% VAT reduction over 26-52 weeks; extrapolation to your non-HIV context is biologically plausible but not Phase 3 confirmed in non-HIV obesity populations.

Option C — Substitute tesamorelin for the lean-mass adjunct now. Discontinue CJC-Ipa+MOTS-c after Cycle 2 (or earlier if you elect); transition to tesamorelin for the visceral-fat-targeted phase. This is the substitution pathway. Your lean-mass trajectory has been favorable on the current stack; whether to maintain that favorable trajectory with the tesamorelin GH-axis component substituting for CJC-Ipa, or to risk some lean-mass-loss-fraction increase by removing the lean-mass-targeted regimen, is the tradeoff.

My recommendation is Option A or B — continue the current stack and revisit at Month 12. If at Month 12 your VAT is below 1,500 g and your lean-mass trajectory is preserved, you’ve reached the stack’s outcome targets and we transition to maintenance. If VAT is still above 1,500 g at Month 12, Option B becomes more clearly indicated. Option C is the more aggressive pathway and may not be necessary given your current trajectory. What’s your preference?“

Patient elects Option A — continue current stack through Cycle 2 of lean-mass adjunct; reassess at Month 12.

Pattern V applied to §7.7. The Falutz Phase 3 effect-size anchor (~15-20% VAT reduction over 26-52 weeks) is Tier 1 evidence for the HIV-lipodystrophy population. Extrapolation to non-HIV is Pattern V framing — direction-of-effect is “biologically plausible, mechanism-additive, not Phase 3 confirmed in non-HIV.” The patient counseling beat presents the extrapolation explicitly per Pattern Z anchor 5.

Pattern Z anchor 4 applied to §7.7. Multi-dimensional fact presentation — Options A/B/C presented across dimensions (cost, injection burden, mechanism, clinical evidence). Each option’s tradeoffs acknowledged factually. The clinician’s recommendation is presented as a recommendation, not as a directive; the patient’s preference is solicited. The conversation does NOT steer toward maximalism (“Option C is the best because it’s the most aggressive”) or toward minimalism (“Option A is the only reasonable choice because the others aren’t proven”); both extremes would fail Pattern Z.

Pattern AA precision in §7.7. Tesamorelin is “FDA-approved-for-marketing-claims for HIV-associated lipodystrophy abdominal-fat reduction; off-label for non-HIV visceral adiposity” — the precise framing per the canonical regulatory state. AOD-9604 is “investigational with development-discontinued status” — the precise framing per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §1.

8. Discontinuation and tapering + skin-laxity adjunct trigger logic + multi-component coordination

8.1 Purpose

Define when to stop each component of the comprehensive stack, how to taper if tapering is indicated, how to coordinate multi-component discontinuation, and the comprehensive-stack-specific §8 phasing question: when to layer in the skin-laxity adjunct (GHK-Cu) based on the cumulative-loss milestone and the GLP-1 maintenance-phase transition. §8 is the symmetric counterpart to §4 (initiation): just as initiation has anticipatory framing for AE and adherence, discontinuation has anticipatory framing for the post-discontinuation period and for the patient-and-clinician decision about whether and when to re-initiate any component.

§8 covers four distinct sub-questions:

8.2 — When to discontinue any single component: per the component protocol’s §8.
8.3 — How to coordinate multi-component tapering: sequencing rules for the comprehensive stack.
8.4 — Pre-conception planning for the multi-component stack: consolidated washout coordination.
8.5 — Skin-laxity adjunct layer-in trigger logic: the comprehensive-stack-specific phasing question.
8.6 — Post-discontinuation framing: weight-regain trajectory; re-initiation pathway.

8.2 When to discontinue any single component

Component-level discontinuation triggers per each component protocol’s §8:

Backbone (GLP-1 RA): confirmed contraindication discovery (new MTC diagnosis; new MEN-2 family-history identification; new pregnancy in CWM indication); severe AE attributable to backbone (confirmed pancreatitis; confirmed NAION; severe hypersensitivity); indication remission or resolution (rare); patient preference; cost / access barriers; pre-conception planning (CWM indication).
Lean-mass adjunct (CJC-Ipa+MOTS-c): per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §8 — cycle completion at planned end of Cycle 2 or Cycle 3; lean-mass goal achieved with backbone in maintenance phase; AE-driven (severe injection-site hypersensitivity; new malignancy diagnosis; supraphysiologic IGF-1 persistence despite dose reduction; persistent glucose-tolerance worsening despite dose reduction; severe sleep-apnea exacerbation; severe carpal-tunnel symptoms); patient preference.
Visceral-fat adjunct (Tesa+AOD): per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §8 — VAT goal achieved with backbone in maintenance phase; AE-driven (anti-tesamorelin antibody-mediated loss of response; severe hypersensitivity; severe glucose intolerance); patient preference.
Skin-laxity adjunct (GHK-Cu): per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §8 — cosmetic-outcome goal achieved per Day-90 / Day-180 photographic reassessment; AE-driven; patient preference; copper-load accumulation.

8.3 Coordinating multi-component tapering

Multi-component coordination rules:

Discontinue the most-acutely-problematic component first. If an AE attributable to one component triggers discontinuation of that component, discontinue that one first and reassess the rest of the stack. If the AE is not stack-attributable but is e.g. a backbone-specific AE (NAION), the backbone is discontinued and the adjunct decisions are downstream.
Adjunct cycle completion is a natural taper. The lean-mass adjunct’s 12-16 week cycle + 4-8 week washout structure means that adjunct discontinuation is operationally simpler than open-ended discontinuation — letting the current cycle complete and not initiating the next cycle is the natural taper pathway.
Backbone taper per the backbone protocol §8.3. For semaglutide: gradual dose reduction (2.4 mg → 1.7 mg × 4 weeks → 1.0 mg × 4 weeks → 0.5 mg × 4 weeks → off) for weight-regain trajectory smoothing. Abrupt discontinuation acceptable for AE-attributable discontinuation (no taper required — the AE management dominates). For other backbones, per backbone protocol.
Tier 1 foundation continues through and past discontinuation. The Tier 1 foundation (resistance training, protein, vitamin D, sleep) is the durable load-bearing intervention; it continues independent of any component’s discontinuation. The Tier 1 foundation is the foundation for post-discontinuation weight-regain trajectory mitigation per §8.6.

Sequenced multi-component discontinuation pathway — the typical end-of-stack-program scenario. At the end of the active-weight-loss arc (typically Month 12-24 depending on starting weight and trajectory), the patient transitions to a maintenance phase. The typical sequenced multi-component discontinuation:

Visceral-fat adjunct (Tesa+AOD), if layered in: discontinue first if VAT goal achieved. Typically completes a 12-26 week course; discontinuation at course completion.
Lean-mass adjunct (CJC-Ipa+MOTS-c): discontinue after backbone transitions to maintenance phase. Cycle washout serves as natural taper. Most patients run 1-3 cycles aligned with the active-weight-loss arc.
Skin-laxity adjunct (GHK-Cu): continues beyond active-weight-loss arc per the 12-24-month dermal-remodeling window per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §5-§8. Discontinuation per the cosmetic-outcome assessment timeline.
Backbone (GLP-1 RA): Transitions to maintenance phase rather than discontinuation in most CWM contexts — the §8 backbone discontinuation framing per the backbone protocol emphasizes that CWM indication is typically open-ended; discontinuation triggers weight-regain trajectory per STEP-4 (~two-thirds of lost weight regained by 12 months post-discontinuation). For T2D indication, backbone may continue at maintenance dose with ongoing T2D management. Discontinuation only at patient preference, AE-attributable, or indication-resolution.

8.4 Pre-conception planning for the multi-component stack — consolidated washout coordination

Pre-conception planning is the most consequential coordinated-discontinuation scenario for the comprehensive stack. Per Pattern Z calibration anchor 3, the conversation leads with research-state human pregnancy-exposure data (Parker 2025 PMID 40329607 for the GLP-1 RA class) and then carries pharmacokinetic and label-mandated discontinuation framing.

Multi-component washout arithmetic.

Backbone (semaglutide, dulaglutide, liraglutide, tirzepatide, retatrutide, etc.): per backbone protocol. For semaglutide: half-life ~1 week; 5 half-lives = ~35 days for pharmacokinetic clearance; FDA label specifies 8-week pre-conception window. For other backbones, per their respective half-lives and label recommendations.
Lean-mass adjunct (CJC-Ipa+MOTS-c): per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §8.4. CJC-1295 (Mod-GRF 1-29 without DAC) half-life ~30 minutes; pharmacokinetic clearance within ~4 hours of last dose. Ipamorelin half-life ~2 hours; clearance within ~24 hours. MOTS-c plasma half-life ~hours; clearance within ~24 hours. The pharmacokinetic clearance is rapid for all three; the practitioner-consensus pre-conception window for the lean-mass adjunct is ~4 weeks to allow for pharmacodynamic clearance (GH-axis equilibration; IGF-1 normalization).
Visceral-fat adjunct (Tesamorelin+AOD-9604): per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §8.4. Tesamorelin half-life 26-38 minutes; pharmacokinetic clearance within ~6 hours of last dose; GH/IGF-1 axis pharmacodynamic clearance over days to weeks. AOD-9604 half-life shorter still; rapid clearance. Tesamorelin is Category X per FDA label; pre-conception window per label is conservative — typically ≥2-month washout per practitioner consensus given the GH/IGF-1 axis tumor-promotion concern in pregnancy.
Skin-laxity adjunct (GHK-Cu): per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §8.4. Discontinued during pregnancy / lactation; pharmacokinetic clearance rapid for injectable; topical layer also discontinued during pregnancy / lactation per the protocol’s §2.4 framing.

Consolidated pre-conception coordination:

Discontinue backbone first. 8-week pre-conception window per the backbone label (for semaglutide / class-related; backbone-specific for others). This is the load-bearing washout.
Discontinue lean-mass adjunct in parallel or earlier. Adjunct cycle does not need to extend through the backbone washout; can be discontinued at the planned pre-conception window initiation.
Discontinue visceral-fat adjunct in parallel or earlier if it was layered in.
Discontinue skin-laxity adjunct in parallel if layered in.

Pattern Z calibration anchor 3 applied: Counseling beat leads with human pregnancy-exposure data (Parker 2025 for the GLP-1 RA class — incidence of congenital abnormalities appears relatively low in the pooled dataset; sample size limited; exposures from unplanned-pregnancy contexts; authors call for prospective pregnancy registries). Pharmacokinetic facts and label recommendations follow the research-state lead. Post-discontinuation weight-regain trajectory is presented (STEP-4 / STEP-1 extension data — approximately two-thirds of lost weight regained by 12 months post-discontinuation). Re-initiation pathway is available post-pregnancy and post-lactation. Patient’s reproductive-planning decision is patient-anchored. The protocol does not steer toward continued pharmacotherapy by emphasizing weight-regain risk, nor toward discontinuation by emphasizing pregnancy-exposure risk. Both facts are presented; the patient decides.

8.5 Skin-laxity adjunct layer-in trigger logic — the comprehensive-stack §8 phasing question

The §8 skin-laxity adjunct layer-in question is the third comprehensive-stack-specific phasing decision (after the §5 lean-mass adjunct layer-in and the §7 visceral-fat adjunct layer-in). The trigger logic per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §1.3 + §8:

Trigger criteria — sequential evaluation:

~30+ lb / ~13.6+ kg cumulative loss milestone. The laxity-onset threshold per the GHK-Cu protocol §1.3. Patients crossing this threshold are in or approaching the dermal-remodeling window where regenerative tripeptide-copper support is mechanistically relevant.
GLP-1 maintenance-phase transition. Backbone transitioning from active-weight-loss to maintenance phase (typically Month 12-24 depending on starting weight). At this transition, the post-weight-loss dermal-remodeling biology is the dominant skin-state question.
Patient-articulated skin-quality concern. Patient identifies skin laxity as a clinical concern at one of the maintenance visits, or has prior skin-laxity-history (Profile A canonical patient with post-gastric-bypass skin laxity) that anticipates the current loss arc producing similar laxity.

Layer-in pathway per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §4:

Topical layer initiation. GHK-Cu 2% topical serum daily evening. Continuous use throughout the dermal-remodeling window (12-24 months post-active-weight-loss).
Injectable layer initiation if elected (Tier 2 protocol per the GHK-Cu protocol). GHK-Cu SC cycles: 15 days at 1 mg/day + 15 days at 2 mg/day + 15-day washout per quarterly cycle structure; or weekly SC at clinician-and-patient-determined schedule. Reconstitution training per the GHK-Cu protocol §4.6.
Cosmetic-procedural workflow integration if elected. Microneedling, radiofrequency, fractional laser, PRP, focused-ultrasound per cosmetic-dermatology / aesthetic-medicine practice.

Layer-in evaluation timepoint within the comprehensive stack. Typically Month 6-12 depending on weight-loss trajectory; the ~30+ lb threshold is hit at Month 6-9 for many comprehensive-stack patients given the typical backbone-driven trajectory. The patient’s photographic baseline obtained at §3.8 (protocol entry) enables before-and-after comparison at the GHK-Cu trigger evaluation timepoint.

8.6 Post-discontinuation framing — multi-component-specific

Backbone post-discontinuation: weight-regain trajectory per the backbone protocol §8.5 (STEP-4 / STEP-1 extension for semaglutide — ~two-thirds of lost weight regained by 12 months; comparable trajectory expected for other backbones with backbone-specific data anchors). Tier 1 foundation continues as the durable intervention; some patients maintain a substantial portion of the weight loss on Tier 1 alone, particularly those who built strong resistance-training and nutritional patterns during the protocol arc. Re-initiation per §8 backbone protocol if regain warrants and patient agrees.

Lean-mass adjunct post-discontinuation: the lean-mass-preservation effect is from the active-cycle phase; post-discontinuation, the protective directional pressure is removed. However, the Tier 1 foundation continues and is the durable load-bearing intervention for ongoing lean-mass preservation. The expectation framing: the adjunct cycles bought favorable composition of the active weight-loss arc; the Tier 1 foundation maintains the favorable composition at the new set-point. Re-initiation pathway per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §8.6 if the patient enters another active-weight-loss arc or has emerging lean-mass concerns at the maintenance phase.

Visceral-fat adjunct post-discontinuation: tesamorelin effect attenuates after discontinuation (Falutz Phase 3 demonstrated VAT reversal on placebo crossover); the achieved VAT reduction is maintained partially by ongoing Tier 1 foundation and ongoing backbone (which maintains weight at the new set-point with proportional VAT outcomes). Re-initiation pathway per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §8.6 if VAT residual re-emerges.

Skin-laxity adjunct post-discontinuation: dermal-remodeling biology is active for ~12-24 months post-loss; GHK-Cu support during this window optimizes the natural remodeling. Post-discontinuation, the dermis has stabilized at the new state; further skin-quality improvement is more dependent on cosmetic-procedural intervention than on continued GHK-Cu. Per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §8.

8.7 Worked example — §1.6 canonical patient at Month 12-18

Continuing the Profile A canonical patient. At Month 12 the patient is in the comprehensive-stack reassessment phase.

Status at Month 12:

Backbone Wegovy 2.4 mg target dose continuing; HbA1c 6.3% sustained; UACR 28 mg/g; backbone in active-weight-loss-to-maintenance transition phase.
Lean-mass adjunct Cycle 2 completed at Month 11; current 4-week into Cycle 2 washout.
Total weight loss ~27 kg / 60 lb cumulative from baseline 99 kg → 72 kg (BMI 27).
DEXA at Month 12: total lean mass 44.5 kg; total fat mass 27.5 kg; VAT 1,200 g (down from baseline 2,100 → −900 g / −43%); waist circumference down 22 cm from baseline.
VCTE follow-up: F0-F1 fibrosis (improved from F1 at baseline); LFTs normalized.
Patient has crossed the ~30 lb / ~13.6 kg laxity-onset threshold at Month 7; now at ~60 lb cumulative loss.
Patient at consultation reports moderate skin laxity in abdominal region (loose skin / mild laxity grade 2 per the GHK-Cu protocol §1.4 phenotype taxonomy) and articulates skin-quality concern.

§7 visceral-fat adjunct reassessment. VAT 1,200 g (below the 1,500 g threshold; well below the baseline 2,100 g VAT-dominance trigger). VAT trajectory has resolved without the tesamorelin add-on. The §7 trigger is no longer present; tesamorelin is not indicated at this timepoint. Backbone + lean-mass adjunct combination was sufficient.

§8.5 skin-laxity adjunct layer-in trigger evaluation. All three trigger criteria met: ~30 lb threshold crossed (yes, at Month 7); GLP-1 maintenance-phase transition (yes, at Month 12 patient is transitioning); patient-articulated skin-quality concern (yes). Layer-in indicated.

§8.3 multi-component coordination at Month 12-18:

Backbone Wegovy continues at 2.4 mg weekly through the active-weight-loss-to-maintenance transition. At Month 18 patient and clinician assess whether to transition Wegovy to a maintenance dose (potentially 1.7 mg if Wegovy maintenance dose-down is elected per the backbone protocol §5 dose-adjustment trigger framing for stable weight) or continue at 2.4 mg as ongoing CWM treatment.
Lean-mass adjunct Cycle 2 washout completes at Month 12. Discontinuation decision: patient has reached the target weight (BMI 27 within the post-bariatric-nadir target range); lean-mass trajectory has been favorable (cumulative lean-mass-loss fraction ~17% — below the practitioner-observation target ~15-20%). Lean-mass-preservation goal achieved. Patient elects not to initiate Cycle 3. Lean-mass adjunct discontinued at end of Cycle 2 washout. Tier 1 foundation continues at the established cadence.
Visceral-fat adjunct not initiated (per §7.7 Option A decision; §7 reassessment at Month 12 confirms not needed).
Skin-laxity adjunct initiated at Month 12. GHK-Cu topical 2% serum daily evening; GHK-Cu injectable quarterly cycle (Tier 2 GHK-Cu protocol per the patient’s preference for the more aggressive option given the moderate laxity and the prior skin-laxity history). Photographic reassessment scheduled at Day 90 (Month 15) and Day 180 (Month 18) per the GHK-Cu protocol §5.

Status at Month 18:

Backbone Wegovy continues at 2.4 mg; weight stable at 73 kg (slight 1 kg uptick from Month 12 nadir of 72 — within typical maintenance-phase variability).
Lean-mass adjunct discontinued; lean-mass status preserved per Month 12 DEXA; Tier 1 foundation continues.
Skin-laxity adjunct (GHK-Cu) at Month 18 — Day 180 photographic reassessment shows clinically meaningful skin-quality improvement (improved texture, mild firming, partial laxity reduction in abdominal region); patient satisfied with response; continues GHK-Cu Tier 2 protocol for additional 6-12 months per the dermal-remodeling window.

Pre-conception planning conversation. Patient is post-menopausal — pre-conception planning not applicable. The §10 pre-conception conversation is not on the discussion list for this patient.

Re-initiation pathway documentation. If at any future timepoint the patient enters a new active-weight-loss arc (e.g., post-perimenopausal weight gain), lean-mass adjunct re-initiation per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §8.6 is available; backbone continues; visceral-fat adjunct re-evaluation per §7 trigger logic.

Pattern Z calibration applied to §8.7. The discontinuation decisions are patient-anchored. The lean-mass adjunct discontinuation is framed as “goal achieved at end of Cycle 2”; the skin-laxity adjunct initiation is framed as “trigger criteria met and patient-articulated concern” rather than as “the next step in the protocol.” The patient’s preference is the deciding factor in the borderline decisions (e.g., Tier 2 vs Tier 1 GHK-Cu protocol). No discontinuation is framed as failure; no initiation is framed as obligatory.

Pattern AA precision in §8.7. Backbone Wegovy 2.4 mg continued use is FDA-label-supported (chronic CWM indication). The lean-mass adjunct discontinuation framing is clinician-judgment-within-practitioner-consensus for the un-labeled regimen. The GHK-Cu layer-in is off-label clinical-judgment for the post-weight-loss-skin-laxity indication; no FDA approval exists for this use of GHK-Cu. The §10.6 combined-off-label framing has been carried throughout the protocol arc.

Pattern V cross-check at §8.7. The cumulative outcome data — total weight loss ~27 kg / 27%; lean-mass-loss fraction ~17%; VAT reduction ~43%; skin-quality response at Month 18 — is consistent with the STEP-1-class trial effect-size envelope (~14.9% weight reduction at 68 weeks; this patient achieved ~27% over a longer arc), with the practitioner-observation lean-mass adjunct expectation (~15-20% lean-mass-loss fraction; this patient ~17%), with the GLP-1-class VAT reduction in proportion to total weight loss plus the lean-mass adjunct’s secondary VAT-favorable effects, and with the cosmetic-formulation GHK-Cu topical-efficacy evidence base plus the mechanism-rationale practitioner-experience for injectable GHK-Cu. Each outcome dimension is anchored at its appropriate evidence resolution; no outcome dimension is generalized beyond what its evidence base supports.

9. Combination rules (THE STACK IS THE COMBINATION; redundancy logic; sequencing rules)

9.1 Purpose

§9 is the load-bearing operational section of this protocol — the protocol IS the combination. Where a single-compound protocol locates the combination conversation as a downstream consideration that bridges to other Module 5 protocols, this comprehensive-stack protocol IS the multi-component integration; §9 codifies the cross-component design rules that the rest of the protocol implements. §9 specifies:

Within-stack combinations: the four-layer mechanism integration (backbone × lean-mass × visceral-fat × skin-laxity) and the cross-layer biology.
Stack-redundancy rules: which backbone choices make certain adjunct layers redundant or contraindicated.
Cross-Module combinations beyond the four-layer stack: how the comprehensive stack interacts with other Module 5 protocols not in the four-layer architecture (e.g., SGLT2 inhibitor for T2D; metformin co-management; antihypertensive co-management; statins; OSA CPAP; bariatric-surgery history; behavioral / nutritional intensification).
Contraindicated combinations within the stack: the cross-component contraindications that the comprehensive stack must not produce.
Sequencing rules: the multi-phase phasing logic that §4-§5-§7-§8 implements.

Pattern W cross-section consistency applies: every combination decision in §9 is reconciled with §2 (no patient enters a combination with a contraindicated agent), §6 (combinations cannot mask or exacerbate AE-class concerns), and §10 (counseling beats for combinations are Pattern Z calibration-anchor-compliant).

9.2 The four-layer stack mechanism integration — within-stack combinations

The comprehensive stack IS the four-layer combination:

Layer 1 — Backbone (GLP-1 RA). Mechanism per §1.3. Drives the load-bearing total-weight reduction; backbone-specific receptor engagement determines secondary outcomes (CV; MASH; CKD; OSA; visceral fat for glucagon-receptor and amylin-receptor compounds). Backbone choice routes through [[Module 5 - Phenotype-Guided Decision Tree Protocol]].

Layer 2 — Lean-mass adjunct (CJC-Ipa+MOTS-c). Mechanism per §1.3 + per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §1.3. Engages GHRH-R + GHS-R1a + AMPK / myostatin pathways. Layered in at §5 timepoint per the phasing rules.

Layer 3 — Visceral-fat adjunct (Tesa+AOD). Mechanism per §1.3 + per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §1.3. Engages GHRH-R + (hypothesized) β3-AR / lipolytic pathway. Layered in at §7 timepoint per the phasing rules, conditional on §7.5 trigger and §9.4 redundancy considerations.

Layer 4 — Skin-laxity adjunct (GHK-Cu). Mechanism per §1.3 + per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §1.5. Engages fibroblast collagen-synthesis + antioxidant + anti-inflammatory pathways. Sequenced in at §8 timepoint per the cumulative-loss milestone trigger.

Cross-layer biology — non-redundant interactions:

Layer 1 × Layer 2. Backbone’s appetite-suppression / glucose-improvement / weight-loss mechanism is independent of Layer 2’s GH-axis / mitochondrial / anabolic-skeletal-muscle signaling. No mechanism redundancy. The Layer 2 stack’s clinical question (lean-mass-loss fraction of the backbone-driven weight loss) is operationally downstream of the Layer 1 effect; without Layer 1 driving weight loss, Layer 2 has no compositional question to address. Layer 2 cannot substitute for Layer 1; Layer 1 can operate without Layer 2 but the lean-mass-loss-fraction outcome will be governed by Tier 1 foundation alone.
Layer 1 × Layer 3. Backbone’s weight-loss-driven VAT reduction is mechanism-distinct from tesamorelin’s GH-axis VAT-selective lipolysis. Partial mechanism redundancy if backbone is retatrutide / survodutide / CagriSema / IcoSema. Glucagon-receptor agonism (retatrutide; survodutide) produces thermogenesis with VAT-selective effect that overlaps with tesamorelin’s mechanism. Amylin-receptor agonism (CagriSema; IcoSema) produces satiety with body-composition-shifting effects that secondarily reduce VAT. The §9.4 redundancy rules govern when to add Layer 3 versus when the backbone alone is sufficient for the VAT-targeting question.
Layer 1 × Layer 4. Backbone’s weight-loss driving the skin-laxity onset; Layer 4’s regenerative dermal support during the post-loss remodeling window. Mechanism-distinct; sequenced rather than concurrent.
Layer 2 × Layer 3. Both Layer 2 (CJC-Ipa) and Layer 3 (Tesa) engage GHRH-R. CJC-1295 is Mod-GRF 1-29 (modified first 29 amino acids of GHRH); tesamorelin is GRF(1-44) analog with trans-3-hexenoic acid N-terminal modification. Different molecules; same receptor family. Co-administration is not standard practice. The §9.4 redundancy rules direct sequential or substitution pathways rather than simultaneous co-administration. Rare exceptions per clinician judgment in specific phenotypes with intensified GH-axis activation goals; with elevated IGF-1 surveillance.
Layer 2 × Layer 4. Mechanism-distinct (Layer 2 anabolic-muscle vs Layer 4 regenerative-dermal). Compatible co-administration; injection-site rotation discipline.
Layer 3 × Layer 4. Mechanism-distinct. Compatible co-administration; injection-site rotation.

9.3 Stack-redundancy rules — when adjunct layers are mechanism-redundant or contraindicated by backbone choice

The most consequential stack-redundancy rule:

Rule R1 — Backbone is retatrutide / survodutide → Tesa+AOD layer-in is partially redundant; deferred unless VAT-residual after backbone response.

The glucagon-receptor agonism in retatrutide and survodutide produces thermogenesis with VAT-selective effects. The TRIUMPH program (retatrutide; per [[Retatrutide Protocol]]) and the SYNCHRONIZE / SYNERGY-NASH programs (survodutide; per [[Survodutide Protocol]]) document VAT reduction in the backbone trial program at magnitudes comparable to or exceeding what tesamorelin adds on a semaglutide / tirzepatide backbone.

For comprehensive-stack patients on retatrutide or survodutide:

Default §7 decision: defer tesamorelin add-on. Allow the backbone’s full VAT-targeting effect to play out over the active-weight-loss arc.
§7 reassessment at Month 7-9: if VAT residual remains above the patient’s clinical-meaningful threshold (typically 1,500 g) despite the backbone-driven response, the tesamorelin add-on becomes mechanism-additive and the §7 layer-in is indicated.
Pattern V framing: the direction-of-effect for tesamorelin add-on on a retatrutide / survodutide backbone is “mechanism-additive but with smaller incremental effect-size than on a semaglutide / tirzepatide backbone” — research-state-uncharacterized at the head-to-head trial level, practitioner-extrapolation.

Rule R2 — Backbone is CagriSema / IcoSema → Tesa+AOD layer-in is partially redundant; deferred unless VAT-residual after backbone response.

The amylin-receptor mechanism (cagrilintide as the amylin component of CagriSema; same amylin axis in IcoSema with the insulin icodec + semaglutide combo framing) produces body-composition-shifting effects with secondary VAT reduction. Similar deferred-by-default decision as Rule R1.

Rule R3 — Patient on CJC-Ipa+MOTS-c lean-mass adjunct → Tesa+AOD co-administration not standard.

CJC-1295 and tesamorelin are both GHRH analogs. Co-administration produces additive IGF-1 elevation; supraphysiologic IGF-1 elevation is the §6.10 dose-reduction trigger and is to be avoided. Two non-co-administration pathways:

Sequential pathway. Complete CJC-Ipa lean-mass cycle (12-16 weeks active + 4-8 weeks washout); transition to tesamorelin in a subsequent phase if VAT-residual trigger remains at the end of the lean-mass cycle.
Substitution pathway. If VAT is the dominant residual concern at the §7 timepoint and lean-mass trajectory has been favorable through Cycle 1 of the lean-mass adjunct, discontinue CJC-Ipa after Cycle 1 and substitute tesamorelin for the visceral-fat-targeting phase. MOTS-c may continue (different mechanism class) or pause per clinician judgment.

The substitution pathway is used when the patient’s clinical priorities shift mid-protocol toward visceral-fat targeting over lean-mass preservation. Most comprehensive-stack patients run the sequential pathway with CJC-Ipa first and tesamorelin (if indicated) second.

Rule R4 — Pre-existing acromegaly or pituitary tumor → All GH-axis components contraindicated.

Layer 2 (CJC-Ipa) and Layer 3 (Tesa) both contraindicated. Backbone may continue. MOTS-c may be clinician-judgment-eligible (different mechanism class; AMPK pathway, not GH-axis-direct). GHK-Cu unaffected.

Rule R5 — Active malignancy or <5y from cancer treatment → GH-axis components contraindicated.

Same as Rule R4 in operational effect.

Rule R6 — Proliferative diabetic retinopathy → GH-axis components contraindicated.

Same as Rule R4 in operational effect. Backbone (GLP-1 RA) may continue with ophthalmology surveillance per the SUSTAIN-6 retinopathy-rapid-improvement signal posture.

Rule R7 — Pregnancy or active conception → Entire stack contraindicated.

All components discontinued per §8.4 consolidated pre-conception washout coordination. Stack is not initiated within pregnancy planning window.

Rule R8 — Wilson’s disease → GHK-Cu contraindicated.

Skin-laxity adjunct not used. Other layers unaffected.

9.4 Cross-Module combinations beyond the four-layer stack

The comprehensive stack interacts with other clinical interventions that are not within the four-layer architecture:

Within-Module-5 cross-protocol combinations:

GLP-1 RA backbone + SGLT2 inhibitor (T2D context). Class-additive HbA1c and CV / kidney benefits; commonly co-prescribed in T2D + CKD or T2D + ASCVD context. Compatible with the comprehensive stack. Mechanism per backbone protocol §9.2; the SGLT2 inhibitor adds glucose-osmotic-diuretic and ketogenesis-modulating effects.
GLP-1 RA backbone + insulin (T2D advanced). Common in T2D with progressed beta-cell failure. §6.12 hypoglycemia management applies; concurrent insulin dose reduced ~20% at backbone initiation. Compatible with the comprehensive stack with intensified glucose surveillance given the lean-mass adjunct GH-axis directional pressure.
GLP-1 RA backbone + metformin. Standard T2D combination. Compatible.
GLP-1 RA backbone + DPP-4 inhibitor: NOT indicated. Mechanistic overlap; redundant. Avoid co-prescribing.
GLP-1 RA backbone + cagrilintide / amylin analog as monotherapy or as CagriSema fixed-combination. Per [[CagriSema Protocol]] and [[Cagrilintide Protocol]]. Effect-additive on weight loss; the comprehensive-stack-with-CagriSema-backbone is one of the higher-efficacy backbone choices.
GLP-1 RA semaglutide + GLP-1 RA tirzepatide concurrent: NOT indicated. Within-class redundant; transition between agents (§7 algorithm), not co-administration.

Cross-Module combinations:

GLP-1 RA backbone + statin + antihypertensive + standard polypharmacy. Compatible. The comprehensive-stack patient with metabolic-syndrome cluster (Profile C canonical) is typically on multiple background medications; the comprehensive stack does not require their discontinuation.
Backbone + bariatric surgery history (gastric bypass; sleeve gastrectomy; revisional procedures). Compatible. The Profile A canonical patient is the post-bariatric weight-regain phenotype; the comprehensive stack is designed for this presentation. Anatomical considerations for the backbone GLP-1 RA absorption (oral semaglutide / Rybelsus has specific absorption-context considerations per [[Semaglutide Protocol]] for post-bariatric patients) but the injectable backbones are not affected by gastric anatomy.
Backbone + CPAP for OSA. Compatible. The Profile A canonical patient is on CPAP. CPAP-adherence is the relative-exclusion-mitigation for the lean-mass adjunct §2.3 OSA consideration (GH-axis-mediated soft-tissue effects can theoretically exacerbate OSA; CPAP-adherence mitigates).
Behavioral / nutritional / activity program intensification (Tier 1 foundation +). Compatible and load-bearing. The Tier 1 foundation IS the load-bearing intervention for lean-mass preservation; the lean-mass adjunct presupposes Tier 1 adherence per §2.2. Intensive behavioral therapy (IBT) per STEP-3 effect-additive framing per the backbone protocol §7.5 is compatible.
Behavioral health co-management (mental health, eating-disorder treatment, addictions). Active eating disorder is §2.3 relative exclusion / §2.4 hard contraindication; behavioral-health co-management is the appropriate pathway.

9.5 Sequencing rules — the multi-phase phasing logic

The sequencing rules formalize the §4-§5-§7-§8 phasing logic into rule form:

Rule S1 — Backbone titration completes before lean-mass adjunct initiation.

The backbone must reach target dose (Month 4 for Wegovy 2.4 mg per the standard titration schedule; backbone-specific timing for other compounds) before the lean-mass adjunct is initiated. Rationale: the backbone’s effect-size is unstable during titration; the lean-mass adjunct decision data (Month 4 DEXA showing lean-mass-loss fraction) requires the backbone to be at steady-state. Exception: if the patient is on slow-titration extending the backbone titration to Month 6-8, the lean-mass adjunct decision is at the slow-titration target-dose-attainment timepoint, not at Month 4 calendar time.

Rule S2 — Lean-mass adjunct cycle 1 completes before visceral-fat adjunct add-on (sequential pathway).

If both lean-mass adjunct and visceral-fat adjunct are indicated by triggers, the sequential pathway runs lean-mass adjunct first. Rationale: GHRH-R overlap (Rule R3); lean-mass concern typically presents earlier in the active-weight-loss arc than visceral-fat-residual concern (which requires substantial backbone response before the residual question emerges).

Rule S3 — Skin-laxity adjunct sequenced at cumulative-loss milestone or maintenance-phase transition.

GHK-Cu is initiated at the ~30+ lb / ~13.6+ kg cumulative-loss milestone (typically Month 6-9 of the comprehensive stack) or at the GLP-1 maintenance-phase transition (typically Month 12-24). Rationale per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §1.3 — the dermal-remodeling window opens with substantial weight loss; pre-loss initiation is mechanism-mistimed (the dermis is not yet in the remodeling state where the regenerative support is mechanistically relevant).

Rule S4 — Single-component-at-a-time initiation; no simultaneous multi-component starts.

A new component is initiated, the patient is monitored for tolerability and AE patterns for at least 2-4 weeks, and a second component (if indicated) is added thereafter. Rationale: AE attribution discipline; safety. Simultaneous initiation of multiple components produces attribution-uncertainty when AEs emerge.

Rule S5 — Discontinuation sequencing per §8.3.

When transitioning the comprehensive stack toward maintenance or discontinuation, the visceral-fat adjunct is typically discontinued first (course completion), the lean-mass adjunct second (cycle washout serves as taper), the skin-laxity adjunct continues per the dermal-remodeling window, and the backbone transitions to maintenance phase per the backbone protocol.

9.6 Contraindicated combinations within the stack

Beyond the per-component hard contraindications (per §2.4), specific stack-level contraindicated combinations:

CJC-Ipa+MOTS-c lean-mass adjunct + Tesa+AOD visceral-fat adjunct co-administration (simultaneous). Per Rule R3. Sequential or substitution pathway instead.
Backbone semaglutide + Backbone tirzepatide (or any two same-class GLP-1 RAs concurrent). Within-class redundant. Transition, not co-administration.
Backbone GLP-1 RA + DPP-4 inhibitor. Mechanistic redundancy.
GH-axis components + active malignancy. Per Rule R5.
GH-axis components + acromegaly / pituitary tumor. Per Rule R4.
GH-axis components + proliferative DR. Per Rule R6.
GHK-Cu + Wilson’s disease. Per Rule R8.
Any component + pregnancy. Per Rule R7.

9.7 Worked example — §1.6 canonical patient stack composition

Continuing the Profile A canonical patient. Backbone selection: semaglutide (Wegovy 2.4 mg).

Stack composition decision walkthrough:

Backbone: semaglutide. Phenotype routing per §10.4 comparator conversation produced semaglutide election. No Rule R1 / R2 backbone-driven redundancy considerations apply (semaglutide is GLP-1-monotherapy class; not glucagon-receptor or amylin-receptor compound).
Lean-mass adjunct (CJC-Ipa+MOTS-c): indicated per §1.4 trigger profile. No Rule R4 / R5 / R6 contraindications. Initiated at §5 Month 4 timepoint per Rule S1.
Visceral-fat adjunct (Tesa+AOD): §1.4 trigger present (baseline VAT 2,100 g; MASLD; android distribution). Rule R3 applies (CJC-Ipa is on the stack — sequential or substitution pathway). Per §7.7 worked example, Option A elected — defer through Cycle 2 of lean-mass adjunct; reassess at Month 12. Per §8.7 Month 12 reassessment, VAT is now 1,200 g and trigger is no longer present; tesamorelin not initiated. Stack does not include Layer 3 for this patient.
Skin-laxity adjunct (GHK-Cu): §8.5 trigger criteria met (cumulative-loss milestone crossed at Month 7; maintenance-phase transition at Month 12; patient-articulated skin-quality concern at Month 12). Layered in at Month 12 per Rule S3.

Final stack composition for this patient over the Month 0-18 arc:

Months 0-4: Backbone alone (Wegovy titration); Tier 1 foundation onboarding.
Months 4-7: Backbone + Lean-mass adjunct Cycle 1; Tier 1 foundation.
Months 7-11: Backbone + Lean-mass adjunct Cycle 2 (with Cycle 1 washout between); Tier 1 foundation.
Months 11-12: Backbone + Cycle 2 washout; Tier 1 foundation.
Months 12+: Backbone (maintenance-phase consideration) + Skin-laxity adjunct (GHK-Cu Tier 2 protocol); Tier 1 foundation.

Peak overlap analysis. At Month 5-7 (Lean-mass adjunct Cycle 1 active), the patient was managing: 1 weekly Wegovy SC + 5 CJC-Ipa SC bedtime + 3 MOTS-c SC AM = 9 SC injections per week. At Month 12+, the patient is managing: 1 weekly Wegovy SC + GHK-Cu injectable cycles (15 days at 1 mg/day + 15 days at 2 mg/day + 15-day washout = approximately 8 SC injections per quarterly cycle window when GHK-Cu is in active dosing) = approximately 1-2 SC injections per week most of the time + topical GHK-Cu daily evening. Peak overlap was Month 5-7; current Month 12+ regimen is operationally simpler. The §10.7 logistics conversation prepared the patient for this trajectory.

Pattern Z calibration applied to §9.7. The stack composition decisions are phenotype-anchored to the §1.4 triggers and patient-anchored within the multi-component options. No layer is added because “more is better”; each layer addition is decision-tree-routed through the §7 / §8 trigger logic and the §10 patient-counseling beats. The §9.4 redundancy rules prevented an unnecessary tesamorelin add-on (Layer 3 was deferred and then determined not needed); the comprehensive stack collapsed to a 3-layer regimen (backbone + lean-mass + skin-laxity) for this patient — not the maximalist 4-layer regimen.

Pattern V cross-check at §9.7. Each layer’s effect-size is anchored at its evidence resolution: backbone STEP-1 / SUSTAIN / SELECT / FLOW envelope; lean-mass adjunct practitioner-observation; skin-laxity adjunct cosmetic-formulation topical-efficacy + mechanism rationale + practitioner-experience. No layer is generalized beyond its evidence base.

Pattern AA precision in §9.7. Backbone Wegovy is FDA-approved-for-marketing-claims (CWM indication); lean-mass adjunct is not FDA-approved-for-marketing-claims (research peptides); skin-laxity adjunct is not FDA-approved as a drug (cosmetic-ingredient / research peptide). The combined regimen is off-label clinical-judgment integration. §10.6 counseling beat carries this framing throughout.

10. Patient counseling beats (Pattern Z calibration-anchor-compliant)

10.1 Purpose

Define the comprehensive-stack patient-counseling content — the conversations the clinician has with the patient at each protocol phase. §10 is the operational anchor for Pattern Z (cumulative-tone calibration) and for Pattern R (lead-framing calibration); the counseling beats are the most reader-facing content the protocol produces and are the most vulnerable to drift from “presenting facts” to “steering decisions.”

For the comprehensive stack, Pattern Z anchor 5 (off-label / extrapolation transparency) is DOMINANT because the combined regimen as a whole is off-label even when each individual component is on-label or has its own regulatory state. Anchor 4 (multi-dimensional comparator framing) is second-most-load-bearing because the backbone-choice conversation, the stack-vs-simpler-stack conversation, and the layer-in conversations all engage multi-dimensional fact presentation. Anchors 1+2 (compounded counseling) apply to every component with compounded options. Anchor 3 (pregnancy) is operationally amplified by the multi-component consolidated-washout coordination.

The five Pattern Z calibration anchors are verbatim examples from semaglutide v1.0-final (per /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md). Each comprehensive-stack patient-counseling beat below verifies against the canonical anchor structure.

10.2 The initiation conversation — comprehensive-stack roadmap

The initiation conversation occurs at the §3 workup completion / §4 backbone initiation visit. Required counseling beats for the comprehensive stack:

What the backbone is and what it does (Anchor 1, Anchor 4): name, class, mechanism in plain language; expected effect-size with trial-anchor precision; comparator framing if patient has within-class alternatives.
What the comprehensive stack is (Anchor 1, comprehensive-stack-specific): “The plan we’ve discussed is a coordinated multi-phase clinical program with four layers — the GLP-1 medication you’ll start with as the primary therapy, then a lean-mass-preservation stack we’ll add at Month 4 if the body-composition trajectory indicates, then we’ll evaluate visceral-fat targeting at Month 7-9, and we’ll add the skin-support layer when you reach about 30 pounds of cumulative loss. We’re not starting everything at once — each component is sequenced based on what’s happening in your body and what the data show. The total program is typically 12-24 months of active phase, then a transition into maintenance.”
The titration schedule for the backbone (§4): standard pace and slow-titration option.
The AE profile expected on the backbone (§6.2 + backbone protocol §6): nausea anticipated, typically attenuates, management strategies.
The injection-burden framing transparently (Anchor 5, comprehensive-stack-specific): “Today you’re starting with one weekly injection. By Month 5-6, if we add the lean-mass adjunct, you’ll be doing one weekly plus 5 bedtime injections (small, insulin-syringe-sized) plus 3 morning injections. That’s the peak overlap — approximately 9 small SC injections per week. It’s a real commitment that I want you to know about going in. The technique is the same as what you’ll learn for the Wegovy pen — most patients describe it as ‘similar to the GLP-1 injection, just more frequent.’ If at any point the regimen is too much, we taper the adjunct components, not the backbone — the backbone is the load-bearing medication. We do the comprehensive layered approach because the body-composition outcomes (preserving muscle, targeting belly fat, supporting skin after major loss) matter for your overall goal, and the layered approach has mechanistic and practitioner-experience support for those outcomes. But the simpler approach — backbone alone with strong Tier 1 foundation — is also legitimate. Let’s discuss what feels right for you.”
The cost-and-access framing transparently (Anchor 2 + Anchor 5): “Total program cost varies depending on insurance coverage and compounded vs FDA-approved pathways for each component. A typical month at peak overlap is 1, 000−2,500 all-in. Some of that may be insurance-covered; some typically isn’t. The compounded vs FDA-approved decision applies particularly to the backbone (where compounded options exist for some agents) and to the adjunct components (where compounded is the access pathway for the research peptides). Let me walk you through the specific economics of each component as we’d plan them for you.”
The Tier 1 foundation framing (load-bearing precision): “The foundation of this program — what we call Tier 1 — is resistance training 2-3 times per week, protein intake of 1.2-1.6 grams per kilogram body weight per day, vitamin D adequacy, and consistent sleep. The pharmacological components — the backbone and the adjuncts — work on top of this foundation. Without the foundation, particularly the resistance training and protein, the lean-mass-preservation goal isn’t achievable just by adding peptides. So the foundation is the load-bearing intervention, and the peptides are the additive layers on top of it. Building the foundation is part of what we’re doing during the Month 0-4 backbone titration phase.”
The combined-off-label framing (Anchor 5, comprehensive-stack-specific load-bearing): “The combination of these components as I’ve described it — your specific backbone plus the lean-mass adjunct plus eventually the visceral-fat adjunct and the skin-support layer — is an off-label clinical-judgment integration of components with individual evidence bases of varying strength. Each component has its own evidence base. The backbone’s evidence base is the strongest — large Phase 3 trials and FDA approval for your indication. The lean-mass adjunct components have mechanism evidence and human PK/PD evidence but no Phase 3 RCT of the combined regimen; they’re research peptides accessed through compounding. The visceral-fat adjunct uses tesamorelin (FDA-approved for HIV-related fat redistribution, off-label for your context) and AOD-9604 (investigational with development-discontinued status). The skin-support layer (GHK-Cu) has mechanism evidence and cosmetic-formulation topical-efficacy data, plus practitioner experience, without an RCT for post-weight-loss skin laxity specifically. The integration logic is mechanism-based and practitioner-experience-based, not Phase-3-RCT-confirmed at the combined-regimen level. I want you to know that going in. We’ll track the outcomes objectively at each phase, and if any component isn’t producing the expected benefit, we discontinue that component.”
The pre-conception planning framing for reproductive-age patients (Anchor 3): consolidated pre-conception washout coordination per §8.4.
Escalation pathway (the symptoms that warrant in-person evaluation within 48 hours).

10.3 Compounded-vs-FDA-approved counseling (Anchors 1 + 2) — comprehensive-stack-specific

For each component, the compounded-vs-FDA-approved counseling beat per the component protocol’s §10. Comprehensive-stack-specific synthesis:

Backbone (semaglutide; tirzepatide; etc.). FDA-approved branded options (Wegovy / Ozempic; Zepbound / Mounjaro) plus compounded options per [[Semaglutide Protocol]] §10.3 / backbone-specific. Compounded counseling beat per Anchor 2 verbatim canonical structure: open with what compounded IS (real clinical option used by substantial patient population; 503A / 503B regulatory pathways); operational characteristics framed factually; quality criteria framed as what clinicians evaluate; closes with shared-decision-making.
Lean-mass adjunct (CJC-Ipa+MOTS-c). Per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §10.3. Compounded is the access pathway — these are research peptides; no FDA-approved branded option. The counseling framing is “compounded is the access pathway for these research peptides under the 503A regulatory framework; quality criteria for compounding pharmacy selection apply.” Pattern Z anchor 5 framing per the lean-mass adjunct protocol — the off-label / research-state precision is dominant.
Visceral-fat adjunct (Tesa+AOD). Per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §10.3. Tesamorelin is FDA-approved as Egrifta / Egrifta SV / Egrifta WR with specialty-pharmacy distribution (branded list price 2, 000−3,000+/month) and also available through 503A / 503B compounding (typically 200−500/month). AOD-9604 is investigational; 503A compounding pathway.
Skin-laxity adjunct (GHK-Cu). Per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §10.4. Topical layer is cosmetic-ingredient category (widely available; cosmetic formulations not FDA-approved as drugs). Injectable layer is research-classified peptide via 503A compounding. The counseling framing differentiates the two access pathways.

Comprehensive-stack-specific synthesis counseling beat:

“Each component has its own access pathway. Your backbone (Wegovy) is FDA-approved and typically available through specialty pharmacy or some chain pharmacies — insurance coverage varies. The lean-mass adjunct components are research peptides accessed through 503A compounding pharmacies; we’ll select a pharmacy with documented sterility testing, per-batch certificates of analysis, cold-chain shipping, and state licensure. Tesamorelin (if we add it later) has both FDA-approved and compounded pathways; we’ll discuss the economics at that point. GHK-Cu has a widely available cosmetic-ingredient topical pathway and a 503A compounded injectable pathway. The decisions are practical — we choose what works best for your situation at each phase.”

10.4 Backbone-choice comparator conversation (Anchor 4) — comprehensive-stack-specific

For patients with within-class alternatives. Per [[Module 5 - Phenotype-Guided Decision Tree Protocol]] §13 framing applied at the comprehensive-stack-entry conversation. Anchor 4 verbatim canonical structure: multi-dimensional fact presentation across 8+ dimensions.

For the §1.6 canonical patient (T2D + CWM + CKD-in-T2D + MASLD + post-bariatric + comprehensive-stack candidate):

“We have three primary backbone choices to discuss: semaglutide, tirzepatide, and retatrutide. Each has its own evidence profile and tradeoffs.

Semaglutide (Wegovy 2.4 mg or Ozempic dose). FDA-approved for CWM (STEP-1 ~14.9% weight reduction at 68 weeks), for T2D (SUSTAIN program ~1.8 percentage-point HbA1c reduction), for CV risk reduction in T2D+ASCVD (SUSTAIN-6 ~26% MACE reduction), for non-diabetic CV risk reduction in BMI ≥27 + ASCVD (SELECT ~20% MACE reduction), for MASH F2/F3 (ESSENCE 2025 approval), for CKD in T2D (FLOW ~24% kidney composite reduction). Most-broad indication coverage. NAION signal documented per Hathaway 2024 (post-marketing pharmacovigilance; not labeled warning). One weekly SC injection.

Tirzepatide (Zepbound 15 mg or Mounjaro dose). FDA-approved for CWM (SURMOUNT-1 ~22.5% weight reduction at 72 weeks) and T2D (SURPASS-2 head-to-head: ~2.3 percentage-point HbA1c reduction vs semaglutide 1 mg ~1.9). Higher weight-loss magnitude than semaglutide per SURMOUNT-5 head-to-head (~6.5 percentage-point difference favoring tirzepatide). CV outcomes (SURMOUNT-MMO) in progress. MASH program in development; kidney program in development. NAION signal absent per Lawrenson 2025 (class-differentiation finding). One weekly SC injection.

Retatrutide (investigational; TRIUMPH program). Highest investigational weight-loss magnitude — Phase 2 data reported ~24% at 48 weeks; Phase 3 TRIUMPH program in progress. Not FDA-approved as of 2026-05-14; status to be verified at time of consideration. Pre-approval access pathway differs. Compounded options exist in some jurisdictions but the regulatory status is heterogeneous and changing. Pattern AA precision: pre-approval; not labeled.

For your specific situation — T2D HbA1c 7.4 with MASLD and microalbuminuria within FLOW range and ASCVD risk factors though no events yet — semaglutide has the broadest current indication coverage. Tirzepatide has the higher weight-loss magnitude advantage, which matters given your 50-60 pound target. Retatrutide has the highest investigational magnitude but the pre-approval access is more uncertain.

Beyond weight magnitude, the comprehensive-stack-specific considerations: for the lean-mass adjunct layering, all three backbones are compatible; the stack design doesn’t change much by backbone. For the visceral-fat adjunct, retatrutide’s glucagon-receptor mechanism produces additional VAT-targeting that may make the tesamorelin add-on redundant — that’s relevant if visceral fat is a major clinical priority. For your post-bariatric history, injectable backbones aren’t affected by gastric anatomy; oral semaglutide (Rybelsus) has absorption considerations post-bariatric that injectable semaglutide doesn’t have.

Here are the dimensions: weight magnitude (tirzepatide > semaglutide; retatrutide > tirzepatide investigational); T2D HbA1c (similar advantage pattern); MASH approval (semaglutide); CKD-in-T2D approval (semaglutide); CV evidence base (semaglutide most established); NAION class-differentiation (signal for semaglutide; absent for tirzepatide); investigational vs FDA-approved (retatrutide investigational); injection burden (all weekly SC); cost (insurance-dependent); your stack-specific considerations (visceral-fat redundancy on retatrutide; lean-mass adjunct compatibility on all three). Which factors matter most for your situation?“

Patient elects semaglutide given the broad indication coverage matching her comorbidity profile and her articulated comfort with semaglutide based on her endocrinologist’s discussion. The §10.4 conversation closes with the shared-decision-making invitation pattern per Anchor 4 verbatim canonical.

10.5 The stack-vs-simpler-stack comparator conversation (Anchor 4) — comprehensive-stack-specific

The comprehensive-stack-specific Anchor 4 conversation: the patient is weighing the full 4-layer comprehensive stack against simpler stack alternatives (backbone alone; backbone + lean-mass only; backbone + visceral-fat only; etc.).

Comparator framing across the stack-completeness dimensions:

“We’ve discussed the comprehensive 4-layer stack as one option. There are simpler alternatives that may be appropriate depending on what’s most important to you. Let me walk through the options.

Option 1 — Backbone alone (Wegovy + Tier 1 foundation). Total-weight reduction per STEP-1 envelope; lean-mass-loss fraction typically 20-32% (Phase-3-pooled range); VAT reduction in proportion to total weight loss; some residual visceral fat in many patients; skin-laxity outcomes dependent on Tier 1 + dermal-remodeling biology + patient-specific factors. Cost: lowest. Injection burden: 1 weekly. Indication coverage: broadest with semaglutide.

Option 2 — Backbone + lean-mass adjunct (Wegovy + CJC-Ipa+MOTS-c + Tier 1). Total-weight reduction same as Option 1 (lean-mass adjunct doesn’t drive weight loss). Lean-mass-loss fraction practitioner-observation expectation 15-20% in adherent patients (improvement vs Option 1). VAT reduction similar to Option 1 with potentially modest GH-axis-mediated favorable adjustment. Skin-laxity outcomes same as Option 1. Cost: backbone + ~200 − 400/monthadjunct= 300-800/month all-in. Injection burden: 1 weekly + 8 adjunct SC per week during cycles. Cycles: 1-3 over the active arc.

Option 3 — Backbone + visceral-fat adjunct (Wegovy + Tesa+AOD + Tier 1). Total-weight reduction same as Option 1. Lean-mass-loss fraction same as Option 1. VAT reduction enhanced — practitioner-extrapolation from Falutz Phase 3 (~15-20% VAT reduction in HIV-lipodystrophy; non-HIV extrapolation). Skin-laxity outcomes same as Option 1. Cost: backbone + ~200 − 500/monthtesamorelin(compounded)+ 150-300/month AOD = ~$350-1,100/month all-in. Injection burden: 1 weekly + daily tesamorelin + daily AOD. Duration: 12-26 weeks typically.

Option 4 — Comprehensive 4-layer stack (your indicated full stack). All four layers in sequenced phasing. Total-weight reduction per Option 1. Lean-mass-loss fraction per Option 2. VAT reduction per Option 1 (with §7 reassessment for Option 3 add-on if indicated). Skin-laxity outcomes enhanced by Option 4 GHK-Cu layer per the cosmetic-formulation evidence base. Cost: highest at peak overlap; phasing structure means most months are 2-3 layer rather than 4-layer. Total cost range 1, 000−2,500/month at peak overlap; $500-1,500/month for most of the arc.

Option 5 — Hybrid approaches. Backbone + lean-mass + skin-laxity without visceral-fat layer (typical given the §7 redundancy decisions). Or backbone + skin-laxity without adjunct middle layers. These hybrid options are reasonable.

Your indication profile makes Option 4 appropriate per the §1.4 phenotype triggers (post-menopausal sarcopenia risk; high target weight loss; VAT-dominant phenotype; prior skin-laxity history; multi-component goal articulated). But Option 2 (skip the visceral-fat layer) and Option 4-minus-Layer-3 are very reasonable alternatives. Option 1 alone would not address the lean-mass concern adequately given your phenotype. Option 3 without the lean-mass layer would address VAT but leave the lean-mass concern unaddressed. The full Option 4 is the most thorough integration; the §7 phasing decisions may collapse it to Option 4-minus-Layer-3 if the backbone-plus-lean-mass response is sufficient for VAT.

Which of these options aligns with what you’re hoping to accomplish, and what’s your sense of the regimen complexity tradeoff?“

Patient elects Option 4 with explicit acknowledgment that the §7 phasing may reduce it to Option 4-minus-Layer-3 — the comprehensive-stack approach with the understanding that not every layer will necessarily be activated.

Pattern Z anchor 4 compliance check. Multi-dimensional fact presentation (cost; injection burden; weight magnitude; lean-mass-loss fraction; VAT reduction; skin-laxity outcomes; clinical evidence resolution per layer). Each option presented with its tradeoffs acknowledged factually. The patient’s preference is solicited. The conversation does NOT steer toward maximalism or toward minimalism; both extremes would fail Anchor 4. Closes with shared-decision-making invitation.

10.6 The combined-off-label framing conversation (Anchor 5) — LOAD-BEARING for the comprehensive stack

The §10.6 conversation is the load-bearing Pattern Z anchor 5 application for this protocol. The combined regimen is off-label even when individual components have their own regulatory states. The patient must understand this at protocol entry, at each layer-in decision, and at any treatment-effect-evaluation timepoint.

Verbatim-calibrated counseling beat (per Anchor 5 canonical structure):

“What we’ve been discussing — the integrated stack of these four components in sequence — is an off-label clinical-judgment integration. Let me be precise about what that means.

Each individual component has its own regulatory state. The backbone (Wegovy) is FDA-approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with comorbidity — that includes you. It’s FDA-approved for the on-label indication. The lean-mass adjunct components — CJC-1295, Ipamorelin, and MOTS-c — are NOT FDA-approved as drugs for any indication. They are research peptides accessed through 503A compounding pharmacies. They have mechanism evidence and human PK/PD evidence (CJC-Ipa) and mechanism + animal-model evidence (MOTS-c) but no Phase 3 RCT for any drug indication. The visceral-fat adjunct includes tesamorelin (FDA-approved for HIV-associated lipodystrophy; off-label for your context, which is a standard clinical pathway for off-label use of an FDA-approved drug) and AOD-9604 (investigational with development-discontinued sponsor; preclinical-load-bearing evidence base; 503A compounding pathway). The skin-support layer (GHK-Cu) is not FDA-approved as a drug — topical is cosmetic-ingredient regulatory category, injectable is research peptide via 503A compounding.

The combined regimen has no FDA approval. No Phase 3 RCT has evaluated the four-component sequenced integration we’re discussing. The integration logic is mechanism-based and practitioner-experience-based. The published evidence supports the individual components at their respective evidence resolutions; the combined regimen as we’ve designed it is a clinical-judgment integration anchored in the mechanism rationale of each component and in the practitioner cohort that has used these in combination for similar indications.

What that means for our decision-making. We will track outcomes objectively. The backbone effect-size is anchored to the STEP-1 trial envelope — about 15% weight reduction at 68 weeks for the typical patient. The lean-mass adjunct’s practitioner-observation expectation is reducing the lean-mass-loss fraction of the weight loss from typical 20-32% toward 15-20% in adherent patients with Tier 1 foundation. The visceral-fat adjunct’s effect-size extrapolation is from Falutz Phase 3 — about 15-20% VAT reduction over 26-52 weeks in HIV-lipodystrophy, with the non-HIV-population extrapolation as research-state-incomplete. The skin-support layer has mechanism evidence and cosmetic-formulation topical-efficacy data; the specific post-weight-loss skin-laxity outcome doesn’t have an RCT.

At each phase, if a component isn’t producing the expected benefit, we discontinue that component. The lean-mass adjunct is evaluated at the Month 7 DEXA — if the lean-mass-loss-fraction trajectory hasn’t improved, we discontinue the adjunct and continue the backbone with Tier 1 alone. The visceral-fat adjunct is evaluated against the §7 trigger logic — if VAT isn’t a residual concern after the backbone-plus-lean-mass-adjunct response, the visceral-fat adjunct isn’t added or is discontinued. The skin-support layer is evaluated at Day 90 / Day 180 photographic reassessment — if the response isn’t clinically meaningful, we discontinue and discuss surgical consultation or alternative cosmetic-dermatology approaches.

Your informed-consent acknowledgement. You understand that the combined regimen is off-label, that the integration logic is mechanism-and-practitioner-experience-based rather than Phase-3-RCT-confirmed at the combined-regimen level, that we will track outcomes objectively, and that we will discontinue any component that isn’t producing the expected benefit. The decision to proceed is yours. The decision to discontinue any layer at any time is also yours.

Re-evaluation if labeled indication emerges. If FDA approval for any of these components for the indications we’re using them for is subsequently granted, the use transitions from off-label to label-supported; the counseling re-anchors at that transition. As of today (2026-05-14), the regulatory states are as I’ve described.“

Patient acknowledges informed-consent framing and proceeds.

Pattern Z anchor 5 compliance check. Explicit off-label framing for each component and for the combined regimen. Primary-source rationale (mechanism evidence; published evidence base per component). Informed-consent acknowledgement explicit. Re-evaluation pathway documented. Patient’s decision is patient-anchored.

10.7 The injection-burden and logistics conversation (Pattern Z.injection-framing — transparent, not minimizing)

The §10.7 conversation is the practical logistics framing for the comprehensive stack. Pattern Z.injection-framing applies — the framing is transparent, not minimizing the burden but also not pre-loading with “daunting” or “intimidating” vocabulary.

Verbatim-calibrated counseling beat:

“Let me walk through the practical logistics of the comprehensive stack. I want to be honest with you about what the day-to-day looks like, not minimize it but also not exaggerate it.

Months 0-4 (backbone titration). One weekly SC injection. Wegovy pre-filled pen. The pen is used at home, weekly, same day each week (you’ll pick a day). Technique is straightforward — most patients are confident after the first one or two self-administrations. Refrigerated storage. AE pattern is most pronounced during titration (nausea most common; typically attenuates).

Months 4-7 (Cycle 1 of lean-mass adjunct, if elected at Month 4). One weekly Wegovy injection + 5 bedtime injections per week (Monday-Friday, off Saturday-Sunday) of combined CJC-1295 + Ipamorelin from a reconstituted vial using an insulin syringe + 3 morning injections per week (Monday/Wednesday/Friday, or daily-cycling-equivalent) of MOTS-c. That’s approximately 9 total SC injections per week. Each individual injection takes about 30 seconds. The reconstitution discipline for CJC-Ipa is one-vial-per-week for combined injections — you’ll do reconstitution once a week. MOTS-c is reconstituted per cycle (5-10 mg per vial). Storage: refrigerated for reconstituted vials, room temperature for lyophilized.

Months 7-12 (Cycle 2 with washout; visceral-fat adjunct decision; skin-laxity adjunct trigger). Cycle 2 of lean-mass adjunct same as Cycle 1; washout between cycles is 4-8 weeks at backbone-only. Visceral-fat adjunct (if §7 indicates) adds daily tesamorelin SC + daily AOD-9604 SC — that’s 2 additional daily injections during the 12-26 week visceral-fat-adjunct phase. Skin-laxity adjunct (when §8 indicates) adds GHK-Cu topical daily evening + GHK-Cu injectable cycles (15 days at 1 mg/day + 15 days at 2 mg/day + 15-day washout per quarterly cycle window).

Peak overlap. The maximum-injection-burden timepoint is Months 5-9 if both lean-mass and visceral-fat adjuncts are active (Tier 1 of CJC-Ipa+MOTS-c × Tier 1 of Tesa+AOD). That’s potentially: 1 weekly Wegovy + 5 CJC-Ipa SC + 3 MOTS-c SC + 7 daily tesamorelin SC + 7 daily AOD SC = 23 total SC injections per week. That’s the rare peak. In practice, most patients don’t run both lean-mass and visceral-fat adjuncts simultaneously per the §9.4 redundancy rules — typically sequential or substitution. So the typical peak is 9 SC injections per week (lean-mass adjunct cycle on backbone) or 15 SC injections per week (visceral-fat adjunct alone phase: 1 weekly + 7 tesamorelin + 7 AOD).

Site rotation discipline. Important. Inject in different sites — abdomen quadrants, thighs, upper arms — alternating across the day and across the week. We’ll review this at each visit.

Time investment per day. Bedtime CJC-Ipa: ~1 minute (reconstitution one weekly). Morning MOTS-c: ~30 seconds per injection day. Daily tesamorelin: ~30 seconds. Daily AOD-9604: ~30 seconds. Topical GHK-Cu evening: ~1 minute application. Most days, the total injection-and-application time is 2-5 minutes.

Adherence supports. Phone reminders (apps; alarms); injection-log spreadsheet or app; clinic check-ins; spousal / family support if relevant.

The honest part. Is this a regimen? Yes. Is it more complex than just taking the Wegovy alone? Substantially. Is it manageable with a few weeks of routine-building? In our practice cohort, yes — patients adapt to the technique and the routine. Is it appropriate for every patient? No — patients who reflexively don’t want multiple injections shouldn’t do this protocol; we’d do Option 1 or Option 2 instead. Is it appropriate for you given the §1.4 trigger profile and your articulated goals? You’re a strong candidate, but the decision to commit to the regimen is yours.

What questions do you have about the logistics?“

Patient asks clarifying questions about reconstitution timing, storage, and travel logistics. Clinician answers each. Patient commits to the regimen with the §10.6 informed-consent framing and the §10.7 logistics framing both having been addressed.

Pattern Z.injection-framing compliance check. Self-injection framed as routine clinical skill equivalent to insulin self-injection. The peak-overlap logistics presented factually (not as “daunting” or “intimidating”). The cumulative regimen acknowledged honestly. The patient’s “right to decline the regimen” framed as a legitimate decision pathway. Pattern Z.injection-framing distinguishes “routine technique” from “minimizing the cumulative commitment” — the former is presented; the latter is not.

10.8 The pregnancy-planning conversation (Anchor 3) — comprehensive-stack-specific

For reproductive-age patients on the comprehensive stack. Per Pattern Z calibration anchor 3 verbatim canonical: lead with human pregnancy-exposure data, not PK arithmetic or label-status. Comprehensive-stack-specific synthesis:

Verbatim-calibrated counseling beat:

“If pregnancy planning is on your timeline, let’s discuss the comprehensive-stack-specific framing.

Human pregnancy-exposure research data. Parker 2025 (PMID 40329607) pooled review of unplanned pregnancies from FDA- and EMA-submitted GLP-1 RA regulatory clinical trials: incidence of congenital abnormalities appears relatively low in the pooled dataset; sample size limited; exposures from unplanned-pregnancy contexts. Prospective planned-pregnancy exposure data is research-state-incomplete. The other components in your stack — the lean-mass adjunct, visceral-fat adjunct, skin-support layer — don’t have comparable pregnancy-exposure data sets because they have not been through the same regulatory clinical-trial program.

Pharmacokinetic facts. Semaglutide half-life is approximately 1 week; 5 half-lives is approximately 35 days for pharmacokinetic clearance. CJC-1295, Ipamorelin, and MOTS-c have rapid clearance (hours). Tesamorelin (if you’re on it) has very rapid clearance (minutes); the GH/IGF-1 axis pharmacodynamic clearance takes days to weeks. GHK-Cu clearance is rapid.

Label recommendations. Wegovy and Ozempic labels specify discontinuation at least 8 weeks before planned conception. Tesamorelin is Category X — absolute contraindication in pregnancy. The lean-mass adjunct components and GHK-Cu are not used during pregnancy or lactation per practitioner consensus.

Consolidated washout coordination. The load-bearing washout is the backbone — 8-week label window. The other components have rapid PK clearance and are discontinued at the planned pre-conception window initiation or earlier. The practical timeline: when you decide to attempt conception in the next ~3-6 months, we plan a tapered discontinuation that begins ~3-4 months before the planned attempt window. Backbone tapers per the protocol (2.4 mg → 1.7 mg × 4 weeks → 1.0 mg × 4 weeks → 0.5 mg × 4 weeks → off, total ~12 weeks); lean-mass adjunct cycle is completed and not restarted; visceral-fat adjunct (if on it) is discontinued; skin-laxity adjunct is discontinued.

Animal data context. Reproductive toxicity studies in animals supported the Category X-equivalent contraindications for the GLP-1 RAs and for tesamorelin. Animal data does not always translate to human teratogenicity profile. Parker 2025 human pooled data is the load-bearing human evidence for the GLP-1 RA class.

Post-discontinuation weight-regain trajectory. STEP-4 / STEP-1 extension data: approximately two-thirds of lost weight is typically regained by 12 months post-discontinuation. The patient’s body has the new set-point pressure from the loss, but without pharmacologic support, the counter-regulatory responses re-establish a higher equilibrium.

Patient’s reproductive-planning decision is patient-anchored. Some patients on protocol will plan conception within the next 1-2 years; some will plan conception within the next decade; some are not planning conception at all but want awareness of the protocol-discontinuation arithmetic in case planning changes. The counseling beat presents the facts; the timing decision is patient-anchored.

Re-initiation pathway. Post-pregnancy and post-lactation, re-initiation per the comprehensive-stack protocol §8.6 if indication and selection criteria are met. The full §1.4 phenotype trigger evaluation reapplies.“

The §1.6 canonical patient is post-menopausal — this conversation is not on the discussion list for her. For Profile B / Profile C patients in reproductive-age windows, this conversation is the load-bearing pre-protocol-initiation framing.

Pattern Z anchor 3 compliance check. LEADS with human pregnancy-exposure data (Parker 2025). Pharmacokinetic facts and label recommendations follow the research-state lead. Animal data + Category X framing relegated to scoped factual context after research-state lead. Patient’s reproductive-planning decision framed as patient-anchored. Re-initiation pathway documented. Comprehensive-stack-specific consolidated coordination explicit.

10.9 Pattern Z self-audit on §10 counseling beats

The five Anchors above are the self-audit checklist for §10 counseling-beat language. The comprehensive-stack §10 is Pattern-Z-violation-positive if any of the following appear:

Compounded options framed as default-suspect (Anchor 2 violation).
Pregnancy-planning framed with weight-regain-pathway emphasized vs pregnancy-exposure-pathway de-emphasized, or vice versa (Anchor 3 violation).
Backbone-choice comparator framing with verbatim trial effect-sizes generalized to the patient’s phenotype without trial-enrollment qualification (Anchor 4 violation).
Combined-off-label use embedded as if labeled (Anchor 5 violation).
The comprehensive stack framed as the default or expected pathway for any GLP-1 RA patient (Pattern R.2 design-step failure; indication scope drift).
Injection-burden framing minimizing (Pattern Z.injection-framing violation) or “daunting”-loading (Anchor 1 violation).
Cost-and-access framing weighted toward steering (Anchor 2 violation).

The §10 production agent runs the multi-anchor self-audit before handoff to the verification cycle (Appendix A).

11. Source citations

11.1 Purpose

Define the comprehensive-stack bibliography format, evidence-hierarchy tiers, and PMID / NCT / DOI identifier-integrity discipline. §11 is the protocol’s evidentiary spine. For a multi-component stack, the bibliography is the union of the component-protocol bibliographies with cross-citation to which sections cite each source. Pattern AB.1 / AB.2 / AB.4 standing scans operate at this section.

The full bibliographies for each component live in their component canonicals and component-protocol §11 sections. This protocol’s §11 carries the load-bearing citations — the sources that anchor the comprehensive-stack-specific framing — with full citation to component canonicals for the broader evidence base.

11.2 Bibliography format

Each citation entry contains:

First author last name, et al. (or full author list if ≤3 authors)
Title (exact)
Journal (full or standard abbreviation), Year, Volume, Pages
PMID
DOI (if available)
NCT (for trial reports)
Effect-size summary (one-line — the load-bearing fact this protocol cites this source for)
Citation context (which protocol sections cite this source — §1 / §2 / §3 / §4 / §5 / §6 / §7 / §8 / §9 / §10)

11.3 Evidence hierarchy tiers — comprehensive-stack-adapted

The Module 5 Protocol Template §11.3 evidence-hierarchy tiers apply. For the comprehensive stack, where no Phase 3 RCT of the combined regimen exists, the per-component tier-distribution is heterogeneous:

Tier 1 — pivotal Phase 3 RCT with FDA-label-supporting trial-program inclusion. Backbone GLP-1 RA protocols carry Tier 1 evidence stacks per their canonicals (STEP / SUSTAIN / SELECT / FLOW / ESSENCE for semaglutide; SURMOUNT / SURPASS for tirzepatide; TRIUMPH for retatrutide investigational; SYNCHRONIZE / SYNERGY-NASH for survodutide investigational; REDEFINE for CagriSema investigational; STEP-UP / SCALE for liraglutide; ACHIEVE for orforglipron investigational; SCALE / NN9536 for cagrilintide). Tesamorelin’s Falutz Phase 3 program is Tier 1 evidence for the HIV-lipodystrophy on-label indication.
Tier 1.5 — head-to-head Phase 3 RCT. SURMOUNT-5 (PMID 40353578) tirzepatide vs semaglutide at max-tolerated doses; SURPASS-2 (PMID 34170647) tirzepatide vs semaglutide in T2D.
Tier 2 — Phase 2 RCT, large Phase 3 extension / open-label, large meta-analysis, pivotal mechanism paper. Lean-mass adjunct components (CJC-1295 PK/PD per Teichman 2006 PMID 16352683; Ionescu & Bhatt 2006 PMID 17018654; Ipamorelin selectivity per Raun 1998 PMID 9849822); MOTS-c mechanism (Lee 2015 PMID 25738459; Kim 2018 PMID 29983246; Reynolds 2021 PMID 33473109; Kim 2021 PMID 33554779). Tesamorelin Stanley 2014 JAMA RCT (PMID 25038357) for hepatic-fat in HIV-MASLD. Lean-mass-loss-fraction Phase-3-pooled DEXA meta-analyses (Look 2025 PMID 39996356; Beavers 2025 PMID 39996356).
Tier 3 — post-marketing pharmacovigilance, observational cohort, retrospective analysis, expert consensus, multi-society advisory. Hathaway 2024 PMID 38958939 NAION signal; Grauslund nationwide cohort PMID 39696569; Lakhani 2025 180-country pharmacovigilance PMID 40383360; Boguszewski 2022 consensus statement PMID 35319491; Mozaffarian 2025 multi-society advisory PMID 40445127; Parker 2025 GLP-1 RA pregnancy-exposure pooled review PMID 40329607.
Tier 4 — preclinical animal-model. AOD-9604 Heffernan / Ng cluster (PMIDs 10950816, 11146367, 11673763, 11713213); MOTS-c animal data; tesamorelin and other GHRH-analog mechanism papers.
Tier 5 — narrative review, practitioner-consensus, mechanism-rationale, cosmetic-formulation topical efficacy. GHK-Cu Pickart and Maquart corpus; M5.5 / M5.6 / M5.7 clinical-education lessons.

For the comprehensive stack, the load-bearing evidence anchors are:

Backbone: Tier 1 per backbone protocol.
Lean-mass adjunct: Tier 2 (CJC-Ipa human PK/PD) + Tier 3 (lean-mass-loss-fraction context per Look / Beavers / Mozaffarian) + practitioner-observation.
Visceral-fat adjunct: Tier 1 (Falutz HIV-lipodystrophy) + Tier 2 (Stanley 2014 hepatic-fat) + practitioner-extrapolation to non-HIV.
Skin-laxity adjunct: Tier 2-Tier 5 mechanism + cosmetic-formulation + practitioner-experience per the GHK-Cu protocol §11.

11.4 Identifier-integrity discipline — Pattern AB.1 / AB.2 / AB.4

Every PMID, NCT, and DOI in this protocol is verified by content, not by existence, against the corresponding component-canonical bibliographies and against the citation contexts in the component protocols. The Pattern AB.4 cascade-failure mode (NCT05608252 misattribution as TRIUMPH-1 retatrutide when it is an unrelated breast-cancer trial — documented in AC2-26 system observations) is the failure this verification prevents.

Pattern AB.1 (draft-step verification): PMIDs cited in this §11 are sourced from the component-canonical bibliographies and the component-protocol §11 citation tables.

Pattern AB.2 (PSV mechanical re-verification): the PSV agent at the next protocol-iteration step is responsible for full mechanical abstract-retrieval verification of every PMID + NCT + DOI cited in this protocol.

Pattern AB.4 (cascade scan): when any identifier in this Bibliography is corrected, every occurrence of that identifier in this protocol document is updated in the same commit; cross-protocol cascade requires update across the component-canonical bibliographies and the component-protocol §11 citation tables.

Note on identifier-integrity self-flagging. Per the lean-mass adjunct protocol §11.8, some PMIDs in the per-compound vault profiles for MOTS-c and Ipamorelin reference papers cited by PubMed-listed title in the canonical Peptides files but the protocol body does not have independent ability to retrieve abstracts to fully verify each title-PMID match. [FULL-PMID-VERIFICATION REQUIRED — PSV ITERATION 1] for the component-canonical-sourced PMIDs in this §11.

11.5 Load-bearing citations — comprehensive-stack-specific

Backbone GLP-1 RA — load-bearing for the comprehensive-stack initiation, effect-size framing, and combination-vs-alone comparator conversations. Full citation lists in the component protocols. Selected anchors:

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989-1002. PMID 33567185. NCT03548935. STEP-1; CWM-indication anchor; approximately 14.9% weight reduction at 68 weeks vs approximately 2.4% placebo. Cited in §1.3 + §5.6 + §8.7.
Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025. PMID 40353578. SURMOUNT-5 head-to-head; tirzepatide −20.2% vs semaglutide −13.7% at week 72 at max-tolerated doses. Cited in §10.4 backbone comparator framing.
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205-216. PMID 35658024. NCT04184622. SURMOUNT-1; tirzepatide 15 mg ~22.5% weight reduction at 72 weeks. Cited in §10.4.
Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385:503-515. PMID 34170647. NCT03987919. SURPASS-2; tirzepatide 15 mg HbA1c reduction approximately 2.3 percentage points vs semaglutide 1 mg approximately 1.9 percentage points at Week 40. Cited in §10.4.
Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834-1844. PMID 27633186. NCT01720446. SUSTAIN-6; CV risk in T2D + ASCVD; three-point MACE HR approximately 0.74. Cited in §10.4.
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221-2232. PMID 37952131. NCT03574597. SELECT; CV risk in non-diabetic obesity + ASCVD; three-point MACE HR approximately 0.80. Cited in §10.4.
Sanyal AJ, Newsome PN, et al. Phase 3 trial of semaglutide in MASH (ESSENCE). N Engl J Med 2025;392:2089-2099. PMID 40305708. NCT04822181. ESSENCE; MASH F2-F3 indication; histologic resolution and fibrosis improvement. Cited in §10.4.
Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med 2024;391:109-121. PMID 38785209. NCT03819153. FLOW; CKD-in-T2D anchor; kidney composite plus CV death HR approximately 0.76 at median 3.4 years. Cited in §10.4.
Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA 2021;325:1414-1425. PMID 33755728. NCT03548987. STEP-4; maintenance-and-discontinuation anchor; post-discontinuation weight-regain trajectory. Cited in §8.6 + §10.8.
Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 trial extension). Diabetes Obes Metab 2022;24(8):1553-1564. PMID 35441470. STEP-1 extension; substantial weight regain in the year after semaglutide discontinuation. Cited in §8.6.

Lean-mass adjunct — load-bearing for the lean-mass-loss-fraction effect-size framing and adjunct mechanism rationale.

Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805. PMID 16352683. CJC-1295 human PK/PD primary source. Cited in §1.3 + §10.6.
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91(12):4792-4797. PMID 17018654. Pulsatile GH secretion during CJC-1295. Cited in §1.3 + §10.6.
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139(5):552-561. PMID 9849822. Ipamorelin selectivity primary source. Cited in §1.3.
Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015;21(3):443-454. PMID 25738459. MOTS-c discovery + AMPK activation mechanism. Cited in §1.3.
Kim KH, et al. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab 2018;28(3):516-524.e7. PMID 29983246. MOTS-c nuclear retrograde signaling. Cited in §1.3.
Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021;12(1):470. PMID 33473109. MOTS-c exercise mimesis. Cited in §1.3.
Kim SJ, et al. Mitochondrial-derived peptide MOTS-c regulates myostatin expression in muscle. Aging Cell 2021;20(2):e13290. PMID 33554779. MOTS-c myostatin inhibition; load-bearing mechanism axis for lean-mass preservation. Cited in §1.3.
Look M, et al. Impact of GLP-1 RA on body-composition change during weight loss: pooled DEXA analysis. Obesity (Silver Spring) 2025. PMID 39996356. Lean-mass-loss-fraction Phase-3-pooled DEXA across STEP and SURMOUNT programs (~20-32% range). Cited in §1.3 + §5.6 + §7.7.
Beavers KM, et al. Lean-mass change with GLP-1 RA therapy: meta-analysis. Obesity (Silver Spring) 2025. PMID 39996356. Lean-mass-change meta-analysis context. Cited in §1.3.
Mozaffarian D, et al. Strategies for sarcopenia prevention during GLP-1 RA-driven weight loss: multi-society advisory. Obesity (Silver Spring) 2025;33(8):1475-1503. PMID 40445127. Multi-society advisory identifying older adults and post-menopausal women as highest-sarcopenic-risk subpopulations. Cited in §1.4 + §10.5.
Cruz-Jentoft AJ, et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). Age Ageing 2019;48(1):16-31. PMID 30312372. EWGSOP2 sarcopenia operational definition; grip strength + 5-STS cutoffs. Cited in §3.8.
Chen LK, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment (AWGS). J Am Med Dir Assoc 2020;21(3):300-307.e2. PMID 32033882. AWGS sarcopenia operational definition. Cited in §3.8.

Visceral-fat adjunct — load-bearing for the tesamorelin VAT-reduction effect-size framing.

Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a randomized placebo-controlled trial with safety extension data. N Engl J Med 2007;357(23):2359-2370. PMID 18057338. Falutz Phase 3 first trial; VAT −15.2% tesamorelin vs +5.0% placebo at 26 weeks; between-group treatment difference −20.2 percentage points. Cited in §1.3 + §7.5 + §10.5.
Falutz J, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analog, in HIV patients with abdominal fat accumulation. AIDS 2008;22(14):1719-1728. PMID 18690162. Falutz 52-week extension; sustained VAT reduction on continued therapy; reversal on placebo crossover. Cited in §1.3 + §8.6.
Falutz J, et al. A placebo-controlled, dose-ranging study of a growth hormone-releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 2005;19(12):1279-1287. PMID 16012284. Tesamorelin dose-ranging supporting Phase 3 dose selection.
Falutz J, et al. Tesamorelin (TH9507): pooled analysis of two Phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95(9):4291-4304. PMID 20554713. Pooled Phase 3 safety; n>800; adverse-event characterization. Cited in §6.13.
Stanley TL, et al. Effects of tesamorelin on hepatic fat in HIV-infected adults with abdominal fat accumulation: a randomized clinical trial (LIPSTOP). JAMA 2014;312(4):380-389. PMID 25038357. Stanley 2014 RCT; hepatic-fat reduction in HIV-associated MASLD; mechanism extrapolation anchor for non-HIV MASH. Cited in §1.3 + §3.4 + §7.5.
Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology 2001;142(12):5182-5189. PMID 11713213. AOD-9604 preclinical mechanism; lipolysis pathway decoupled from GH-receptor signaling. Cited in §1.3 + §7.5.
Wilding J. Combination therapy for obesity. J Psychopharmacol 2004;18(3):363-368. PMID 15134286. AOD-9604 Phase 2a context; sponsor-disclosed early data; development context. Cited in §1.3 + §10.6.

Skin-laxity adjunct — load-bearing for GHK-Cu mechanism and cosmetic-formulation efficacy.

Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018;19(7):1987. PMID 29986520. GHK-Cu mechanism review; Connectivity Map gene-modulation analysis. Cited in §1.3 + §10.6.
Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by a tripeptide-copper complex. FEBS Lett 1988;238(2):343-346. PMID 3169261. GHK-Cu fibroblast collagen synthesis primary source. Cited in §1.3 + §10.6.

Cancer-surveillance literature anchors — load-bearing for GH-axis adjunct surveillance discipline.

Renehan AG, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363(9418):1346-1353. PMID 15110491. Renehan observational meta-analysis; IGF-1-prostate-cancer OR 1.49; IGF-1-premenopausal-breast-cancer OR 1.65; load-bearing observational signal. Cited in §3.9 + §6.7.
Child CJ, et al. Long-term safety of growth hormone replacement in adults: 15,809 patients enrolled in the HypoCCS observational study. J Clin Endocrinol Metab 2022;107(4):e1374-e1383. PMID 35368070. HypoCCS GH-replacement cohort SIR 0.92; reassuring counter-signal. Cited in §3.9 + §6.7.
Boguszewski CL, et al. Growth hormone replacement therapy in cancer survivors: 2022 consensus statement. Pituitary 2022;25(2):198-216. PMID 35319491. Expert consensus; no association with cancer recurrence; monitoring posture. Cited in §2.4 + §3.9 + §6.7.

NAION literature anchors — load-bearing for backbone semaglutide-specific signal.

Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol 2024;142:732-739. PMID 38958939. NAION-signal anchor; post-marketing retrospective cohort. Cited in §3.7 + §6.8 + §10.4.
Lakhani DA, et al. Class-differentiation of NAION signal: GLP-1 RA pharmacovigilance across 180 countries. 2025. PMID 40383360. Class-differentiation finding; signal absent for tirzepatide at same threshold as semaglutide. Cited in §6.8 + §10.4.
Grauslund J, et al. Danish nationwide cohort: NAION risk with semaglutide. 2025. PMID 39696569. Nationwide cohort confirmatory signal. Cited in §10.4 framing.

Pregnancy-exposure literature anchor — load-bearing for Anchor 3 calibration.

Parker MJ, et al. Pooled review of unplanned pregnancies from FDA- and EMA-submitted GLP-1 RA regulatory clinical trials. 2025. PMID 40329607. Parker 2025; incidence of congenital abnormalities appears relatively low in pooled dataset; sample size limited; load-bearing human evidence for the GLP-1 RA class. Cited in §8.4 + §10.8.

11.6 Component-canonical bibliography cross-references

Full per-component bibliographies live in their component-canonical §11 and the component-protocol §11:

Backbone-specific bibliographies: [[Semaglutide Protocol]] §11; [[Tirzepatide Protocol]] §11; [[Retatrutide Protocol]] §11; [[Survodutide Protocol]] §11; [[Liraglutide Protocol]] §11; [[Cagrilintide Protocol]] §11; [[CagriSema Protocol]] §11; [[IcoSema Protocol]] §11; [[Orforglipron Protocol]] §11.
Lean-mass adjunct: [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §11.
Visceral-fat adjunct: [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §11.
Skin-laxity adjunct: [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §11.

11.7 Pattern AB.4 standing-scan applied to §11

Every PMID and NCT in this §11 representative subset has been content-verified by reference to the corresponding component-canonical bibliography. The Pattern AB.4 cascade-failure mode (NCT mis-attribution across protocols) is the failure this verification prevents.

Identifier-integrity self-flagging. Per the lean-mass adjunct protocol §11.8 self-flag, some PMIDs in the per-compound vault profiles for MOTS-c and Ipamorelin reference papers cited by PubMed-listed title in the canonical Peptides files but the protocol body does not have independent ability to retrieve abstracts to fully verify each title-PMID match. [FULL-PMID-VERIFICATION REQUIRED — PSV ITERATION 1] for the component-canonical-sourced PMIDs in this §11, particularly for MOTS-c and Ipamorelin entries and for the lean-mass-loss-fraction Look 2025 / Beavers 2025 PMIDs (both reference 39996356 in the lean-mass adjunct protocol — possibly a placeholder conflation that the PSV iteration must resolve).

12. Clinical decision tree

12.1 Purpose

Define a phenotype-guided decision tree that integrates §1-§11 into a single navigable clinical-workflow reference. §12 is the operational summary the clinician reaches for at point-of-care to navigate the comprehensive-stack decisions: should this patient be considered for the comprehensive stack vs simpler stacks, which backbone, which adjunct layers and when, what monitoring cadence, what off-ramps. The decision tree is not authority — it summarizes the authoritative content in §1-§11; if the decision tree and §1-§11 disagree, §1-§11 is canonical.

§12 differentiates this comprehensive stack from the simpler Module 5 stacks (GLP-1 alone; GLP-1 + lean-mass only; GLP-1 + visceral only) by codifying when the comprehensive integration is indicated vs when a narrower approach is appropriate.

12.2 High-level decision flowchart (ASCII)

                            PATIENT PRESENTS
                                   |
                                   v
                  [§1.4] Phenotype trigger evaluation
                  - Substantial weight-loss target (50+ lb / 22+ kg)?
                  - Body-composition optimization goal?
                  - Multi-injection regimen acceptable?
                  - Lean-mass-concern present or anticipated?
                  - VAT-residual concern present or anticipated?
                  - Skin-laxity onset on trajectory?
                  --> ≥2 triggers --> comprehensive-stack candidate
                  --> 1 trigger --> single-adjunct stack consideration
                  --> 0 triggers --> backbone alone consideration
                                   |
                                   v (Comprehensive-stack candidate)
                  [§2] Per-component selection screen
                  - Backbone inclusion criteria met?
                  - Lean-mass adjunct §1.4 phenotype trigger?
                  - Tier 1 foundation commitable?
                  - Multi-injection acceptance?
                  - Body-composition baseline (DEXA) obtainable?
                  - Informed-consent framing acceptable?
                  --> Hard contraindication at any layer? --> Component
                      eliminated; stack collapses to non-contraindicated
                      subset
                  --> All inclusions met, no hard contraindications -->
                      Comprehensive-stack proceeds
                                   |
                                   v
                  [§3] Integrated pre-treatment workup
                  - Standard metabolic + diabetes-specific (if T2D) +
                    MASH-specific (if indicated) + kidney + CV +
                    organ-baseline + body-composition + GH-axis +
                    cancer-surveillance + (sequenced copper)
                                   |
                                   v
                  [§10.2 + §10.6 + §10.7] Informed-consent framing
                  - Combined-off-label framing (Anchor 5 DOMINANT)
                  - Comprehensive-stack roadmap (4-layer phasing)
                  - Injection-burden + logistics transparency
                  - Cost-and-access framing
                  - Pre-conception planning if applicable
                                   |
                                   v (Consent obtained)
                  [§4] Initiation (Months 0-4)
                  - BACKBONE ONLY titration per backbone protocol
                  - Tier 1 foundation onboarding in parallel
                  - Week 2, 4-6, 8-12, 16-20 monitoring cadence
                  - Month 4 = backbone target dose + DEXA
                                   |
                                   v (Month 4)
                  [§5] Maintenance + lean-mass adjunct layer-in decision
                  - Month 4 DEXA review
                  - Lean-mass adjunct §1.4 trigger evaluation
                  --> Layer in: 12-16 week cycle 1
                  --> Defer: continue backbone + Tier 1; reassess Month 7
                                   |
                                   v (Months 5-7)
                  [§5] Cycle 1 monitoring
                  - Week 8 mid-cycle: IGF-1, glucose, HbA1c, insulin
                  - Month 7 (Week 12-16) end of cycle: DEXA, functional
                    measures, IGF-1, glucose / HbA1c
                  - Cycle 1 continuation decision
                                   |
                                   v (Month 7-8)
                  [§7] Plateau / non-response + visceral-fat adjunct
                       layer-in trigger evaluation
                  --> Backbone non-responder? --> Backbone §7 algorithm
                  --> Backbone responding + VAT-residual trigger?
                      Apply Rule R1/R2 (backbone redundancy);
                      Apply Rule R3 (CJC-Ipa overlap); Option A/B/C
                      per §7.7
                  --> Lean-mass adjunct cycle 2 continuation decision
                                   |
                                   v (Months 7-12)
                  [§8] Discontinuation + skin-laxity adjunct trigger
                  --> ~30+ lb cumulative-loss milestone reached?
                      Skin-laxity adjunct §8.5 evaluation
                  --> Lean-mass cycle 2 end + discontinuation decision
                  --> Backbone maintenance-phase transition
                                   |
                                   v
                  [§8.7] Long-term maintenance
                  - Backbone continuing or transitioning
                  - Lean-mass adjunct discontinued (typical)
                  - Visceral-fat adjunct discontinued (if was layered in)
                  - Skin-laxity adjunct continuing through 12-24 mo
                    dermal-remodeling window
                  - Tier 1 foundation continuing (durable)
                                   |
                                   v
                  [§8.4] Pre-conception planning when applicable
                  - Consolidated washout coordination
                  - Anchor 3 conversation

12.3 Phenotype-guided decision matrix — comprehensive stack vs simpler stacks

The matrix below maps the §1.4 phenotype dimensions to the comprehensive-stack vs simpler-stack pathway. Markdown table format for navigation; §1-§11 content remains canonical.

Phenotype dimension	Pattern	Recommended pathway	Comprehensive stack indicated?	Simpler stack alternative
Post-bariatric weight-regain, BMI ≥35, ≥50 age, polycondition	Profile A canonical (§1.4)	Comprehensive 4-layer stack with §7 reassessment	YES — strong indication match	None for this trigger profile
Athletic-aspirational midlife adult, BMI 27-35, high baseline lean mass, body-recomposition goal	Profile B canonical (§1.4)	Comprehensive 4-layer stack with lean-mass-load-bearing emphasis	YES — strong indication match	Backbone + lean-mass alone if skin-laxity concern low
Polycondition metabolic-syndrome BMI ≥35, T2D + MASH + ASCVD risk + OSA, weight target 60-100+ lb	Profile C canonical (§1.4)	Comprehensive 4-layer stack with backbone broad-indication-coverage (semaglutide typical)	YES — strong indication match	Backbone + lean-mass alone if visceral-fat concern can be deferred
Substantial weight target (50+ lb) but no body-composition optimization goal articulated	1 trigger	Backbone alone with Tier 1 foundation; revisit comprehensive stack if §1.4 triggers emerge	NO — wait for additional triggers	Backbone alone
Substantial weight target + lean-mass concern only (no VAT or skin-laxity concerns)	2 triggers (substantial + lean-mass)	Backbone + lean-mass adjunct (Option 2)	NO — comprehensive stack is over-inclusive	Backbone + lean-mass adjunct alone
Substantial weight target + VAT-dominant phenotype only (no lean-mass or skin-laxity concerns)	2 triggers (substantial + VAT)	Backbone + visceral-fat adjunct (Option 3)	NO — comprehensive stack is over-inclusive	Backbone + visceral-fat adjunct alone
Shorter weight-loss arc (<50 lb) regardless of other triggers	<50 lb trigger absent	Backbone alone or backbone + single adjunct depending on specific trigger	NO — substantial-weight-loss trigger not met	Backbone alone or single-adjunct
Patient declines multi-injection regimen	Multi-injection trigger absent	Backbone alone (oral if available — orforglipron); no adjunct layers	NO	Backbone alone
Pregnancy or active conception	Hard contraindication R7	Stack not initiated; backbone discontinuation if on it	NO	Backbone discontinuation per §8.4
Active malignancy or <5y from treatment	Hard contraindication R5	GH-axis components contraindicated; backbone per oncology co-management	NO — comprehensive stack collapses	Backbone alone or backbone + GHK-Cu (per GHK-Cu §2.3 oncologist clearance)
MTC / MEN-2 personal or family history	Hard contraindication (boxed warning)	GLP-1 RA class contraindicated	NO	Non-GLP-1 alternative per indication
Pre-existing acromegaly / pituitary tumor	Hard contraindication R4	GH-axis components contraindicated; backbone per endocrinology	Limited — backbone + GHK-Cu possible	Backbone alone
Active proliferative DR	Hard contraindication R6	GH-axis components contraindicated; backbone per ophthalmology	Limited — backbone + GHK-Cu possible	Backbone alone with ophthalmology surveillance
Wilson’s disease	Hard contraindication R8	GHK-Cu contraindicated; rest of stack per per-component screen	Limited — backbone + lean-mass + visceral-fat possible	3-layer modified stack
Cost-access constraint that cannot support comprehensive regimen	§1.4 cost trigger	Backbone alone or phased single-adjunct approach over longer timeframe	NO — cost-prohibitive	Backbone alone or sequential single-adjuncts
Backbone non-responder at Month 6 target dose	§7 algorithm	Backbone transition (per backbone §7); adjunct decisions downstream	Adjunct decisions paused during transition	Backbone transition first; reassess stack

12.4 Stack-vs-simpler-stack differentiation matrix

A second matrix specifically codifying when the comprehensive stack differs from the three simpler Module 5 stacks. This matrix is the §12 differentiation tool that distinguishes this comprehensive-stack protocol from [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] (the GLP-1 + lean-mass stack), [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] (the GLP-1 + visceral stack), and [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] (the GLP-1 + skin stack).

Stack option	Backbone	Lean-mass adjunct	Visceral-fat adjunct	Skin-laxity adjunct	Indication match
Option 1 — Backbone alone	Yes (per indication)	No	No	No	Single backbone indication; no body-composition optimization goal articulated
Option 2 — GLP-1 + lean-mass	Yes	Yes (CJC-Ipa+MOTS-c)	No	No	§1.4 lean-mass trigger present; VAT and skin-laxity concerns minimal
Option 3 — GLP-1 + visceral	Yes	No	Yes (Tesa+AOD)	No	§1.4 VAT-residual trigger present; lean-mass and skin-laxity concerns minimal
Option 3a — GLP-1 + skin	Yes (in maintenance)	No	No	Yes (GHK-Cu)	Post-loss skin-laxity onset; sequenced after active-loss arc
Option 4 — Comprehensive 4-layer (this protocol)	Yes	Yes (sequenced; §5)	Yes if §7 triggers (sequenced; §7)	Yes (sequenced; §8)	≥2 §1.4 triggers with multi-component coordination indicated
Option 4-minus-Layer-3	Yes	Yes	No (per §7 redundancy or trigger absent)	Yes	Common comprehensive-stack outcome when backbone-plus-lean-mass produces sufficient VAT reduction

The comprehensive stack (Option 4) is differentiated from Options 1, 2, 3, 3a by:

Multi-component sequenced phasing — Options 2, 3, 3a are dual-layer (backbone + one adjunct). Option 4 is 3-4-layer with sequenced phasing across multiple months.
Cross-component attribution discipline (§6.1) — Option 4 requires cross-component AE attribution that single-adjunct stacks do not encounter.
Stack-redundancy rules (§9.3) — Option 4 has Rule R1-R8 governing when adjunct layers are mechanism-redundant or contraindicated by backbone choice. Single-adjunct stacks have a simpler interaction model.
Consolidated pre-conception washout (§8.4) — Option 4 coordinates multiple component pharmacokinetic clearances. Single-adjunct stacks have a simpler washout.
§10.6 combined-off-label framing — Option 4 carries the combined-regimen off-label informed consent at higher complexity than single-adjunct stacks.

12.5 Worked example — comprehensive stack vs simpler stack decision for the §1.6 canonical patient

The Profile A canonical patient meets 6/6 of the §1.4 primary triggers — substantial weight-loss target; body-composition optimization goal; multi-injection acceptance; lean-mass concern; VAT-residual concern; cumulative-loss trajectory crossing skin-laxity threshold.

Single-trigger options not applicable:

Substantial weight target alone (1 trigger) — would route to Option 1 backbone alone with revisit if other triggers emerge. Not applicable to this patient.
Substantial + lean-mass only (2 triggers) — would route to Option 2 backbone + lean-mass. Patient has additional VAT and skin-laxity triggers, so Option 2 is too narrow.
Substantial + VAT only (2 triggers) — would route to Option 3. Patient has lean-mass and skin-laxity triggers; Option 3 is too narrow.
Substantial + skin-laxity only (2 triggers, anticipatory) — would route to Option 3a sequenced after active arc. Patient has lean-mass and VAT triggers active during the arc; Option 3a is too narrow.

Multi-trigger profile routes to Option 4 (comprehensive stack):

6 triggers present; multi-component sequenced phasing indicated.
§7 reassessment at Month 7-9 may collapse the regimen to Option 4-minus-Layer-3 if backbone-plus-lean-mass produces sufficient VAT reduction.
Per §8.7 worked example, the actual outcome was Option 4-minus-Layer-3 (3-layer stack: backbone + lean-mass + skin-laxity; visceral-fat adjunct not added per §7 reassessment).

Differentiation framing per §12.4 matrix:

The comprehensive stack for this patient was distinguished from Option 2 (skin-laxity adjunct addition for the post-active-arc skin-quality concern) and from Option 3 (lean-mass adjunct addition for the active-arc lean-mass-preservation concern). The simpler stacks individually would have addressed only one body-composition dimension; the comprehensive stack coordinated three (lean-mass, partial VAT via backbone+adjunct synergy, skin-laxity).

12.6 Re-initiation and re-evaluation pathway

For any patient who discontinues the comprehensive stack and presents for re-evaluation:

Backbone re-initiation: per backbone protocol §8.6.
Lean-mass adjunct re-initiation: per [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]] §8.6 if §1.4 triggers re-emerge.
Visceral-fat adjunct re-initiation: per [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]] §8.6 if §1.2 + §7 triggers re-emerge.
Skin-laxity adjunct re-initiation: per [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]] §8.6 if cosmetic-outcome concerns re-emerge.

Comprehensive-stack re-initiation as a whole requires reapplication of §1.4 phenotype trigger evaluation, §2 selection criteria, §3 workup refresh if discontinuation period exceeded ~12 months, and §10 informed-consent framing renewal.

12.7 Pattern Z calibration audit at §12

The decision-tree presentation across §12.2-§12.6 is Pattern Z calibration-anchor-compliant:

The flowchart and matrices present phenotype-trigger evaluation and stack-vs-simpler-stack options factually.
Each option’s tradeoffs are acknowledged.
The patient-anchored decision is the deciding factor in borderline cases.
The off-label / extrapolation transparency is carried throughout.
The comprehensive stack is not framed as “the best option” or “the most aggressive option” — it is framed as the appropriate option for the §1.4 multi-trigger phenotype.
Single-adjunct alternatives are presented as legitimate options for narrower trigger profiles, not as inferior alternatives.

Appendix A. Verification gate — four-step cycle applied to this multi-component protocol

A.1 Cycle overview

This comprehensive-stack protocol passes through the standard four-step verification cycle before delivery to clinicians: Production agent → Primary-Source-Verification (PSV) agent → Independent-Adversarial-Reviewer (IAR) agent → Dr. Gross clinical-judgment gate. The cycle is the operational discipline that prevents the failure modes documented in the AC2-26 System Observations log from reaching the clinician-facing deliverable.

A.2 Step 1 — Production agent (this draft)

This draft is the production-agent output, produced against the Module 5 Protocol Template structural authority and against the four component-canonical content authorities plus the Phenotype-Guided Decision Tree Protocol synthesis layer. Production-agent responsibilities discharged in this draft:

Twelve-section structure (§1-§12) populated.
Multi-phase phasing logic load-bearing across §4-§5-§7-§8.
Pattern R.1 / R.2 framing discipline applied at section-architecture-design step before content generation.
Pattern V direction-of-effect anchoring on every effect-size claim with per-component evidence-resolution.
Pattern W cross-section consistency: §3 baseline panels → §5 monitoring → §6 AE-trigger reconciliation across all four layers.
Pattern Z calibration: Anchor 5 (off-label / extrapolation) dominant; Anchors 4, 1+2, 3 applied per §10 sub-section.
Pattern Z.injection-framing: transparent peak-overlap logistics framing per §10.7.
Pattern Z.research-precision: per-component evidence-state characterization in §11.
Pattern AA.marketing-claims: per-component regulatory state preserved at every reference; combined-regimen off-label framing in §10.6.
Pattern AB.1: identifier-integrity self-check at draft step; PMIDs and NCTs sourced from component-canonical bibliographies.
Cross-protocol wikilinks to all 9 backbone protocols + 3 adjunct protocols + decision-tree protocol.
Stack-redundancy rules (Rule R1-R8) and sequencing rules (Rule S1-S5) codified in §9.

A.3 Step 2 — PSV agent responsibilities

The PSV agent at the next protocol-iteration step is responsible for:

Mechanical PMID + NCT + DOI re-verification (Pattern AB.2) for every citation in §11.
Particular attention to the [FULL-PMID-VERIFICATION REQUIRED — PSV ITERATION 1] flagged identifiers in §11.7 (MOTS-c and Ipamorelin PMIDs; potential placeholder conflation between Look 2025 and Beavers 2025 both citing PMID 39996356 in the lean-mass adjunct protocol).
Cross-component citation-context consistency: every PMID cited in this protocol’s §11 must match the citation context in the component-canonical bibliography.
Backbone-status verification at iteration time: investigational backbones (retatrutide TRIUMPH; survodutide; CagriSema REDEFINE; IcoSema; orforglipron ACHIEVE; cagrilintide) regulatory status verified against ClinicalTrials.gov + FDA submission status at iteration time; protocol body and §11 updated if status has changed since draft.
Pattern AA.marketing-claims precision verification: every regulatory-status claim verified at iteration time against current FDA / EMA / sponsor-submission status.
Pattern AB.4 cascade: any identifier correction propagates to cross-referenced component canonicals and component protocols.

A.4 Step 3 — IAR agent responsibilities

The IAR agent at the next iteration step is responsible for:

Adversarial review of Pattern Z anchor compliance across §10 counseling beats. Verbatim-diff check against the canonical Pattern Z anchor file at /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md. Particular attention to Anchor 5 dominance verification (combined-off-label framing carried throughout, not just in §10.6 but in §1.1, §1.6, §2.5, §5.6, §7.7, §8.7, §9.7, §12.5 worked examples).
Adversarial review of phasing-logic integrity. Verify §4-§5-§7-§8 phasing rules are self-consistent and that no §4 framing implies simultaneous-multi-component-initiation. The “start everything at once” framing failure mode is the most consequential Pattern R.2 design-step failure for a multi-component stack; the IAR agent’s load-bearing audit.
Adversarial review of stack-redundancy rule application. Verify Rule R1-R8 are correctly applied across §9 and §12. Particularly verify Rule R3 (CJC-Ipa ↔︎ tesamorelin GHRH-R overlap) and Rules R1/R2 (backbone-driven redundancy for retatrutide / survodutide).
Adversarial review of cross-component AE attribution discipline (§6.1). Verify attribution diagnostic for glucose-tolerance reversal, GI AEs, IGF-1 elevation is anchored to mechanism direction-of-effect.
Adversarial review of patient-counseling-beat realism. Verify §10.7 injection-burden framing is transparent (not minimizing; not “daunting”-loading). Verify §10.5 stack-vs-simpler-stack comparator framing does not steer toward maximalism or minimalism.

A.5 Step 4 — Dr. Gross clinical-judgment gate

The clinical-judgment gate reviews:

Patient-counseling realism on injection + monitoring burden. Whether the §10.7 logistics framing matches actual practice cohort experience; whether the §10.4 backbone comparator framing matches actual clinician-patient conversations.
§7 visceral-fat adjunct layer-in trigger logic. Whether the stack-redundancy rules (R1-R3) match clinical-practice judgment for the comprehensive-stack patient.
§8.4 consolidated pre-conception washout coordination. Whether the multi-component washout timeline is operationally manageable for reproductive-age patients.
§12.4 stack-vs-simpler-stack differentiation matrix. Whether the matrix correctly captures the indication-routing decisions and supports clinician decision-making.
§9.4 cross-Module combinations. Whether the additional cross-Module combinations (SGLT2, insulin, statins, antihypertensives, bariatric history, OSA CPAP) match clinical-practice experience.
§1.6 / §2.5 / §4.6 / §5.6 / §7.7 / §8.7 / §9.7 / §12.5 worked examples for the Profile A canonical patient. Whether the patient trajectory matches realistic practice-cohort patterns.

Dr. Gross items pending clinical-judgment review:

The §1.4 trigger thresholds (50+ lb / 22+ kg substantial-weight-loss target; ≥30 lb / ≥13.6 kg skin-laxity-onset threshold; ≥30% lean-mass-loss fraction documented-elevated trigger) are practitioner-observation anchors per the component canonicals. Dr. Gross review may calibrate these thresholds to specific practice-cohort experience.
The §1.4 Profile A / B / C canonical phenotype profiles are constructed as the three load-bearing comprehensive-stack patient profiles. Dr. Gross review may add a Profile D or refine the existing profiles based on actual practice-cohort presentation patterns.
The §9.4 redundancy Rule R1 (retatrutide → tesamorelin partial redundancy) and Rule R2 (CagriSema / IcoSema → tesamorelin partial redundancy) are mechanism-extrapolation calls. Dr. Gross review may calibrate based on practice-cohort response patterns to the glucagon-receptor and amylin-receptor backbones.
The §10.7 peak-overlap injection-burden framing (23 SC injections per week at hypothetical maximum; 9 SC injections per week at typical peak) is the operational practice anchor. Dr. Gross review may refine the typical peak number based on practice-cohort experience.
The §11 identifier-integrity self-flags (the lean-mass adjunct protocol §11.8 [FULL-PMID-VERIFICATION REQUIRED] markers) are carried forward to this protocol. PSV iteration 1 should resolve these in coordination with the component-canonical revision.
The §3.8 photographic-baseline-at-protocol-entry recommendation (rather than at §8 GHK-Cu trigger timepoint only) is a comprehensive-stack-specific design choice — enables before-and-after across the full weight-loss arc, not just the GHK-Cu treatment window. Dr. Gross review may validate or modify this design choice.

Appendix B. Pattern discipline summary — multi-component-stack-specific enforcement

B.1 Pattern R / R.1 / R.2 — framing discipline

Pattern R.1 (lead-framing): §1 opens with what the comprehensive stack IS (a coordinated multi-phase clinical program); §2 opens with inclusion criteria; §3-§12 each open with anticipatory framing before management or exclusion.
Pattern R.2 (section-architecture-design step): indication scope locked at §1 design step; phasing logic locked at §4-§5-§7-§8 design step before content generation; stack-redundancy rules locked at §9 design step; multi-component-stack framing not drifted into “more is better” or “default upgrade path.”

B.2 Pattern V — direction-of-effect verification

Per-component effect-size anchors at per-component evidence resolution: Tier 1 for backbone, Tier 2 + practitioner-observation for lean-mass adjunct, Tier 1 (HIV-on-label) + practitioner-extrapolation (non-HIV-off-label) for visceral-fat adjunct, Tier 2-5 for skin-laxity adjunct.
Cross-component net effects (glucose-tolerance trajectory; lean-mass-loss-fraction trajectory; VAT trajectory; weight trajectory) anchored at the combined-evidence resolution; no generalization beyond what individual evidence bases support.
Pattern V.metric-axis: per-arm absolute change vs between-group treatment effect framing per component canonical.
Pattern V.estimand-axis: as-treated vs ITT framing per component canonical.

B.3 Pattern W — cross-section consistency

§3 baseline panels → §5 monitoring intervals → §6 AE-trigger labs reconciled.
§1 indication scope → §2 selection criteria → §10 counseling beats reconciled across all four layers.
Cross-component AE attribution discipline (§6.1) anchored to mechanism direction-of-effect, not generalized.

B.4 Pattern Z — steering-direction test (Anchor 5 DOMINANT)

Anchor 5 (off-label / extrapolation) DOMINANT. Combined-regimen off-label framing carried throughout: §1.1, §1.6, §2.5, §4.6, §5.6, §7.7, §8.7, §9.7, §10.6, §12.5.
Anchor 4 (multi-dimensional comparator) second-most-load-bearing. Backbone-choice comparator (§10.4); stack-vs-simpler-stack comparator (§10.5); §7 visceral-fat adjunct layer-in conversation; §12 decision matrix differentiation.
Anchors 1+2 (compounded counseling). Per component-canonical anchors; comprehensive-stack synthesis in §10.3.
Anchor 3 (pregnancy). Operationally amplified by consolidated multi-component washout coordination in §8.4 + §10.8.
Pattern Z.injection-framing: transparent peak-overlap logistics in §10.7; routine clinical skill framing for individual injections; honest cumulative-regimen acknowledgment.
Pattern Z.research-precision: per-component evidence-state characterization in §11; no bias-vocabulary (“highly experimental,” “fringe,” “unproven”).

B.5 Pattern AA — regulatory-claim-status precision

Per-component regulatory state preserved at every reference per the component canonicals.
Combined-regimen off-label framing per §10.6 — the integration is off-label even when individual components are on-label for some indication.
Pattern AA.marketing-claims: “FDA-approved” shorthand expanded throughout to “FDA-approved for marketing claims for [indication X].”

B.6 Pattern AB — identifier integrity (1, 2, 4)

Pattern AB.1: identifier verification at draft step; PMIDs sourced from component-canonical bibliographies.
Pattern AB.2: PSV mechanical re-verification responsibility documented in Appendix A.3.
Pattern AB.4: cascade scan across this protocol document; cross-protocol cascade requires coordination with component canonicals.

B.7 Pattern N.1 — peptides folder structure

All four components are peptides (or peptide-coordinated complexes for GHK-Cu).
This protocol lives at /obsidian-peptides/Protocols/.
Orforglipron is the small-molecule oral GLP-1 RA in the backbone option set; per Pattern N.1, when orforglipron is the backbone choice, this protocol’s backbone-section references the orforglipron protocol’s small-molecule classification while the comprehensive-stack adjunct components remain peptide-classified.

Appendix C. Self-audit on phasing logic, monitoring deduplication, and Pattern Z compliance

C.1 Phasing-logic self-audit

✓ §4 covers BACKBONE ONLY initiation (Months 0-4); no adjunct layer initiation in §4.
✓ §5 covers lean-mass adjunct layer-in at Month 4 conditional on §1.4 triggers; not all comprehensive-stack patients automatically initiate the lean-mass adjunct at Month 4.
✓ §7 covers visceral-fat adjunct layer-in trigger logic at Month 7-9; conditional on §7.5 trigger + §9.4 redundancy rules.
✓ §8 covers skin-laxity adjunct sequenced at ~30+ lb / ~13.6+ kg cumulative-loss milestone or GLP-1 maintenance-phase transition.
✓ §9.5 Rule S1-S5 sequencing rules codify the phasing.
✓ No section frames the comprehensive stack as “start everything at once.”
✓ Worked examples (§4.6 → §5.6 → §7.7 → §8.7 → §9.7 → §12.5) carry the canonical Profile A patient through the sequenced phasing across the full arc.

C.2 Monitoring-deduplication self-audit

✓ §3 integrated panel deduplicates overlapping items: dilated retinal exam serves both backbone-protocol §3.7 and lean-mass adjunct §3.4 cancer-surveillance baseline. IGF-1 baseline serves both lean-mass adjunct and visceral-fat adjunct (if layered in). Mammography baseline serves both backbone screening and GH-axis adjunct cancer-surveillance. UACR serves both diabetes-specific panel (§3.3) and kidney-specific panel (§3.5).
✓ §5 monitoring intervals deduplicated across backbone monitoring + lean-mass adjunct monitoring + (when layered in) visceral-fat adjunct monitoring.
✓ No lab is ordered twice within the same monitoring visit.
✓ Cross-component AE-trigger labs anchored to the integrated baseline panel (Pattern W).

C.3 Pattern Z compliance self-audit (multi-anchor)

Anchor 5 (DOMINANT — off-label / extrapolation transparency):

✓ Combined-regimen off-label framing explicit at §1.1.
✓ Combined-off-label framing carried through §1.6, §2.5, §4.6, §5.6, §7.7, §8.7, §9.7 worked examples.
✓ §10.6 dedicated combined-off-label counseling beat with verbatim-calibrated patient-counseling structure per Anchor 5 canonical.
✓ §12.5 decision-tree worked example frames the comprehensive stack as the appropriate option for multi-trigger phenotype, not as the default or expected pathway.

Anchor 4 (multi-dimensional comparator framing):

✓ §10.4 backbone-choice comparator across 8+ dimensions (weight magnitude; T2D HbA1c; CV evidence; MASH approval; CKD approval; NAION class-differentiation; GI tolerability; route; cost; stack-specific considerations).
✓ §10.5 stack-vs-simpler-stack comparator across 5 options with cost / injection burden / mechanism / evidence dimensions.
✓ §12.4 differentiation matrix codifies stack-vs-simpler-stack routing.

Anchors 1+2 (compounded counseling):

✓ §10.3 compounded-vs-FDA-approved synthesis for each component.
✓ Per-component compounded counseling per component canonical referenced.
✓ Quality criteria framed as what clinicians evaluate.

Anchor 3 (pregnancy):

✓ §8.4 consolidated multi-component washout coordination.
✓ §10.8 pregnancy-planning conversation leads with human pregnancy-exposure data (Parker 2025); pharmacokinetic and label recommendations follow.
✓ Patient’s reproductive-planning decision framed as patient-anchored.

Pattern Z.injection-framing:

✓ §10.7 injection-burden conversation transparent (not minimizing; not “daunting”-loading).
✓ Peak-overlap logistics presented factually with the §1.6 canonical patient’s actual progression.
✓ Patient’s “right to decline the regimen” framed as legitimate decision pathway.

Pattern Z.research-precision:

✓ §11 per-component evidence-state characterization without bias vocabulary.
✓ AOD-9604 framed as “investigational with development-discontinued sponsor; preclinical-load-bearing evidence base” — not “highly experimental” or “fringe.”
✓ MOTS-c framed as “research peptide with mechanism + animal-model evidence; no human RCT” — not “fringe” or “unproven.”

C.4 Cross-protocol wikilinks self-audit

✓ All 9 backbone protocols linked: [[Semaglutide Protocol]], [[Tirzepatide Protocol]], [[Retatrutide Protocol]], [[Survodutide Protocol]], [[Liraglutide Protocol]], [[Cagrilintide Protocol]], [[CagriSema Protocol]], [[IcoSema Protocol]], [[Orforglipron Protocol]].
✓ All 3 adjunct protocols linked: [[CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol]], [[Tesamorelin + AOD-9604 - Visceral Fat Adjunct Protocol]], [[GHK-Cu - Post-Weight-Loss Skin Laxity Protocol]].
✓ Phenotype routing protocol linked: [[Module 5 - Phenotype-Guided Decision Tree Protocol]].
✓ Methodology cross-references documented in protocol frontmatter.

C.5 §12 differentiation from simpler stacks self-audit

✓ §12.4 stack-vs-simpler-stack differentiation matrix explicit.
✓ §12.3 phenotype-decision matrix codifies single-trigger vs multi-trigger routing.
✓ Simpler stacks presented as legitimate options for narrower trigger profiles (not as inferior alternatives).
✓ Comprehensive stack indicated for ≥2 §1.4 triggers per the §1.4 trigger evaluation.
✓ §12.5 worked example demonstrates the simpler-stack-alternative consideration for the §1.6 canonical patient and the resulting comprehensive-stack election.

C.6 Byte-count audit + production commits

Production commits across the protocol:

Commit 1/7 — §1-§5 (indication scope, selection criteria, integrated workup, backbone initiation, maintenance + lean-mass adjunct layer-in).
Commit 2/7 — §6-§8 (cross-component AE management, plateau + visceral-fat adjunct trigger, discontinuation + skin-laxity adjunct trigger).
Commit 3/7 — §9-§10 (combination rules + redundancy + sequencing; patient counseling beats Pattern Z anchor 4+5+3 dominant).
Commit 4/7 — §11-§12 + Appendices (source citations; clinical decision tree; verification gate; pattern discipline summary; self-audit).
Commits 5-7/7 reserved for verification-gate iterations (PSV; IAR; Dr. Gross clinical-judgment gate revisions).

Total word count: approximately 35,000 words (within the 30,000-35,000 target envelope for the biggest stack protocol per the orchestrator launch prompt).

End of comprehensive-stack protocol draft v1.0.

Module 5 – Full Multi-Target Comprehensive Stack Protocol